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ABSTRACT
Tethered IL-15 to augment the therapeutic potential of T cells expressing chimeric
antigen receptor: Maintaining memory potential, persistence, and antitumor activity
Adoptive immunotherapy can retarget T cells to CD19, a tumor-associated antigen (TAA)
expressed on B-cell malignancies, by the expression of a chimeric antigen receptor (CAR).
Infusion of CAR-modified T cells for the treatment B-cell malignancies has demonstrated
promise in preclinical and clinical trials. These data highlight the ability of infused CD19specific T cells to be synchronously activated by large burdens of CD19+ leukemia and
lymphoma. This can lead to dramatic antitumor effects, but also exposes the recipient to
toxicity associated with tumor-cell lysis and cytokine storm. Clinical trials will now be
addressing the targeting of minimal burdens of CD19+ malignancy as patients are enrolled
earlier in their disease course and receive concomitant chemotherapy. It is likely that the
existing populations of CAR T cells generated ex vivo to address relapsed disease may not
be able to address minimal residual disease (MRD). Therefore, we have developed a
clinically appealing approach to sustaining the persistence of CAR T cells independent of
TAA by providing signaling through the common gamma chain receptor (γc). Administration
of exogenous soluble recombinant cytokines that signal through the γc, such as interleukin
(IL)-2, have been used clinically to sustain the persistence of adoptively transferred T cells.
However, systemic high-dose administration has resulted in dose-limiting toxicities. Unlike
IL-2, IL-15 possesses numerous attributes desirable for adoptive therapy and has been
ranked among the most valuable immunotherapeutic agent for cancer treatment. It is a prosurvival cytokine that promotes the survival of long-lived T-cell memory subsets and in vivo
antitumor activity. Unlike other γc family cytokines, IL-15 is transpresented to responding T
cells in the context of IL-15 receptor alpha (IL-15Rα). Therefore, we hypothesized that a
membrane-bound IL-15 fusion protein (mIL15) tethered to the cell surface would enhance
T-cell costimulation to support persistence independent of CAR activation by preserving Tcell memory potential and maintain antitumor activity in the presence of low TAA. Using
clinically compliant methods, the generated mIL15-CAR T cells mimicked the physiologic
mechanism of transpresentation to sustain costimulation via phosphorylation of signal
transducer and activator of transcription (pSTAT5).

In contrast to conventional CD19-

specific CAR T cells, mIL15-CAR T cells persisted in mice independent of the presence of
TAA and mediated potent rejection of a systemically distributed CD19+ leukemia. The
potential for sustained immunity against B-cell malignancies was shown as, in the absence
vi

of antigen, mIL15-CAR T cells were long-lived and adopted a desirable CD45ROnegCCR7+
“low-differentiation” state with a memory-like molecular profile and phenotype. These
results have direct implications for the design of an adoptive immunotherapy clinical trial
evaluating mIL15-CAR T cells in the setting of MRD and warrants further investigation of
mIL15 to engineer T cells targeting other tumor cells that have sequestered or low levels of
TAA.
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CHAPTER 1
Background

1.1 B-cell Acute Lymphoblastic Leukemia
B-lineage acute lymphoblastic leukemia (ALL) occurs in both pediatric and adult
populations where approximately 60% of B-ALL cases are in individuals younger than 20
years old (1, 2).

This tumor cell type typically initiates at the pro-B cell stage where

development is halted and the cells retain progenitor characteristics without further
differentiation to a mature state (3). Initial induction therapy with chemotherapeutics is
aggressive, toxic, and long-term (4). Chemotherapeutic treatment of adult and pediatric
ALL have disease relapse rates of 65% and 20%, respectively, due to drug-resistant
residual disease (5, 6). Adults have poor prognosis, where greater than 60% will succumb
to their disease, but about 80% of pediatric patients have long-term survival (7). However,
children who relapse have a cure rate of 25-40% (8). As leukemia is the most frequently
occurring childhood malignancy at 34% (9), though, the absolute number of relapses is
substantial and makes it one of the most common pediatric malignancies (10, 11).
Especially concerning for pediatric patients are the late treatment effects that may have to
be fought years after treatment. The aggressive induction treatments, and even some of
the less toxic therapies introduced more recently, increase the risks of other chronic and
serious health conditions of childhood cancer survivors and can include organ impairment
and secondary cancers (12).

The high incidence of ALL relapse, especially in poor

prognostic groups such as those with very early relapse or CR3+ (13, 14), coupled with the
associated long-term health effects of aggressive chemotherapeutic treatment has
prompted the use of immune-based therapies.

1.2 CD8 T Cell Differentiation During Immune Response
Cytotoxic T lymphocytes (CTLs) are a component of the adaptive immune system that
participates in the elimination of cells that have been infected by virus or intracellular
bacteria. Quiescent naïve T cells residing in secondary lymphoid organs can be described
as CD45RA+CCR7+CD62L-CD27+CD28+ (15).

Upon being alerted to pathogen, antigen

presenting cells (APC) interact with naïve CD8 T cells in secondary lymphoid organs and
1

initiate the expansion phase of antigen-specific T cells that will go on to address clearance
of the viral or intracellular bacteria (16).

In a progressive T cell differentiation model,

priming of the naïve T cells (TN) results in activation, proliferation, and phenotypic changes
ultimately endowing them with effector function (Fig. 1) (17). CD45RO expression when
paired with CD62L and CCR7 signifies central memory T cells (TCM), which traffic amongst
lymphoid organs and have the hallmark capability of producing IL-2 (18, 19).

As,

differentiation continues, CD62L and CCR7 are lost, signifying effector memory cells (TEM),
which are relegated to trafficking in peripheral tissues and are capable of producing copious
levels of IFNγ (18, 20). The further along the differentiation path the cell is, the greater the
acquisition of effector function, but it is concomitant with a loss of longevity. Progression
through the stages of differentiation is characterized by stepwise changes in phenotype and
loss of function that ultimately impacts efficacy in clearing pathogen or, as in the topic of
this dissertation, clearance of tumor (21, 22). The contraction phase follows pathogen
clearance where CD8 T cells quickly become apoptotic and die, leaving only 5-10% to
remain in the memory T cell pool (16).
The road travelled between the initial naïve state of a T cell and the final terminally
differentiated T cell that dies, is under considerable debate. Several models have been
proposed to explain T cell differentiation and diversification: separate-precursor model,
decreasing–potential model, signal–strength model, asymmetric cell fate model (reviewed
in (16, 23)). They aim to explain how heterogeneous populations of short-lived effector and
long-lived memory CD8 T cells are formed during an immune response, but no consensus
has been reached in making a model determination since numerous experiments support
each of the models. Moreover, these conflicting studies have been done in models of viral
or bacterial infection and thus studying the determination of T cell lineage in tumor models
may contribute to this debate and it has remained relatively unexplored.
What there is more agreement about is that intrinsic factors are modulated throughout T cell
progression from naive to long-lived memory precursors to short-lived terminally
differentiated effector cells (reviewed in (16, 17, 24). Alteration of transcription factor levels
is not necessarily an on-off switch, but can take the form of a reciprocal gradient of
transcriptional

programs

controlling

effector

and

memory

differentiation.

Well-known axes are: eomesdermin (EOMES) opposing T-bet and B cell lymphoma 6
(BCL-6) opposing B lymphocyte maturation-induced protein 1 (BLIMP-1), where EOMES
and BCL-6 institute memory programs (16). The frequency and intensity of T cell receptor
(TCR) induction from antigen encounter, signals from costimulatory molecules such as
2

Figure 1. Progressive T cell differentiation model. Naive T (TN) cells are primed by
antigen-presenting cells (APCs) at the initiation of an immune response. The strength and
quality of stimulatory signals influences T cell progression along a differentiation pathway
that ends in the generation of terminally differentiated short-lived effector T (TEFF) cells.
Upon pathogen clearance, antigenic and inflammatory stimuli diminish enabling primed T
cells to become quiescent and enter into various memory subsets depending on the
intensity of extrinsic signals received. T cell differentiation increasingly progresses from
memory stem cell (TSCM), central memory (TCM) cell, to effector memory (TEM). The
phenotypic characteristics are illustrated as: not expressed (–), low expression (+),
intermediate expression (++), and high expression (+++).
Adapted from: Gattinoni L, Klebanoff C, Restifo NP. 2012. Paths to stemness: building the
ultimate antitumour T cell. Nature Reviews Cancer 12(10). Adapted by permission from
Macmillan Publishers Ltd.
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CD28, and inflammatory cytokines are extrinsic factors that merge with intrinsic elements to
mold T cell differentiation (Fig. 2). The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is
a central node to which these signals coalesce. Akt integrates these converging signals
leading to downstream regulation of the Wnt/β-catenin pathway, forkhead box O (FOXO),
glycogen synthase kinase 3 (GSK3), and mammalian target of rapamycin complex 1
(mTORC1) in a rheostat-like manner (25-27). Strong induction of Akt activation institutes a
transcription program that drives T cell differentiation and results in enhanced effector
function with concomitant decline in differentiation to a memory state and loss of survival
potential (26). Gaining further understanding of the modulation of external conditions and
manipulation of intrinsic elements is ultimately the key to modulating T cell responses in
adoptive cell therapy (ACT). Work in this dissertation aims to evaluate the intrinsic state of
genetically-modified T cells.

1.3 Harnessing the Immune System to Target ALL Minimal Residual Disease
CD8 T cells, and other elements of the immune system, are not limited to responding
to viral or intracellular bacterial pathogens, but they have also emerged as crucial players in
holding back cancer development.
immunosurveillance.

This concept has come to be known as cancer

The immune system can recognize cells that have undergone

changes predisposing them to cancer, or that have transformed to malignancy, and
eliminate these abnormal cells (28, 29). This process may fail and cancer may then arise
but, with intervention and appropriate assistance, the immune system can be reenergized
to enable it to return to what it was specifically made to do.
The high incidence of ALL relapse, especially in poor prognostic groups, has prompted
the

use

of

immune-based

therapies

using

allogeneic-hematopoietic

stem

cell

transplantation (Allo-HSCT) (30). This therapy is dependent on alloreactive cells present in
the donor graft for the eradication of remaining leukemic cells to achieve a graft-versusleukemia (GVL)-effect to improve disease-free survival (31). Donor lymphocyte infusions
have been used to enhance the ability of engrafted T cells to target residual ALL after alloHSCT, but this treatment approach for patients with ALL achieves less than a 10%
remission rate and is associated with a high degree of morbidity and mortality from the
frequency and severity of graft-versus-host disease (32, 33). High risk of relapse for

4

Figure 2. Activation of PI3K/Akt signaling in the CD8 T cell. In CD8 T cells, PI3K
activation is initiated by engagement of the TCR with peptide/MHC I complex, signals from
costimulation, cytokines, and/or chemokines. Functioning at the plasma membrane,
activated PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) yielding
phosphatidylinositol-3,4,5-triphosphate (PIP3), which recruits PH domain-containing
proteins such as Akt. Phosphoinositide-dependent protein kinase (PDK1) and mammalian
target of rapamycin complex 2 (mTORC2) are required for full activation (phosphorylation)
of the Ser/Thr kinase Akt. Upon activation, Akt localizes to and functions in the cytosol. It
phosphorylates and inhibits tuberous sclerosis complex 1/2 (TSC1/2), which is part of a
negative regulatory complex of mTORC1. Resultant mTORC1 activity initiates protein
synthesis and cell growth via S6K and 4E-BP. Akt also inhibits GSK3 which regulates the
canonical Wnt/β-Catenin pathway. Additionally, Akt translocates to the nucleus to
phosphorylate FOXO transcription factors resulting in their nuclear export that plays a role
in cell quiescence, apoptosis, and memory.
Reprinted from: Kim EH, Suresh M. 2013. Role of PI3K/Akt signaling in memory CD8 T
cell differentiation. Frontiers in Immunology 4(20):1-11. With permission from the Creative
Commons Attribution License.
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particular malignancies has been observed in pediatric transplants with high risk ALL and
Ph+ALL transplants achieving 58% and 37% disease free survival (34, 35). With relapse
still a common and lethal problem in these refractory malignancies, adoptive therapy using
T cells after HSCT may be used to target residual leukemic cells. Increasing the GVL-effect
toward the minimal residual disease (MRD) can be accomplished by redirecting the
specificity of donor T cells.
1.4 Adoptive Immunotherapy: Redirecting T Cell Specificity
In the absence of a tumor-associated antigen and/or a T cell expressing an
endogenous αβ TCR with specificity for a tumor, T-cell therapy hinges on the ability to
genetically engineer cells with redirected antigen specificity. Manipulating T cell specificity
toward a tumor antigen is possible by the introduction and the expression of a chimeric
antigen receptor (CAR). Infusion of such antigen redirected T cells is developing into a
targeted treatment for the elimination of malignant cells and prevention of disease relapse.
Numerous formulations of CARs that are specific for several target antigens have been
developed with some of these approaches progressing into phase I clinical trials (36).
A CAR is typically composed of an extracellular antibody-derived single-chain variable
domain (scFv) for antigen recognition and is joined by a flexible linker connected to a
transmembrane domain and an intracellular signaling domain(s) that includes CD3ζ for Tcell activation (Fig. 3) (37, 38). In this way, CAR T-cell recognition of tumor targets occurs
independently of the major histocompatibility complex enabling their application to be
universal (37). Clinical trials using these 1st generation CARs demonstrated the feasibility
of adoptive transfers, however while some patients did show evidence of tumor responses
others did not respond with lasting effects (BB-IND11411, LJNC) (39, 40). In the study by
Park et al. (40), the persistence of CAR-modified T cells was found to be short and ranged
from one to seven days in patients with bulky disease.

Numerous studies have now

demonstrated that T cell persistence correlates with therapeutic efficacy (41-43) and this
dissertation aims to address the issue of poor or inconsistent persistence of CAR-modified
T cells.
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Figure 3. Schematics of prototypical CARs used to redirect T cell specificity. CARs
exist in a dimerized form and are expressed as a fusion protein that links the extracellular
scFv (VH linked to VL) region, a flexible hinge, an Fc region such as IgG4, a transmembrane
domain, and intracellular signaling motifs. The endodomain of the 1st generation CAR
induces T cell activation solely through CD3-ζ signaling. The second generation CAR
provides activation signaling through CD3-ζ and CD28, or other endodomains such as 41BB or OX40. The 3rd generation CAR activates T cells via a CD3-ζ-containing
combination of three signaling motifs such as CD28, 4-1BB, or OX40.
Adapted from: Kebriaei P et al. 2012. CARs: Driving T-cell specificity to enhance antitumor immunity. Frontiers in Bioscience 4:520-31. With permission from Frontiers in
Bioscience.
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1.5 Improving Adoptively Transferred T Cell Persistence
Despite the design of the 1st generation CARs to mimic T cell receptor (TCR) induction by
signaling via a CD3ζ endodomain to activate modified-T cells, this did not provide the fully
competent signal that T cells receive in the physiological context. It has been revealed that
1st generation CARs could induce proliferation for a few cycles but T cell death quickly
ensued (44). Normally when T cells are activated in vivo they receive a primary antigeninduced TCR signal with secondary costimulatory signaling from CD28 that induces the
production of cytokines (i.e., IL-2 and IL-21), which then feed back into the signaling loop in
an autocrine/paracrine fashion (45-47).

With this in mind, 2nd generation CARs were

constructed to include CD28 cytoplasmic signaling domain (41) or other costimulatory
molecule signaling domains such as 4-1BB (48)(Fig. 3). Chimeric CD28 co-stimulation
improves T-cell persistence over the 1st generation CAR by up-regulation of anti-apoptotic
molecules and production of IL-2, as well as expanding T cells derived from peripheral
blood mononuclear cells (PBMC) (41).

Though T cell survival is enhanced, murine

experiments demonstrated a significant decline in 2nd generation CAR T cell persistence
within the first seven days after adoptive transfer (41), indicating key supportive factors are
still missing.
Efforts are still underway to identify the optimal combination of signaling endodomains
and to develop new strategies to further enhance in vivo survival of CAR T cells. The
continued development in CAR technology has led to the construction of 3rd generation
CARs that create triple endodomain fusion receptors and appear to improve in vitro function
in comparison to the 2nd generation CAR (49) (Fig. 3). Other reported approaches that
demonstrated enhanced T cell persistence in adoptive transfers are: (i) the infusion of
effector CD8+ T cells derived from central memory (TCM), naïve (TN), and memory stem cell
(TSCM), which demonstrated progressively increasing therapeutic potential (50-52); (ii)
generation of bi-specific T cells with tumor antigen recognition via an introduced CAR and
viral antigen specificity via the endogenous TCR that provided a more competent activation
signal (39); ex vivo propagating CAR T cells in specific cytokine cocktails (53, 54); and (iv)
the expression of the costimulatory molecules CD80 and 4-1BBL on T cells that provide
auto- and trans-costimulatory signals (42).
While each of these approaches have significant implications for the generation of cells for
adoptive immunotherapy, continued development of new strategies to enhance modified T
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cell persistence is still necessary as the described advances that have been made either:
have not yet demonstrated robust long-term persistence in humans (50-52), may not be
appropriate across clinical platforms of immunotherapy (39), or persisted only in a tumor
associated antigen (TAA)-dependent manner (42). Thus, alternate means for improving Tcell persistence is warranted and the specific aims of this dissertation address this.

1.6 Cytokines Support Adoptively Transferred T Cell Persistence
Cytokines in the common gamma chain receptor (γc) family collectively share a four αhelical bundle structure which signal through hetero-dimeric and trimeric receptor
complexes that share the γc sub-unit (reviewed in reference (55)). Interleukin (IL)-2, IL-7,
IL-15, and IL-21 are members of this family and signal through Janus family tyrosine kinase
(JAK)1 and JAK3. IL-2, IL-7, and IL-15 primarily activate both signal transducer and
activator of transcription (STAT)5, whereas IL-21 mainly activates STAT3 (56). Cross-talk
also occurs with the Ras, PI3K (57), and nuclear factor-κB (NF-κB) (58) pathways. While
the shared signaling of the γc may contribute to the overlapping functions of these
cytokines, signaling of their private receptors as well as coupling with other signaling
pathways lends to the unique and pleiotropic effects of these cytokines (57).
IL-2 has been the cytokine historically used in the clinic to improve transferred T cell
persistence. IL-2 signals through a low affinity state via a hetero-dimeric receptor with IL2/IL-15 receptor beta chain (IL-2/IL-15Rβ; also known as CD122) and γC subunits. High
affinity signaling is enabled by IL-2 receptor alpha chain (IL-2Rα) when it is present in the
heterotrimeric receptor complex with IL-2Rβ and γc subunits (59). IL-2 is a growth factor
that promotes T cell activation and proliferation (60) while also being important for the
differentiation of T cells to the TH2 phenotype (61). The administration of IL-2 is used to
boost T cell survival in vivo during adoptive therapy (62, 63). However, prolonged systemic
dosage of IL-2 is associated with severe toxicities including respiratory distress and
vascular leak syndrome, resulting in limits to IL-2 usage in the treatment (62, 64).
Additionally, IL-2 can even hinder the effectiveness of infused T cells via the expansion of
regulatory T cells that induce peripheral tolerance (65) and the promotion of activationinduced cell death (AICD) (66). The focus is now shifting to investigating the other γc
cytokines to (i) generate higher quality T cells in vitro and (ii) to better support adoptively
transferred T cells in vivo.
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IL-15 has leapt into the spotlight in the past few years due to its potential for use in the
immunotherapy field. It is a homeostatic cytokine that appears to exert a preferential effect
on the homeostatic proliferation of CD8 memory T cells (67, 68). It has also been reported
that IL-15 can induce rapid homeostatic proliferation of naïve T cells in lymphopenic
conditions, with the resultant expanded cells possessing central memory characteristics
(69).

Moreover, it was observed that in vitro culture with low-dose IL-15 resulted in

proliferation without phenotypic change (67), which is an attribute of great potential with
regard to following the paradigm shift toward generating T cells with maximal memory
potential.
IL-15 has been established to function in vivo by a transpresentation mechanism.
Activated monocytes or dendritic cells present a membrane-bound IL-15 receptor alpha
chain (IL-15Rα)/IL-15 complex to the IL-2/IL-15Rβ and γc receptor complex on the T cell
(70) (Fig. 4). IL-15Rα is the high affinity receptor that binds IL-15 resulting in qualitatively
different signal transduction than that achieved by soluble IL-15 (71). In addition, the IL15/IL-15Rα complex undergoes endosomal recycling back to the surface thereby extending
the cytokine’s persistence in the system (70, 72) (Fig. 4).

Interestingly, the

transpresentation of IL-15 occurs in the immunological synapse. It is speculated that this
severely restricts IL-15 exposure to prevent unintended immune stimulation (73).
Consideration of the transpresentation mechanism is important in harnessing the
cytokine’s potency and biological activity. The use of IL-15/IL15Rα complexes resulted in
increased potency over the soluble cytokine and was able to promote the eradication of
established tumors via alleviating functional suppression of tumor-resident cells (74). A
non-human primate study indicated that IL-15 was far superior to IL-2 in generating longlived memory T cells (75). In addition, safety has been evaluated in non-human primate
models.

An intermittent dosing schedule was found to be well tolerated, and it was

observed that memory CD8 and CD4 T cells as well as NK cells were detected in the
peripheral blood in this lymphoreplete model (76). The potential for IL-15 in modulating
cellular responses in ACT therapies has excited the field and numerous clinical trials have
been initiated and are rapidly gaining momentum. The demonstrated biological responses
of IL-15 make it an excellent candidate for incorporation into our CAR T cell therapy treating
ALL MRD.
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Figure 4. Transpresentation of IL-15 by IL-15Rα to neighboring CD8+ T cells. Type I
or type II interferons induce coordinate expression of IL-15 and the IL-15Rα on monocytes
or dendritic cells. The IL-15/IL-15Rα complex recycles from the cell surface through
endosomal vesicles to be re-expressed at the cell surface. IL-15 is presented in trans by
IL-15Rα to T cells expressing the IL-2/15Rβ and γc receptor complex.
Reprinted from: Waldmann T.A. 2006. The biology of interleukin-2 and interleukin-15:
implications for cancer therapy and vaccine design. Nature Reviews Immunology 6(8):595601. Reprinted by permission from Macmillan Publishers Ltd.
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1.7 Specific Aims
The primary goal of this dissertation is translationally driven and seeks to develop an
alternative approach to address a clinical need and contribute to furthering the therapeutic
potential of adoptive cell therapy (ACT). Three specific aims are pursued that bring forth
novel information or improve upon an immunotherapeutic approach contributing to the
above gaps in knowledge or prevailing clinical issues.

There is consensus that the

persistence of adoptively transferred CAR T cells remains inconsistent and impacts the
therapeutic efficacy of ACT. More specifically, persistence of transferred T cells may pose
to be more challenging in low or sequestered TAA environments. With that clinical context
in mind, our approach capitalized on the pleiotropic effects and unique mechanistic features
of IL-15 to develop a membrane-bound IL-15/IL-15Rα fusion protein (mIL15) to be coexpressed on CAR T cells. The overarching hypothesis of this dissertation is that mIL15
sustains costimulation to improve CAR T cell persistence and antitumor activity whilst
preserving memory potential.
Specific Aim 1: IL-15 mediates numerous immunomodulatory effects that are beneficial for
ACT, including supporting the homeostasis of long-lived TCM, and is therefore a
costimulatory molecule suitable for improving the persistence of CAR T cells. Incorporating
the prevailing in vivo mechanistic action of IL-15, we generated mIL15. In this specific aim
we hypothesize that mIL15 can sustain STAT5 signaling to costimulate CAR T cells by
mimicking transpresentation. Additionally, as part of the translational aspect of this project,
we aimed to generate sufficient numbers of functional and clinically relevant mIL15-CAR T
cells. Using a clinical platform to genetically modify and expand mIL15-CAR T cells, these
cells will be evaluated by: (i) phosflow to assess the mIL15 costimulatory effect via pSTAT5
induction (ii) extended phenotyping for T cell and memory-associated markers using flow
cytometry, and (iii) assess redirected specificity by a chromium release assay (CRA) and
IFNγ production in response to CD19neg and CD19+ targets.
Specific Aim 2: IL-15 can enhance in vivo antitumor activity and support homeostasis of
CD8 TCM, which persist long-term without requiring contact with antigen. We hypothesize,
therefore, that mIL15-CAR T cells will possess enhanced antitumor activity in vivo and
persist in vivo independently of TAA. Immunocompromised mice will be used to assess
mIL15-CAR T cell performance (antitumor activity and/or T cell persistence) under three
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models: (i) a high-dose leukemia xenograft, (ii) a preventative low-dose disseminated
leukemia xenograft, and (iii) T cell engraftment in the absence of TAA.
Specific

Aim 3: The differentiation fate of long-term persisting cytokine and CAR co-

modified T cells is ambiguous and it is unknown whether intrinsic factors play a role in
addition to the extrinsic elements. IL-15 plays a critical role in the homeostatic maintenance
of CD8 TCM. We therefore hypothesize that persisting mIL15-CAR T cells will possess
attributes associated with TCM. Moreover, intrinsic elements will be representative of their
differentiation state. We sought to characterize long-term persisting mIL15-CAR T cells by
first modeling the persistence in vitro to assess: (i) mIL15 and CAR phenotype by flow
cytometry, (ii) mIL15 functionality by phosflow and functionality of CAR by IFNγ production
assessed by flow cytometry, (iii) gene expression analysis by nCounter, (iv) phenotyping of
transcription factors and surface markers associated with T cell differentiation state, (v)
memory-associated function via assessment of IL-2 production, and (vi) CCR7 subset
viability by Annexin V staining. In vivo assessments followed up by assessing mIL15-CAR
T cells persisting in immunocompromised mice in the absence of TAA and evaluated: (i)
phenotyping of surface markers associated with T cell differentiation state, (ii) mIL15 and
CAR phenotype, and (iii) CAR functionality by IFNγ production in response to CD19+/targets assessed by flow cytometry.
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CHAPTER 2
Generation of Clinically Relevant CD19-specific
T Cells Co-expressing mIL15

2.1 Introduction
CARs are used to retarget T cell specificity to a desired surface expressed TAA (37).
Although adoptive transfer of CAR T cells have shown objective clinical responses in
treating B cell leukemias, successful outcomes in adoptive immunotherapy are associated
with persistence of transferred antigen-specific T cells (43, 63, 77, 78). CAR-modified T
cells are designed to receive costimulation for activation, survival, and proliferative signaling
via the introduced immunoreceptor when engaged with a TAA (79). This approach, even
with the addition of other costimulatory molecules, predictably lead to in vivo accumulation
of T cells only in a TAA-dependent manner (41, 42).

In low level TAA environments,

infused T cells may not receive sufficient CAR-mediated signaling for robust persistence.
This raises concerns for their capacity to persist at therapeutic levels to mediate durable
tumor surveillance in leukemic relapse prevention or to treat MRD. Clinical trials will now
be increasingly targeting the treatment of MRD as patients are enrolled earlier in their
disease course and are receiving concomitant chemotherapy. Thus, optimizing adoptively
transferred T cell persistence under low TAA conditions is paramount to improving clinical
response and this aspect remains aggressively pursued.
Administration of exogenous interleukin IL-2 has been the cytokine historically relied
upon to enhance survival of adoptively transferred T cells (62, 63). Systemic high-dose IL-2
has proven to potentiate dose-limiting toxicities that include respiratory distress and
vascular leak syndrome (62, 64, 80), as well as risks AICD that may limit the therapeutic
response of transferred T cells (81, 82). While low-dose IL-2 has been shown to be better
tolerated, it appears to contribute to peripheral tolerance and the production of regulatory T
cells (65, 83, 84). IL-2 is also used in the in vitro expansion of T cells for adoptive therapy
and is associated with inducing a differentiated effector phenotype (53), which have been
demonstrated to have far poorer in vivo persistence and therapeutic potential than other
less differentiated T cell subsets (52). Contrasting the detrimental biological effects of IL-2,
IL-15 possesses a plethora of immunomodulatory attributes desirable to adoptive therapy.
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It is a pro-survival cytokine required for the homeostatic maintenance of long-lived CD8
memory T cells (85, 86), inhibits AICD (87), enhances in vivo antitumor activity (88), and
reverses T cell anergy (89). With this valuable arsenal, IL-15 has been ranked the most
important immunotherapeutic agent for cancer treatment (90) and has been used in
metastatic melanoma and renal carcinoma trials with recently registered trials with natural
killer (NK) cell and T cell immunotherapies (www.clinicaltrials.gov: NCT01385423,
NCT01369888, NCT01875601).
Clinical trials, thus far, have administered soluble recombinant IL-15 and pre-clinical
studies have engineered antigen-specific human T cells that secrete monomeric IL-15 (9193). However, unlike IL-2 which is secreted, IL-15 is uniquely transpresented in the context
of IL-15Rα to responding T cells by the producing cells (i.e., dendritic cells) (94, 95).
Limitations exist to the use of monomeric IL-15 as it is an unstable low molecular weight
protein resulting in a short serum half-life thus necessitating frequent supra-physiologic
dosing to attain biological responses in vivo (76, 96, 97).

Mimicking physiologic

transpresentation by coupling IL-15 with a soluble form of IL-15Rα remedies this
shortcoming and has shown greater potency and antitumor efficacy of T cells in vivo (97),
likely due in part to the qualitatively different signaling achieved by transpresentation which
result in more robust activation of the cells (71).

Moreover, it was demonstrated that

targeting complexed IL-15 to the tumor microenvironment, and thus to responding immune
cells, further enhanced the antitumor effect (98).
The hypothesis of this chapter is that expression of mIL15 on CAR T cells will function
by the physiologic mechanism of transpresentation and will induce enhanced STAT5
costimulation. This work aims to generate pre-clinical data for the development of a Phase
I clinical trial testing the therapeutic efficacy of mIL15-CAR T cells in treating MRD and is
therefore also focused on generating mIL15-CAR T cells that can meet specific clinically
relevant criteria, including generating sufficient numbers of modified T cells, retaining
redirected specificity, and a quality phenotype that includes the expression of memory–
associated surface markers. Here we show the co-modification of CAR T cells with mIL15
in primary human cells that are independent of exogenous cytokine stimulation with the
generated mIL15-CAR T cells suitable for adoptive transfer.
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2.2 Results
2.2.1 mIL15 Plasmid Construction
To provide human primary T cells with self-sustained IL-15 signaling that mimics the
primary in vivo mechanism of action of transpresentation, we designed a tethered IL-15
fusion protein to be expressed on the surface of the CAR T cell. The expression of IL-15 is
highly regulated at multiple levels, but with several critical elements functioning at the posttranslational level, including the signal peptide and coding sequence (99). Alternate codon
usage and signal peptides have been shown to increase IL-15 expression levels (91, 100).
The mIL15 construct is codon-optimized and consists of a fusion of IL-15 cDNA
(NM_000585.4) to the full length IL-15Rα (NM_002189.3) with a flexible linker and is
inserted within a Sleeping Beauty (SB) expression plasmid. The signal peptides for IL-15
and IL-15Rα were omitted and the IgE signal peptide (gb|AAB59424.1) was used for the
mIL15 construct (Fig. 5A).

The mIL15 DNA sequence was codon optimized and

synthesized by GeneArt (Regensburg, Germany) and subsequently subcloned into a SB
transposon plasmid.

SB transposons are used as part of a non-viral gene transfer

approach that is directly translatable to the clinic as it is used in some CAR T cell clinical
trials for genetic modification of the T cells (IND#s: 11470, 14577, 14739) (101, 102).
Translation of this tethered IL-15 fusion protein is expected to synthesize a membranebound IL-15 that, based on similar molecules (103, 104), is expected to emulate
presentation of IL-15 in context with IL-15Rα (Fig. 5B).
2.2.2 Generation and Expression of mIL15 and CAR on Primary Human T Cells
To keep with the direct translational applicability of this study, the genetically modified
T cells were generated and ex vivo propagated using clinically compliant methods (Fig. 6)
(102, 105). Primary normal donor human T cells were co-electroporated with a CD19specific CAR transposon, with or without the mIL15 transposon, and the SB-11 transposase
to generate mIL15-CAR T cells and the conventional CAR T cells to serve as a clinically
relevant comparison. The CAR used was ‘2nd generation’, thus comprised of CD3ζ and
CD28 signaling endodomains (41). Propagation of the genetically modified T cells was
achieved by recursive stimulation (Stim) with a K562 artificial antigen presenting cell line
(aAPC) variant expressing CD19 antigen, as well as 41BBL and CD86 co-stimulatory
molecules. The presence of CD19 on the aAPC allows for the selective outgrowth of
antigen-specific T cells while the costimulatory molecules improve in vitro expansion (106).
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Figure 5. Schematics of mIL15. (A) Sleeping Beauty DNA plasmid map for mIL15 [IL15IL15Ra-Flag(Coop)/pSBSO] for the expression of a fusion protein consisting of IL-15 linked
with the full-length IL-15Rα. (B) A schematic representing the protein structure of mIL15
consisting of IL-15 linked with the full-length IL-15Rα. Abbreviations: hEF-1alpha/p, human
elongation factor-1 alpha promoter; TM, transmembrane domain, BGH, polyadenylation
signal from bovine growth hormone; IR/DR, Sleeping Beauty inverted repeat; ColE1, E. coli
origin of replication; Kan/R, gene encoding kanamycin resistance for bacterial selection;
Kan/p, prokaryotic promoter.

17

Figure 5. Schematics of mIL15
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Figure 6. Generation and ex vivo expansion of mIL15-CAR T cells using a clinical
platform. Schematic of the clinically compliant methods adopted for generating and
numerically expanding mIL15 and CAR co-modified T cells. PBMC were electroporated
with mIL15 and CAR Sleeping Beauty (SB) DNA transposons and SB transposase. Cells
were then cocultured with γ-irradiated K562 (Clone 9)-derived aAPC (modified to express
CD19, CD64, CD86, and CD137L) and, unless otherwise stated, had supplementation with
IL-21 (30ng/ml). The genetic modification and expansion of CAR T cells was similarly
performed, but using only the CAR SB transposon and SB transposase during
electroporation with subsequent cultures supplemented with IL-21 (30ng/ml) and IL-2
(50U/ml).
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Transient transfection levels of CAR were similar between CAR and mIL15-CAR T cells.
The mIL15 was detected at modest levels in mIL15-CAR T cells (Fig. 7A). After four Stims,
nearly all T cells expressed CAR and expression was equivalent between CAR and mIL15CAR T cells (Fig. 7B). The mIL15 molecule was stably co-expressed with the CAR at 51 ±
14% (mean ± SD), and a minimal expression of mIL15 without the CAR was observed (2 ±
4%; mean ± SD; Fig. 7A,C).

CAR mean fluorescence intensity (MFI) was equivalent

between CAR T cells and mIL15+CAR+ T cells. However, mIL15negCAR+ T cells showed
significantly lower CAR MFI compared to mIL15+CAR+ T cells (P < 0.001; Fig. 7D), but the
functional implications remain unknown. These data show that mIL15 and CAR can be
stably co-expressed in primary T cells.
2.2.3 Numeric Expansion of Clinically Significant Numbers of mIL15-CAR T Cells
After redirecting T cell specificity with the CAR, suitable numbers of these modified T
cells must be generated to allow for adoptive transfer of therapeutic doses of CAR T cells.
To assess whether mIL15 could provide enhanced costimulation sufficient for sustaining in
vitro numeric expansion, mIL15-CAR T cells were propagated as previously described but
without exogenously added IL-21 (Fig. 6) and compared to CAR T cells that received (i) no
cytokine supplementation (baseline growth control), (ii) IL-15 complex (soluble cytokine
control), or (iii) IL-2 and IL-21 (clinical or positive control). Unlike CAR T cells that received
no cytokine supplementation, numeric expansion of mIL15-CAR T cells was achieved in the
absence of exogenous cytokine supplementation (P < 0.0001; Fig. 8A). And, while mIL15CAR T cell expansion was equivalent to CAR T cells supplemented with IL-15 complex,
these cells could not parallel the expansion of conventional CAR T cells supplemented with
IL-2 and IL-21 (P < 0.0001; Fig. 8A). This may have been due, in part, to the persistent
overgrowth of NK cells at early time points (Stim 2) which was observed to comprise
greater than 70% of the cells in the culture but was not an issue in conventional CAR T cell
cultures (P < 0.01; Fig. 8B,C). Despite CD56 depletion of mIL15-CAR T cell cultures,
phenotyping after ex vivo expansion (Stim 4) revealed moderate levels of CD3negCD56+ and
CD3negCD56neg populations in T cell cultures.

These non-T cell subsets cumulatively

comprised 19% - 55% of the culture and a concomitant decrease in the outgrowth of
desirable CD8+ T cells for adoptive transfer was observed (Fig. 8D). IL-15 may have
played a role in supporting the growth of the non-T cell subsets, as CAR T cell cultures
supplemented with IL-15 complex also showed these subsets cumulatively comprise up to
86% of the cells in culture (Fig. 8D).
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Figure 7. Stable co-expression of mIL15 and CAR on T cells after propagation on
aAPC. (A) Transient (24-hours post-electroporation) and stable (Stim 4) expression of
mIL15 and CAR on Sleeping Beauty-modified T cells. A representative flow plot is shown
for one of 10 normal donors. Gate frequencies are displayed in the top right corner of the
plot. (B) Frequency of expression of CAR on CAR T cells and mIL15-CAR T cells.
Horizontal bar represents the mean. (C) Frequencies of mIL15 and/or CAR expressing
subsets of mIL15-CAR T cells. Data are mean ± SD, n = 4. (D) The CAR mean
fluorescence intensity (MFI) on CAR and mIL15-CAR T cells. The mIL15-CAR T cells were
sub-divided based on their mIL15 expression. ***P < 0.001, ns = not significant, paired t
test (B), one-way ANOVA (C).
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Figure 7. Stable co-expression of mIL15 and CAR on T cells after propagation on
aAPC
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Figure 8. Numerical expansion of mIL15-CAR T cells on aAPC without exogenous
cytokines is accompanied by an NK cell expansion. (A) Rate of CAR-specific
expansion of mIL15-CAR T cells with no exogenous cytokine administration and CAR T
cells supplemented with IL-2 (50U/ml) and IL-21(30ng/ml), IL-15 complex (5ng/ml), or
unsupplemented.
At Stim 2, cultures containing > 15% CD3-CD56+ cells were
paramagnetic bead sorted to deplete CD56+ cells. Data are expressed as mean ± SD, n =
6. ****P < 0.0001, ns = not significant, two-way RM ANOVA (Tukey’s post-test). (B)
Expression of CD3 and CD56 on cells at Stim 2. Representative flow plots are shown for
one of three normal donors. (C) Frequencies of CD3-CD56+ NK cells detected in cultures
at Stim 2 from (b). Data are expressed as mean ± SD, n = 3. **P < 0.01, one-way ANOVA
(Tukey’s post-test). (D) Frequencies of T cell sub-populations co-expressing combinations
of CD3, CD4, CD8, or CD56. Data are expressed as mean ± SD, n = 3.
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Figure 8. Numerical expansion of mIL15-CAR T cells on aAPC without exogenous
cytokines is accompanied by an NK cell expansion
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In generating CAR T cells for adoptive therapy, the focus in ex vivo propagation is on
driving high numeric expansion of CAR+ T cells. In accordance with GMP protocols that
yield high numbers of CAR T cells (102), the conventional CAR T cell cultures were
supplemented with IL-2 and IL-21.

This study capitalized on the reported synergistic

proliferative effect of IL-21 with IL-15 on CD8+ T cells (107) to increase expansion of CD8+
mIL15-CAR T cells. With IL-21 supplementation to the culture protocol, mIL15-CAR T cells
demonstrated comparable expansion to conventional CAR T cells, yielding 2.3 x 107 – 7.4 x
1010 and 6.1 x 108 – 4.4 x 1010 CAR+ T cells, respectively (Fig. 9). In sum, while mIL15
may provide some costimulatory support during ex vivo expansion, IL-21 is a necessary
addition to enable the generation of clinically relevant numbers of mIL15-CAR T cells.
2.2.4 Enhanced costimulation of mIL15-CAR T Cells Via pSTAT5 Induction
Additional investigation of the costimulatory capability of mIL15 was performed by
phosflow assessing phosphorylated signal transducer and activator of transcription 5
(pSTAT5), the primary signaling molecule involved in IL-15 receptor complex signal
transduction (108).

Unlike cytokine unsupplemented CAR T cells, mIL15-CAR T cells

(receiving no exogenous cytokines) demonstrated sustained pSTAT5 levels (P < 0.01; Fig.
10A,B).

Moreover, the costimulation intensity was below that induced by the supra-

physiologic dosing of soluble IL-15 in CAR T cells (P < 0.05; Fig. 10B), suggesting that the
phosphorylation of STAT5 molecules was not saturated and thus mIL15 may induce more
of a physiologically relevant signal strength.
A primary reason for designing mIL15 as membrane-bound and with IL-15Rα, was to
mimic the mechanism of IL-15 transpresentation that occurs in vivo. To assess whether
mIL15 can transpresent IL-15, a co-culture experiment was performed where CAR and
mIL15-CAR T cells were co-cultured at a ratio greater than 1:4 and at high density to
ensure cell-cell contact. IL-15-specific or Flag antibodies were used to distinguish the two
populations. Unlike CAR T cells cultured alone, those in co-culture with mIL15-CAR T cells
were able to receive IL-15 signal induction in trans, as indicated by sustained pSTAT5
levels (Fig. 10C). Together these data show that mIL15 provided sustained costimulation
that induced STAT5 signal transduction and that this costimulation could be initiated in
trans to mimic physiologic mechanisms.
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Figure 9.
Numerical expansion of mIL15-CAR T cells on aAPC with IL-21
supplementation. Rate of CAR-specific T cell expansion of mIL15-CAR T cells cultured
with exogenous IL-21 (30ng/ml) and CAR T cells supplemented with IL-2 (50U/ml) and IL21(30ng/ml). Cultures exceeding > 15% CD3-CD56+ cells were paramagnetic bead sorted
to deplete CD56+ cells. Data are expressed as mean ± SD, n = 6, ns = not significant, twoway RM ANOVA (Bonferroni post-test).
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Figure 10. Induction of pSTAT5 by mIL15. Functionality of mIL15 was validated by
phosflow of pSTAT5 in CAR and mIL15-CAR T cells under serum and cytokine starved
conditions. (A) A representative histogram showing the flourescence intensity of pSTAT5 in
CAR and mIL15-CAR T cells (n = 6). CAR T cells treated with soluble IL-15 (100ng/ml) for
1-hour prior to fixation served as the positive control whereas unsupplemented CAR T cells
indicate baseline pSTAT5 levels. (B) Mean flourescence intensity (MFI) of pSTAT5 of
modified T cells from (A). Horizontal bar represents the mean. *P < 0.05, **P < 0.01, oneway ANOVA. (C) The representative historgram shows pSTAT5 flourescence intensity of
CAR T cells in co-culture with mIL15-CAR T cells (transpresented mIL15) at a ratio of 1:4,
CAR T cells supplemented with IL-15, and unsupplemented CAR T cells (n = 4). Histogram
is gated on IL-15neg cells.
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2.2.5 Immunophenotype and Function of mIL15-CAR T Cells is Unaltered by mIL15
Concerns have arisen that T cells generated for adoptive therapy undergo excessive
culture time, excessively driven expansion, or exposure to cytokines such as IL-2 that
promote T cell differentiation toward terminal effector cells, thereby diminishing antigenspecific T cell therapeutic potential (17, 109, 110). For that reason expanded CAR T cells,
also considered the infusion product for adoptive transfers, are assessed for surface
markers that may indicate the cell product’s in vivo or clinical potential.

The

immunophenotype of CAR and mIL15-CAR T cells was not significantly altered by mIL15
expression. CAR and mIL15-CAR T cells nearly all expressed CD3, CD8, and CD45RO.
CAR and mIL15-CAR T cells expressed: CD62L ranging from 57% - 85% and 64% - 88%;
CCR7 ranging from 3% - 31% and 7% - 31%, CD27 ranging from 7% - 50% and 5% - 87%;
and CD28 ranging from 28% - 77% and 25% - 95%, respectively (Fig. 11A-C). Only a low
level of IL-7Rα expression by mIL15-CAR T cells was noted (P = 0.0470). The moderate to
high expression levels of various memory-associated markers (17, 18, 21, 111) for both
sets of modified T cells indicates a heterogeneous mix of T cell differentiation subsets.
There is no indication of dominance of the potentially more therapeutically limited terminally
differentiated effector or effector memory subsets, which would be characterized by a lack
of CD62L and CCR7.

To the contrary, these modified T cells display characteristics

predictive of in vivo persistence and treatment responses (52, 112-114). After ex vivo
expansion of the modified T cells, it is important to validate, for clinical purposes, that the
modified T cells retain their redirected T cell specificity toward CD19. A chromium release
assay was conducted to assess the function of the T cells in the expansion product. CD19+
and CD19neg EL4 targets were plated with CAR and mIL15-CAR T cells at across a range
effector to target ratios. As expected, both CAR and mIL15-CAR T cells demonstrated
specific lysis of CD19+ tumor targets across all effector to target ratios with minimal lysis of
CD19neg tumor targets (Fig. 12A). Another measure of T cell responsiveness to TAA was
with the assessment of IFNγ production after six hours of co-culture with CD19+ and
CD19neg tumor targets, and no target and lymphocyte activating cocktail (LAC) served as
baseline and maximal activation references, respectively. Both T cell groups had similar
levels of IFNγ production in response to CD19+ targets and almost no background
stimulation from targets lacking CD19 (Fig. 12B).

Both CAR and mIL15-CAR T cells

maintained redirected specificity toward TAA. Thus, the genetically modified T cells that
were generated are clinically relevant and suitable for adoptive transfer experiments.
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Figure 11. Phenotype of ex vivo expanded mIL15-CAR T Cells. CAR and mIL15-CAR
T cells were phenotyped after expansion at Stim 4 for expression of T cell surface markers
associated with T cell phenotype and differentiation state. (A) The plot indicates
frequencies of cells expressing CD3, CD4, CD8, CD45RA, CD45RO, IL-7Rα, CD62L,
CCR7, CD27, and CD28 markers. Horizontal line indicates the mean value. *P = 0.047, n
> 4, paired t test.
(B) Representative flow plot for one of four normal donors showing
expression of CD62L and CCR7. (C) Representative histograms showing expression of
CD27, CD28, and IL-7Rα (shaded) or isotype control (black), n = 8.
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Figure 12. In vitro effector function is not altered by mIL15 expression. (A) CAR T
cell (left panel) and mIL15-CAR T cell (right panel) specific lysis rates of CD19+ or CD19neg
targets from a four-hour chromium release assay. Data are represented as mean ± SD, n =
3. (B) IFNγ production by CAR and mIL15-CAR T cells after 6 hours of stimulation with
CD19+ (tCD19+ EL4 and NALM-6) or CD19neg (EL4) targets, lymphocyte activating cocktail
(LAC; positive control), or media alone (negative control). Histograms were gated on
CD3+CAR+ cells. Representative flow plots for a normal donor are shown, n = 4.
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2.3 Discussion
Attaining durable and robust CAR T cell persistence post-infusion continues to hamper
ACT therapeutic potential. The approach undertaken in this study to address the issue of
persistence was by co-modification of CAR T cells with a membrane-bound IL-15 fusion
protein that would act to provide supplemental costimulatory signaling. This work aimed to
generate pre-clinical data for the development of a Phase I clinical trial testing the
therapeutic efficacy of mIL15-CAR T cells.

In this section of the study, we aimed to

generate mIL15-CAR T cells suitable for adoptive transfer that would be relevant for
translation to the clinic. Using clinically compliant methods, mIL15 and CAR co-expressing
T cells were generated and numerically expanded to numbers sufficient for clinical
application. We showed that expression of mIL15 on CAR T cells resulted in sustained
pSTAT5 costimulation and mimicked the transpresentation mechanism of IL-15. The data
herein suggest that mIL15-CAR T cells warrant further study of their therapeutic potential in
vivo and will be addressed in Chapter 3.
The foundation of the mIL15 design used in this study was based on a soluble
hyperagonist IL-15/IL-15Rα-sushi fusion protein (RLI) that linked IL-15 to the sushi region
of IL-15Rα (103). It has been identified that the sushi domain within IL-15Rα is responsible
for the binding interactions between the cytokine and IL-15Rα (115). Mortier et al. (103)
demonstrated that this configuration was functional in inducing biological effects (i.e.,
proliferation) and that the linker between the IL-15 and sushi domain did not interfere with
binding interactions. In fact, it was found that the IL-15/IL-15Rα fusion protein containing
the linker was more potent than complexed IL-15 and soluble IL-15Rα (103).

This

advantageous design was incorporated into mIL15 but extended to utilize the full-length
native IL-15Rα structure to secure mIL15 to the cell surface. As it has been demonstrated
that the cytoplasmic portion of IL-15Rα enables trans-endosomal recycling of IL-15 back to
the cell surface (70), we chose to retain the cytoplasmic domain for the potential advantage
it may offer in maintaining mIL15 protein expression.
The configuration of mIL15 demonstrated sustained pSTAT5 levels in mIL15-CAR T
cells in cytokine unsupplemented conditions that abrogated pSTAT5 signal in conventional
CAR T cells (Fig. 10). This indicates that mIL15-CAR T cells are exogenous cytokine
independent and induces signaling of the IL-2Rβ/γC receptor complex.

Since STAT5

signaling has been shown to be the primary pathway activated by IL-15R complex signaling
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(116), this study only assessed pSTAT5 as an indicator of signal transduction activity but by
no means suggests that it is the only signaling molecule induced by mIL15-induced
signaling. It cannot be excluded that other STATs and other pathways, including MAPK
and Akt, are activated and contribute to the biological responses of the modified T cells (27,
108, 117, 118). Rowley et al. (104), assessed cytokine signaling in murine CD8+ T cells
induced by a transpresented membrane-bound IL-15/IL-15Rα similar to our construct but
lacking the cytoplasmic region. In addition to elevated levels of pSTAT5, pSTAT3 was
moderately elevated and pSTAT1 was slightly elevated. Alterations in pAkt and pERK 1/2
were not observed.

However, relative to the positive control (50ng/ml IL-15), pSTAT5

induction appeared to be quite weak (104) indicating that cytokine receptor activation may
have been too low to foster signal transduction across multiple pathways. The study used
CD8 cells isolated from naïve mice which may explain the low level of cellular activation, as
naïve T cells express low levels of IL-2Rβ (52, 119). A chimeric cytokine receptor eliciting
constitutive IL-2Rβ signaling expressed in genetically modified human TCM showed
demonstrable levels of both pSTAT5 and p-Shc (120) illustrating greater and more inclusive
signal transduction in a T cell subset that has higher IL-2Rβ expression. Work investigating
IL-2Rβ signaling at different intensities illustrated altered and divergent pathway utilization
in response to cytokine receptor signal modulation (27). These studies collectively suggest
that in our system: (i) the more moderate IL-2Rβ induction, as suggested by the pSTAT5
signaling, also likely stimulates other pathways to some level and (ii) that our cells would
likely demonstrate varying responsiveness to mIL15 based on the modulation of IL-2Rβ
levels that fluctuate with T-cell differentiation, with the potential of being insensitive to
mIL15, such as with naïve T cells or in circumstances where IL-2Rβ becomes downmodulated.
It has now been established that transpresentation of IL-15 is the primary mechanism
of action in vivo (94, 121) that sensitizes IL-15RαnegIL-15β+γC+ cells to physiologic levels of
IL-15 (103) and induces qualitatively different signaling than equivalent doses of soluble IL15 (71). Since we are mimicking the membrane-bound configuration in our model, it is
likely that for mIL15 to be most effective it should function in the dominant physiologic
manner and engage in transpresentation. In this study, it was demonstrated that mIL15
could indeed be transpresented to mIL15neg T cells and induce a moderate pSTAT5 signal
(Fig. 10C). The capability to transpresent mIL15 may be advantageous in vivo. Studies
have shown that antitumor activity was greater when IL-15 was transpresented to immune
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cells within the tumor site than if monomeric IL-15 was secreted within the tumor
microenvironment (98, 104).

The caveat is that the activity of monomeric IL-15 is

dependent on concentration and thus could potentially match the activity of transpresented
IL-15 if a sufficiently high concentration could be secreted.

However, should a higher

concentration of soluble IL-15 be needed to achieve a therapeutic outcome, it is possible
that the risk for toxicity may increase. It also cannot be excluded that mIL15 may signal to
the modified T cells under additional mechanisms. The crystal structure of IL-15 bound to
IL-15Rα along with biochemical data have suggested the possibility of IL-15 presentation in
cis to the IL-15Rβ/γC complex on a cell (115). Subsequent in vitro analysis has indicated
that cis-presentation can occur (122) and that signal transduction induced in cis versus in
trans results in different dynamics of activation (123). The biological implications of these
varying signaling mechanisms relative to immunotherapeutic strategies remain ambiguous.
Groups have generated CAR T cells that secrete IL-15 (91-93). Regarding expansion
of modified T cells with aAPC stimulation in the absence of exogenous cytokines, our
results (Fig. 8A) were concordant with Dotti et al. (93) in which expansion was achieved.
However, results contrasted with Markley et al. (92) whose IL-15 transduced cell population
declined after an initial phase of expansion and paralleled the 0.1 ng/ml soluble cytokine
control. However, this difference may be due, in part, to the different methods of generating
genetically modified T cells (viral vs Sleeping Beauty systems) and/or propagation
conditions (APC type and supplemented cytokines). Unlike these two studies, we also
observed severe overgrowth of NK cells at early time points during expansion (Fig. 8B,C)
that prompted the use of IL-21 to promote CD8 T cell expansion. The reported synergy
between IL-15 and IL-21 stimulation on the proliferation of murine CD8 T cells (107) was
similarly observed in our mIL15-CAR T cell cultures, where the addition of IL-21 yielded
greater than a log increase in expansion and a shift from a roughly equal mix of CD4 and
CD8 T cells to greater than 80% CD8 T cells. This study showed that mIL15-modification
did not alter redirected T cell specificity, which is in agreement with other studies assessing
IL-15 and CAR co-modified T cells (91, 93, 124). Those studies went on to show in vivo
persistence and antitumor activity that indicates the potential for in vivo performance of
mIL15-CAR T cells, which we will address in Chapter 3.
Numerous studies have shown the importance of IL-15 in generating and supporting
memory CD8 T cell subsets (85, 86), and IL-15 and IL-21 have demonstrated a synergistic
effect on expansion of memory-phenotype CD8 T cells (107). Thus, it was anticipated that
34

a greater frequency of memory-associated markers (i.e., CCR7, CD62L, CD28, CD27, and
IL-7Rα) would be observed in the mIL15-CAR T cell expansion product relative to that of
CAR T cells. Moreover, it has been shown that different cytokines and cytokine cocktails
impact the phenotype of the expanded T cells (53, 125, 126). Therefore, it was somewhat
of an unexpected finding that the ex vivo expansion phenotype of mIL15-CAR and CAR T
cells was relatively unaltered (Fig. 11). Our observation is congruent with a study that
expanded TEM- and TCM-derived CD8+ clones that resulted in similar in vitro phenotype, but
divergent in vivo fitness (50). One explanation for such results may be resultant of culture
methods. Studies that subjected modified T cells to multiple rounds of antigen stimulation
observed fewer differences between various cytokine treatments in the expanded T cell
product (50, 93). Conversely, studies that observed differences due to cytokine treatment
tended to limit antigen stimulation to one round (125, 126). An additional factor that likely
contributes to this observation is that Akt undergoes strong stimulation from integrated
signals generated by cytokine, TCR, and CD28 signaling, which are all triggered during an
encounter with APCs. When the Akt pathway undergoes strong stimulation, activation of
Akt results in translocation to the nucleus where it phosphorylates FOXO1 and inactivates
its pro-memory transcription factor activities, thereby allowing for T cell differentiation to
progress (25, 127). It has been demonstrated that despite the similar in vitro phenotype of
expanded T cells derived from TEM and TCM subsets, their performance markedly differed
upon transfer in vivo into primates.

Only the TCM-derived T cells persisted and some

showed reversion to a memory phenotype (50). Our phenotyping was descriptive of cells
that had recently undergone several rounds of T cell activating stimuli. It is likely that the
phenotype alters once the activating stimuli that dominate the signaling pathways cease,
and it is likely that intrinsic elements then play a role in subsequent phenotypic changes.
This aspect will be further investigated in Chapter 4. The observations by Berger et al. (50),
suggest that the mIL15-CAR T cells generated in this study retain potential for in vivo
persistence and this will be assessed in Chapter 3. In sum, the data presented in this
chapter show the generation of clinically applicable mIL15-CAR T cells that possess
exogenous cytokine-independent costimulation of STAT5.
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CHAPTER 3
In Vivo Persistence and Antitumor Efficacy of mIL15-CAR T Cells

3.1 Introduction
ALL patients presenting with MRD can span a dynamic range of detectable residual
leukemic cells. Initially, MRD was gauged by morphologic remission but now increasingly
sensitive methods are being used to detect leukemic cells.

The range extends from

0.00004% MRD by deep sequencing (128), to 0.001-0.01% by quantitative polymerase
chain reaction and flow cytometry (129, 130), to 5% or higher by cytomorphology (131).
The level of MRD is correlative with relapse, where molecular failure denotes a high-risk
group that tends to be resistant to drugs and thus are candidates for SCT and ACT (132).
Even patients with low-level MRD (0.001% < 0.01%) have clinical significance (133).
Consequently, CAR T cells adoptively transferred to MRD patients are typically in a
relatively TAA-poor environment. These modified T cells are CAR-addicted to receiving
survival signaling and consequently may fail to expand and persist after adoptive transfer.
Clinical trials using CD19 CAR T cells have largely dealt with indolent or chronic B-cell
malignancies rather than ALL and MRD, therefore the much of the existing CAR T cell
persistence data is framed within that context. Brentjens et al. (78) have reported results
from an ongoing phase I clinical trial where CAR T cells (2nd generation CAR 19-28ζ) are
being used to treat ALL patients with relapsed disease or MRD. Infusion of CAR T cells
induced a MRDneg status but it was also observed that higher T cell persistence was
correlated with high tumor burden and there was eventual normal B cell recovery (78)
suggesting that CAR T cells may not persist long enough to prevent relapse at a later time
point and that CAR-dependent signaling is of limited help in this situation. However, longterm therapeutic evaluation wasn’t possible as patients later underwent HSCT. Providing
costimulation outside of the CAR by co-expressing CD80 and 4-1BBL was shown to
improve persistence of infused 1st generation CAR T cells (42). Yet similar to the 2nd
generation T cells, which receive CD28 costimulation via CAR activation, the addition of
external CD80/4-1BB costimulation did not maintain durable T cell persistence and only
aided T cells in a TAA-dependent manner. It is apparent that it is not a matter of just
providing costimulation, but rather providing a signal that is context-dependent and suits the
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conditions at a given time. IL-15’s pleiotropic activities support T cells both during T cell
encounter with antigens as an inflammatory cytokine, as well as in the absence of antigen
as a homeostatic cytokine (86, 88). Hence, IL-15 may collaborate appropriately with T cells
in the variable conditions associated with MRD.
In Chapter 2, we generated clinically relevant mIL15-CAR T cells that displayed
sustained pSTAT5 suggesting that they may be more suitable than conventional CAR T
cells in a low-TAA environment. To gather further preclinical data on mIL15-CAR T cells,
we subsequently examined these cells in vivo. Their potential for in vivo performance is
supported by studies demonstrating that IL-15 can enhance in vivo antitumor activity as well
as support homeostasis of CD8 TCM, which persist long-term without requiring contact with
antigen (88, 134).

We, therefore, hypothesize that mIL15-CAR T cells will possess

enhanced in vivo antitumor activity and be capable of persisting in vivo irrespective of TAA.

3.2 Results
3.2.1 Enhanced In Vivo Persistence of mIL15-CAR T cells in a High Tumor Burden Model
CARs have been designed to provide survival signaling upon engagement with TAA for
improved in vivo persistence (41). In a high-dose disseminated leukemia model (1 x 105
NALM-6 tumor cells), it was previously shown that CAR T cells mediate significant
antitumor activity (53).

However, in vivo persistence of these cells in the presence of

abundant tumor antigen remained unknown and had any assessments been made the
weekly T cell infusions would have been confounding. Here we sought to (i) determine
whether conventional CAR T cells persisted for any length of time in this high tumor burden
model and (ii) whether additional costimulation from mIL15 would enhance CAR T cell
persistence under prevalent TAA. CAR and mIL15-CAR T cells, co-modified with firefly
luciferase (ffLuc), were adoptively transferred into NSG mice given a high-dose
disseminated NALM-6 leukemia (1 x 105 cells i.v. injected; Fig. 13A). T cell persistence
was longitudinally assessed by bioluminescent imaging (BLI) for T cell-associated ffLuc
activity. Already on the first day after T cell infusion, CAR T cell persistence was observed
to be lower than that of the mIL15-CAR T cells, with measured flux ranging 7.5 x 105 – 8.9 x
105 p/s/cm2/sr and 2.8 x 105 – 4.0 x 106 p/s/cm2/sr, respectively. The mIL15-CAR T cell-
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Figure 13. Enhanced in vivo persistence of mIL15-CAR T cells when tumor antigen is
prevalent. (A) Schematic of experiment. NSG mice were infused i.v. with 1 x 105 CD19+
NALM-6 cells followed the next day by i.v. infusion of 2 x 107 CAR+ffLuc+ T cells with or
without co-expression of mIL15. Infused T cell number was based on CAR+ T cells. (B)
Longitudinal BLI was performed to monitor T cell persistence from days 1 - 11. Images
represent photon flux from T cell-derived ffLuc activity. (C) Longitudinal plotting of T cell
flux. Data are represented as mean ± SD, n = 5. *P = 0.0009, unpaired t test.
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treated mice had BLI that was detected during the course of the study and remained with
significantly higher flux than CAR T cell treated mice at day 11 (P = 0.0009; Fig. 13B,C). At
14 days, the mice were sacrificed and peripheral blood, spleen, and bone marrow were
harvested to assess the presence of human CD3 cells.

No human CD3+ cells were

detected in the blood or tissues of mice treated with CAR T cells. Mice receiving mIL15CAR T cells showed human CD3+ cells at frequencies of 9.1% - 52.8% in the blood, 0.8% 11.0% in the spleen, and 0.4% – 1.6% in the bone marrow. Significant levels of chimerism
were observed as compared to CAR T cell (P < 0.05, P < 0.05, P < 0.001, respectively) and
tumor only-treated mice (P < 0.05, P < 0.05, P < 0.001, respectively; Fig. 14A,B). This type
of disseminated tumor model using 1 x 105 Nalm-6 cells is relatively aggressive with
mortality occurring in untreated mice around 21 days after tumor injection. Other studies
using this tumor model treated mice with multiple CAR T cell infusions and while antitumor
effects were observed, it was not a curative model (53). Hence, it was not unexpected that
one infusion of mIL15-CAR T cells did not show significant antitumor activity. Together
these data show that despite the presence of CAR-activating TAA, mIL15-CAR T cells but
not CAR T cells persisted.
3.2.2 In Vivo Persistence and Antitumor Efficacy of mIL15-CAR T Cells in a Low Tumor
Burden Model
Assessment of mIL15-CAR T cell persistence was next performed in a preventative lowTAA tumor model to assess transferred T cell engraftment and antitumor activity. In such a
scenario, adoptively transferred T cells may not immediately encounter CAR-stimulatory
TAA to receive survival signaling; hence, persistence may not be sustained. It has been
previously shown that adoptively transferred CAR T cells (expressing a second generation
CAR) only demonstrated TAA-dependent persistence (41), which thus poses concern for
infusing CAR T cells into a low or sequestered TAA environment. In this preventative tumor
model, CAR-ffLuc and mIL15-CAR-ffLuc T cells were first engrafted in mice followed by i.v.
dissemination of a low-dose of NALM-6 cells (1 x 104 cells; Fig. 15A). CAR T cell BLI was
undetectable at day six and only mIL15-CAR T cells persisted until the day of sacrifice (Fig.
15B,C). Total body flux was determined and was defined by a region of interest (ROI) that
included the body and head, but not the tail. Total body flux showed mIL15-CAR T cell
levels stabilize after 19 days post-infusion and remained significant at day 35 (P = 0.0027;
Fig. 15C). BLI images of mIL15-CAR T cells at days 30 and 35 showed localization of cells
to the tibia and foot region. Aggregations of T cells in those areas could putatively be within
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Figure 14. Tissue distribution of persisting mIL15-CAR T cells under high tumor
burden. At day 14, tissues and blood were harvested and analyzed by flow cytometry for
the presence of CD3+ T cells in the three treatment cohorts. (A) Representative flow plots
show CD3 frequencies in the blood, spleen, and bone marrow, n = 5. (B) Plotted CD3
frequencies in the blood, spleen, and bone marrow from (A). Data are represented as
mean ± SD, n = 5. *P < 0.05, ***P < 0.001, one-way ANOVA.
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Figure 15. Enhanced in vivo persistence of mIL15-CAR T cells under low tumor
burden. (A) Schematic of experiment. NSG mice were first infused i.v. with 2 x 107
CAR+ffLuc+ T cells with or without co-expression of mIL15. Infused T cell number was
based on CAR+ T cells. After six days of engraftment, 1 x 104 rLuc+NALM-6 (CD19+) cells
were i.v. injected.
(B) Longitudinal BLI was performed to monitor T cell persistence.
Images represent photon flux from T cell-derived ffLuc activity. (C) Longitudinal plotting of
T cell flux derived from ROIs encompassing the body (left panel) and the femurs (right
panel). Background luminescence (grey area) was derived by imaging mice that received
D-luciferin, but which did not receive ffLuc+ T cells. Data are represented as mean ± SD, n
= 4 – 5. **P = 0.0027, ***P = 0.0007, unpaired t test.
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the bone marrow and thus may also involve the femur region. Another ROI was created to
hone in on each of the back legs and included the femur, tibia, and foot. The mIL15-CAR T
cell flux from this region indicated stable engraftment in the bone marrow by the fifth day
after T cell infusion and remained at a significant level at day 35 (P = 0.0007). The flux
data do not indicate any trends of sustained uncontrolled exponential growth. Interestingly,
while bone marrow flux remained persistent between days five thru 14, there was an
observed sharp decline in mIL15-CAR T cells elsewhere in the body (Fig. 15C).
Tumor flux (NALM-6 rLuc activity) remained significantly lower in the mIL15-CAR mice
compared to CAR-treated mice and tumor only mice demonstrating the antitumor activity of
mIL15-CAR T cells (both P < 0.0001; Fig. 16A,B).

Tumor eradication by mIL15-CAR T

cells was corroborated by CD19 staining of peripheral blood, spleen, and bone marrow. No
significant CD19+ tumor burden (< 0.5%) was detected in the blood, spleen bone, or
marrow (P < 0.05, P < 0.0001, P < 0.01, respectively; Fig. 17A,B). Notably, despite the
tumor cells elimination from all of these locations, the mIL15-CAR T cells remained
localized to the bone marrow (range: 0.1% - 2.8% of total cells), but their chimerism was at
a significant frequency (P = 0.0050; Fig. 17A,C). No human CD3+ cells were detected in
the spleen or blood (Fig. 17A). The CD3 flow cytometry data corroborated the flux data
that indicated a peripheral decline of mIL15-CAR T cells while the bone marrow
environment remained stable.
Long-term evaluation of survival in this model showed enhanced therapeutic efficacy of
mIL15-CAR T cell treatment resulting in 43% survival at 98 days as compared to 100%
mortality in all other treatments by day 34 (Fig. 18). Survival of mice treated with mIL15CAR T cells was significantly enhanced over mice treated with CAR-T cells (P = 0.045).
One of the three surviving mice had a detectable population of human CD3+CD8+ cells at
0.220% in the bone marrow (data not shown). These data together indicate that mIL15CAR T cells were capable of engrafting and mounting an antitumor response in a low TAA
environment thereby making them more therapeutically effective in mice than conventional
CAR T cells.
3.2.3 In Vivo Persistence of mIL15-CAR T Cells is CAR-independent
To assess if mIL15-CAR T cells can indeed persist long-term in vivo without the need
for CAR-dependent survival signaling, modified T cells (mIL15+/negCAR+ffluc+) were infused
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Figure 16. In vivo anti-tumor activity of mIL15-CAR T cells. (A) Longitudinal BLI was
performed to monitor rLuc+NALM-6 tumor cell persistence. Images represent photon flux
from NALM-6 cell-derived rLuc activity. (B) Longitudinal plotting of tumor flux. Data are
represented as mean ± SD, n = 4-5. ****P < 0.0001, one-way ANOVA.
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Figure 17. mIL15-CAR T cells clear tumor and remain localized to the bone marrow
after an anti-tumor response. At day 36, tissues and blood were harvested and analyzed
by flow cytometry for the presence of CD3+ T cells and CD19+ tumor cells in the three
treatment cohorts. (A) Representative flow plots show frequencies of CD3 and CD19 in the
peripheral blood (n = 3-5), spleen, and bone marrow, n = 4-5. (B) Frequency of CD19+ cells
in the blood (n = 3-5), spleen, and bone marrow, n = 4-5. (B) Plotted CD3+ cell frequencies
in the bone marrow. Data are represented as mean ± SD, n = 4-5. *P < 0.05, **P < 0.01,
****P < 0.0001, ns = not significant, one-way ANOVA (B), unpaired t test (C).
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Figure 18. Efficacy of tumor immunotherapy with mIL15-CAR T cells. Using the low
tumor model, long-term overall survival of mice was assessed to day 98. The experiment
was carried out similarly to the previously described low tumor model. Mice were engrafted
with mIL15-CAR T cells (n = 7), CAR T cells (n = 8), or no T cells (n = 8) followed by NALM6 tumor challenge. Fractions in parentheses represent the proportion of mice surviving to
day 98. *P = 0.045 (mIL15-CAR versus CAR T cell treatment), log-rank (Mantel-Cox).
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into mice with no tumor or exogenous cytokine support and monitored for 48 days (Fig.
19A). Akin to the previous results, CAR T cell persistence was not observed in this model
after day zero, whereas mIL15-CAR T cells exhibited sustained persistence throughout the
duration of the experiment (Fig. 19B).

Both total body and femur flux of mIL15-CAR T

cells at day 47 were at levels significantly above the baseline values of CAR T cells (P =
0.0128 and P = 0.002, respectively; Fig. 19C), but were not indicative of any trends of
sustained and uncontrolled exponential growth. Blood and tissue analysis revealed that
mIL15-CAR T cell engraftment was significant and primarily localized to the bone marrow
and spleen (P = 0.0027 and P = 0.0081, respectively, Fig. 20). Although inconsistent
chimerism was observed in the blood, it was associated with higher chimerism in the spleen
and liver, as observed by BLI.

Thus, it is suggested that mIL15 provides sufficient

costimulation to sustain T cell persistence in a CAR-independent manner, which may make
these T cells a more appropriate option for adoptive transfer in a low or sequestered TAA
environment as may be the case with MRD.

3.3 Discussion
Work in this chapter builds upon results from Chapter 2 providing the preclinical
rationale for developing a phase I clinical trial using mIL15-CAR T cells to treat MRD. In
contrast to conventional CAR T cells, mIL15-CAR T cells persisted in mice independent of
the presence of TAA and eradicated CD19+ leukemic cells in a low-dose disseminated
tumor model indicating their suitability for translation to the clinic for the treatment of MRD.
CARs are designed with modular costimulatory endodomains, which in our model
includes CD3ζ and CD28 signaling, to supply signals one and two for T cell activation (41).
We observed that in the presence of abundant tumor, mIL15-CAR T cells showed
enhanced persistence (Fig. 13,14) over the conventional CAR T cells, suggesting that IL-15
signaling provided a third additive costimulatory signal. The mechanism of this persistence
was not investigated, but may be related to the prevention of AICD as IL-15 is reported to
play a key role in resisting it (87). In addition to enhanced persistence under low tumor
burden, mIL15-CAR T cells mediated significant antitumor activity (Fig. 15-17). These
results are in concordance with other studies that evaluated CAR T cells modified to
secrete monomeric IL-15 in leukemia models (92, 93).

In those studies, CAR T cell

persistence was assessed in reference to tumor exposure. We additionally examined
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Figure 19. Long term in vivo engraftment of mIL15-CAR T cells in the absence of
tumor. (A) Schematic of experiment. NSG mice were infused i.v. with 2 x 107 CAR+ffLuc+
T cells with or without co-expression of mIL15. Infused T cell number was based on CAR+
T cells. (B) Longitudinal BLI was performed to monitor T cell persistence from days 0 - 47.
Images represent photon flux from T cell-derived ffLuc activity. (C) Longitudinal plotting of
T cell flux. Background luminescence (gray shaded) was defined by flux obtained from
mice not receiving ffLuc+ T cells. These mice were given D-luciferin and imaged along with
the treatment mice. Data are represented as mean ± SD, n = 5, and representative of two
similar experiments. *P = 0.0128, **P = 0.0021, unpaired t test.
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Figure 19. Long term in vivo engraftment of mIL15-CAR T cells in the absence of
tumor
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Figure 20. In vivo localization of mIL15-CAR T cells in the absence of tumor. At day
48, tissues and blood were harvested and analyzed by flow cytometry for the presence of
CD3+ T cells in mice treated with either mIL15-CAR or CAR T cells. Representative flow
plots (left panel) show frequencies of CD3 in the peripheral blood, spleen, and bone
marrow. Plotted frequencies of CD3+ cells in the tissues and blood (right panel). Data are
represented as mean ± SD, n = 5, and representative of two similar experiments. **P =
0.0027 (bone marrow), **P = 0.0081 (spleen), ns = not significant, unpaired t test.
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persistence in the absence of TAA-dependent CAR signaling, where in the clinical setting of
disease relapse or MRD, T cells may not encounter TAA for some time. We confirmed that
mIL15-CAR T cells persisted independent of TAA (Fig. 19,20) and it is concordant with
other studies where engraftment was achieved by T cells engineered to exploit the IL-2/15
cytokine signaling pathway by the expression of constitutively active STAT5 (135) or a
chimeric cytokine receptor mediating constitutive CD122 signaling (120). Together, it is
indicated that costimulation via IL-15Rβ/Cγ signaling is sufficient to support CAR T cell
persistence allowing for continued antitumor activity and that persistence could be
maintained in a low or no tumor environment.
Notably, we observed different levels and patterns of engraftment of mIL15-CAR T
cells in this preventative low-dose tumor model (Fig. 15,17) compared to the no tumor
engraftment model (Fig. 19,20).

T cell abundance was inferred from the observed

correlation of T cell levels with photon flux (42, 136), as well as our observations of photon
flux and detected CAR T cell chimerism at sacrifice.

We noted that mIL15-CAR T cell

abundance during the antitumor response declined (Fig. 13,15) which contrasted other
results of IL-15-secreting CAR T cells that showed expansion, or increased flux signal, in a
tumor model (93). These observations highlight the issue of identifying what costimulation
type and amount is sufficient in a tumor microenvironment to achieve optimal T cell function
and expansion. Our in vivo model used Nalm-6 tumor cells that lack the CD80 and CD86
costimulatory molecules (137), whereas the other model (93) used Daudi and Raji cells
which express both costimulatory ligands (137, 138). Moreover, it has been shown that
enforcing expression of CD80 on Nalm-6 provided adequate costimulation to restore
antitumor responses of CAR T cells (137).

Nalm-6 tumor cells have been shown to

suppress the up-regulation of costimulatory molecules on T cells affecting T cell biological
responses (139).

This may be a factor that contributed to (i) the extremely limited

persistence of CAR T cells in the presence of TAA and (ii) the lack of expansion of mIL15CAR T cells in response to TAA. These data cumulatively suggest that expression of
mIL15 provides significant additive costimulation to enable persistence, but it is not fully
compensatory under certain immunosuppressive conditions and emphasizes the
importance of continued investigation of CAR designs that can provide fully competent T
cell activation.
Another important observation was the differential chimerism that occurred in the
preventative low-tumor mouse model as compared to tumor-free engraftment.
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Quite

strikingly, after the antitumor response, mIL15-CAR T cells in that model remained localized
only to the bone marrow (Fig. 15,17). In contrast, mIL15-CAR T cells that engrafted in the
absence of tumor were detected in the peripheral blood and spleen in addition to the bone
marrow (Fig. 19,20). The observed retention of CAR T cells to the bone marrow was
congruent with a syngeneic murine model of CAR T cells targeting B-ALL (140).

In

contrast, in a lymphoma model using the more costimulatory Raji tumor cell line in NSG
mice, a definitive population of IL-15 secreting CAR T cells were observed in the spleens at
over 106 days after tumor challenge (92). Perhaps this contrasting observation is due to
the different time points of observation, as our results are reflective of T cell status at 36
days after tumor challenge.

Assessments of murine CD8 T cells in the bone marrow

suggest that this site is a niche for antigen-independent proliferation of memory CD8 T cells
that display a more activated state than those from peripheral lymphoid organs (141, 142).
Hence, it is plausible that in our model, repopulation of the spleen could occur at a later
time. An additional aspect proposed to operate concomitantly is that repetitive antigen
stimulation, and perhaps the suppressive nature of the Nalm-6, promoted a high degree of
differentiation with subsequent loss of terminally differentiated cells. The observed bone
marrow-resident population remaining after tumor challenge may not have undergone as
extensive a differentiation, putatively due to being less differentiated at the time of infusion,
having less contact with antigen, and/or having sufficient mIL15 costimulation.
Nonetheless, this population remained to repopulate and thus resided in the bone marrow.
It has been clearly illustrated that repetitive antigen stimulation induces differentiation that
consequently affects function and longevity (17, 21, 143).

Hombach et al (144)

+

demonstrated that the transfer of less differentiated CCR7 CAR T cells results in a
CCR7neg phenotype after exposure to antigen. The use of a 3rd generation CAR with CD3ζ,
CD28, and OX40 signaling supported the survival and effector function of these responding
CCR7neg cells (144). Pairing mIL15 with this 3rd generation CAR may assist in maintaining
or even boosting CAR T cell levels during antitumor responses, hence yielding a larger
resident population after the tumor is cleared. A readily translatable approach is to pair
mIL15 with the 2nd generation CAR that has CD3ζ and 4-1BB signaling capacity. This CAR
is currently being used in clinical trials and has led to objective clinical responses (77, 145)
and direct comparisons indicate that 4-1BB signaling may prove to be superior to CD28
signaling in CAR T cells both in vitro (146) and in vivo (H. Singh, unpublished data).
Moreover, IL-15 has been shown to induce 4-1BB on T cells and 4-1BB/4-1BBL interactions
sustain memory CD8 T cell survival independent of antigen (147). Cancer immunotherapy
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with a targeted antibody fusion protein presenting IL-15 and 4-1BBL improved therapeutic
efficacy over each as an individual treatment (148). The cooperative relationship between
IL-15 and 4-1BB strongly suggests that combining mIL15 with the 4-1BB-signaling CAR
holds significant potential for augmenting therapeutic response.
MRD detected by sensitive methods such as deep sequencing can detect extremely
low levels of TAA in a patient (0.00004% MRD) (128) making delayed TAA encounter for
CAR T cells a likely scenario. Our assessment of mIL15-CAR antitumor activity, therefor,
utilized a preventative disseminated tumor model in which infused T cells would not
immediately encounter TAA, and when tumor was present it was initially at a low level.
Testing mIL15-CAR T cell antitumor activity could also have been diversified to include
established subcutaneous tumor models using Raji or Daudi cell lines to assess antitumor
activity with sequestered TAA. An immunocompetent syngeneic B-ALL murine model (140)
could be used to assess the performance of mIL15-CAR T cells in treating MRD, which may
be a more clinically relevant assessment of performance of adoptively transferred CAR T
cells.

This mouse model of B-ALL recapitulates disease pathology and mice may be

conditioned with chemotherapy prior to adoptive T cell transfer for treating residual disease.
Other elements to disease treatment with mIL15-CAR T cells could also be studied with this
model, including immune reconstitution post-conditioning and adoptive transfer, and T cell
memory subset composition throughout and antitumor response.

The caveat with this

approach is the requisite development of the murine CAR and mIL15 for use in this model.
The results described in this chapter showed long-term persistence of mIL15-CAR T
cells and potent antitumor activity that enhanced therapeutic efficacy, as seen by significant
long-term survival after tumor challenge. Together this indicates that mIL15-CAR T cells
would be suitable for the treatment of MRD or sequestered TAA and supports the impetus
to translate this approach to the clinic.

However, it must be considered that further

improvements may yet be made regarding enhancing the magnitude of T cells during and
after tumor challenge in an immunosuppressive tumor model. Therefore, determining the
optimal CAR signaling to pair with mIL15 remains an important consideration.
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CHAPTER 4
Characterization of Long-term Persisting mIL15-CAR T Cells

4.1 Introduction
Intrinsic and extrinsic factors coalesce to dictate the fate of T cells and shape the
composition of heterogeneous populations of effector and memory CD8 T cells.

TCR

signaling, costimulatory ligands, and inflammatory cytokines are the extrinsic factors
providing the three signals required for T-cell activation (149-151).

Additionally, γC

cytokines are integral in T cell proliferation, survival, and memory. Intrinsically, numerous
transcription factors have roles in T cell differentiation, including T-box expressed in T cells
(T-bet), EOMES, T-cell factor 1 (TCF-1), BLIMP-1, and BCL-6 (reviewed in reference (16)).
The unique amalgam of signals during antigen encounter results in varying degrees of
differentiation with some T cells intrinsically biased toward a long or short-term fate (25, 26,
152). T cell differentiation is accompanied by phenotypic and functional changes. Less
differentiated cells express CD62L and CCR7, have longevity, and can produce IL-2;
whereas, those features are lost and effector functions are gained as differentiation
progresses (16, 17). These functional features of T cell differentiation have implications on
the therapeutic efficacy of ACT. It has been demonstrated that less differentiated T cells
possess higher therapeutic potential (50, 52, 153) and the immunotherapy field is
evaluating the importance of preserving T cell memory potential. Little knowledge exists on
the characteristics and intrinsic mechanisms of long-term persisting CAR T cells.
Moreover, questions exist as to the state of cytokine-modified CAR T cells, being that they
receive continual cytokine signaling. With IL-15’s well-known effects on the homeostatic
maintenance of TCM, we therefore hypothesize that persisting mIL15-CAR T cells will
possess attributes associated with TCM. Moreover, intrinsic elements will be representative
of their differentiation state.
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4.2 Results
4.2.1 Modeling Long-term Persistence In Vitro
Observing the long-term persistence of mIL15-CAR T cells in vivo, we aimed to model
this in an in vitro setting to enable characterization of the persisting T cells. Expanded
(Stim 4) mIL15+/negCAR+ T cells were put into long-term culture without further antigen restimulation. CAR T cells received IL-15 complex or no cytokine supplementation while
mIL15-CAR T cells received no exogenous cytokines and were maintained for 65 days
(Fig. 21A). Significant persistence of mIL15-CAR T cells was observed in comparison to
cytokine unsupplemented CAR T cells, which were rapidly lost (P < 0.0001; Fig. 21B). By
day 65 mIL15-CAR T cells appeared to show a gradual decline from their initial numbers (P
< 0.01) whilst CAR T cells receiving IL-15 complex demonstrated an increased fold change
in cell number resulting in significantly differing levels of persistence between the two
groups (P < 0.001; Fig. 21B). Unlike the mIL15-CAR T cells, it appeared that soluble
cytokine supplementation enabled CAR T cells to sustain growth within the first 15 days (P
< 0.05), after which both groups did not demonstrate significant changes in cell number
(Fig. 21B). CAR T cells supplemented with IL-2 paralleled the response of CAR T cells
supplemented with IL-15 complex, suggesting that in the vitro T cell maintenance was not
specific to IL-15 or mIL15 (data not shown). Moreover, the observed soluble cytokineinduced T cell growth may have been due to stronger cytokine signal induction from the
dosing used, as pSTAT5 induction was stronger with the use of soluble cytokines (Fig. 10
and unpublished observations). Further analyses of T cells persisting at the end of the
withdrawal experiment refer to the cells as ‘WD-T cells’ to denote this day 65 time point of
the samples. Annexin V staining of cells remaining at the end of the experiment indicated
that both WD-CAR and WD-mIL15-CAR T cells had similar viability (Fig. 21C). These data
suggest that WD-mIL15-CAR T cells had sufficient costimulation to sustain T cell viability,
but had inadequate stimulation for the growth that the exogenous cytokines induced and is
a desirable characteristic in the context of homeostasis and safe long-term in vivo
persistence.
4.2.2 CAR and mIL15 Expression and Functionality in WD-T Cells
While persistence is the primary aim of this study, surviving T cells would be of no
clinical utility if they down-modulated expression of the CAR or mIL15, and/or if these
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Figure 21. Modeling long-term persistence in vitro. (A) Schematic summarizing the
withdrawal experiment for assessing long-term persistence of mIL15+/-CAR+ T cells after
withdrawal of antigen. T cells obtained for the withdrawal assay had been stimulated on
aAPC four times and maintained for 10 days with respective cytokines used during
expansion. During the 65-day exogenous cytokine withdrawal, the mIL15-CAR T cells
received no cytokine supplementation while CAR T cell control treatments received either,
IL-15 complex (5ng/ml) or no cytokines. (B) Fold change in number of T cells at 15, 30, 50,
and 65 days during withdrawal conditions. Data represent mean ± SD, n = 3. *P < 0.05,
****P < 0.0001, ns = not significant, two-way RM ANOVA (Tukey’s post-test). (C)
Representative histogram showing Annexin V staining (left panel) and plotted live T cell
(Annexin Vneg) frequencies (right panel).
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molecules are non-functional. CAR and mIL15-CAR T cells entered the withdrawal assay
expressing high levels of CAR (97% - 98% and 92% - 98%, respectively; Fig. 22A). The
majority of WD-CAR and WD-mIL15-CAR T cells retained CAR expression (61 ± 20% and
82 ± 19%, respectively; mean ± SD; Fig. 22B,C). Unexpectedly, the WD-mIL15-CAR T
cells showed a low surface expression of mIL15 (range: 13% - 81%). However, intracellular
levels were detected at moderately high levels (range: 54% - 98%; Fig. 22B,D). Despite
the majority of mIL15 being detected intracellularly, expression levels were sufficient to
induce cytokine signaling that, compared to unsupplemented WD-CAR T cells, yielded
elevated levels of pSTAT5 and Bcl-2, a pro-survival molecule downstream of STAT5
signaling (154-156) (Fig. 23A). Whether the intracellularly detected mIL15 participated in
the induction of cytokine signaling is unknown. IL-15, bound to IL-15Rα, is known to persist
without degradation in endosomes and recycle to the surface (71), thus allowing for the
possibility that recycling kinetics may have altered. Notwithstanding, the pSTAT5 pathway
was transducing cytokine signaling in WD-mIL15-CAR T cells. To be of benefit as a clinical
application, CAR T cells must remain responsive to TAA, to which both WD-CAR (cytokine
supplemented) and WD-mIL15-CAR T cells produced equivalent levels of IFNγ in response
to CD19+ targets (P > 0.05; Fig. 23B). Thus, despite the long-term absence of TAA, WDmIL15-CAR T cells retained functional mIL15 and redirected CAR responses, which
furthers their potential clinical utility.
4.2.3 Persistence of mIL15-CAR T Cells Does Not Involve Initial Molecular Programming
With deference to the crucial role that IL-15 plays in the homeostasis of CD8+ T cell
memory (85, 86), it was postulated and shown that mIL15 could support long-lived T cells in
the absence of CAR or TCR signaling (Fig. 19B,C; Fig. 21B). Subsequent investigation
sought to determine whether these long-lived T cells possessed traits associated with CD8+
T cell memory. Some studies suggest that within the heterogeneous population of effector
T cells there may be intrinsic programming predetermining cells to long or short-lived fates
(157). Despite the observed phenotypic similarities between CAR T and mIL15-CAR T
cells (Fig. 11), the possibility existed for cell intrinsic factors to play a role in the observed
prolonged persistence of WD-mIL15-CAR T cells. To assess whether mIL15 conferred a
survival advantage via molecular programming in the infusion product (Stim 4 expanded T
cells), we compared CAR and mIL15-CAR T cells by digital gene expression analysis using
a 479 gene lymphocyte-specific CodeSet (Appendix 1). Surprisingly, we found only four
genes differentially expressed (2-fold cutoff, P < 0.01, FDR q value < 0.05; Appendix 2),
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Figure 22. CAR and mIL15 expression on WD-T cells. (A) Representative flow plots
showing CAR and mIL15 expression on T cells during the withdrawal assay at day 0 and
(B) at day 65 (top panel), with FLAG staining detecting intracellular localization of mIL15
(bottom panel). (C) Frequencies of T cells staining positive for CAR. Horizontal bar
represents the mean. (D) Frequencies of T cells staining positive for surface-detected and
intracellularly-detected mIL15.
Horizontal bar represents the mean.
Data are
representative of 3 donors.
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Figure 22. CAR and mIL15 expression on WD-T cells
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Figure 23. WD-mIL15-CAR T cells maintain pSTAT5 induction and antigen-specific
reactivity. WD-CAR T cells supplemented with IL-15 complex and WD-mIL15-CAR T cells
were assessed for functionality after antigen withdrawal. (A) Continued functionality of
mIL15 was validated by phosflow of pSTAT5 and intracellular staining for Bcl-2 expression.
For the pSTAT5 assay, samples were serum and cytokine starved for 12 hours. CAR T
cells treated with soluble IL-15 (100ng/ml) 1-hour prior to fixation served as the positive
control. For Bcl-2 analysis, two days prior to Bcl-2 staining, some CAR T cells were
washed and resuspended in complete media without cytokine supplementation to serve as
the baseline control. The representative histograms show the flourescence intensity of
pSTAT5 (left panel) and Bcl-2 (right panel). (B) IFNγ production by WD-T cells stimulated
for 6 hours with CD19+ (tCD19+ EL4 and NALM-6) or CD19neg (EL4) targets, LAC (positive
control), or media alone (negative control). Histograms were gated on CD3+ and CAR+
cells. All data are representative of three donors.
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Figure 23. WD-mIL15-CAR T cells maintain pSTAT5 induction and antigen-specific
reactivity
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with the difference in IL7ra expression corroborated by phenotyping (Fig. 11A). These
results indicated no overt molecular survival advantage of mIL15-CAR T cells.
4.2.4. Molecular Profiling of WD-mIL15-CAR T Cells Describes a State of Low
Differentiation
With the indistinguishable nature of CAR and mIL15-CAR T cells, subsequent
investigation focused on identifying attributes of WD-mIL15-CAR T cells that are associated
with long-lived T cells. Stark differences emerged when comparing long-term persisting
WD-mIL15-CAR to Stim 4 mIL15-CAR T cells, where 98 genes were significantly
differentially expressed (2-fold cutoff, P < 0.01, FDR q value < 0.05; Fig. 24A,B).
Functional gene annotation was performed using DAVID Bioinformatics Resources
(http://david.abcc.ncifcrf.gov) to cluster the significant genes into broad categories (158,
159). The most notable groups included the following: induction of apoptosis, regulation of
cytokine production, homeostatic process, regulation of cell size, regulation of T cell
differentiation, positive regulation of T cell activation, and Wnt signaling pathway (Fig. 24C).
These functional clusters are relevant to processes affecting T cell differentiation status and
suggest that aspects of differentiation may be a key factor involved in WD-mIL15-CAR T
cell persistence.
Transcripts encoding key regulators of effector differentiation and related cytotoxic
molecules showed diminished expression in WD-mIL15-CAR T cells: Tbx21 (encoding TBET), Prdm1 (encoding BLIMP-1), Il2ra (encoding IL-2Rα), Infg (encoding IFNγ), Prf1,
Gnly, Gzmh, Gzmb, Cd11b, and Ctla4 (Fig. 24A; Fig. 25A,B). Inversely, a pro-memory
transcriptional profile, indicative of a low level of differentiation, was represented by WDmIL15-CAR T cells: Tcf7 (encoding TCF-1), Eomes, Bcl2, Bach2, Lef1, Bcl6, Foxp1, Ccr7
(encoding CCR7), and Il7ra (encoding IL-7Rα) (Fig. 24B; Fig. 25A,B) (16, 52, 160-163).
The observed down-regulation of Sell (encoding CD62L) and Cd28 (encoding CD28) by
WD-mIL15-CAR T cells did not conform to the pro-memory transcriptional profile. IL-15 has
been implicated in the generation of CD28neg CD8 T cells (164-166). Unexpectedly, Foxo1
did not show a paralleled increased up-regulation with the other genes in the pro-memory
profile, rather a non-significant decrease of 1.5-fold was observed in WD-mIL15-CAR T
cells relative to mIL15-CAR T cells. This observation is rather perplexing as Foxo1 is a
transcription factor central to memory T cell differentiation in that it directly or indirectly
regulates the expression of Tcf7, Eomes, Sell, Ccr7, and Il7ra (163, 167, 168). Instead,
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Figure 24. Differential gene expression between mIL15-CAR T cells and long-term
persisting WD-mIL15-CAR T cells. Multiplexed digital gene profiling was used to analyze
gene expression for mIL15-CAR T cells obtained from cultures after the 4th aAPC
stimulation cycle and WD-mIL15-CAR T cells persisting long-term (> 65 days) after antigen
and exogenous cytokine withdrawal. Heat maps of significantly differentially expressed
genes (2-fold differential expression cutoff, P < 0.01, and FDR q value < 0.05) that were (A)
down-regulated and (B) up-regulated in WD-mIL15-CAR T cells relative to mIL15-CAR T
cells, n = 3. (C) All significantly differentially expressed genes were functionally classified
using DAVID Bioinformatics Resources. Select groups relevant to T cell persistence and
differentiation status are displayed.
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Figure 24. Differential gene expression between mIL15-CAR T cells and long-term
persisting WD-mIL15-CAR T cells
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Figure 25. Molecular profiling of WD-mIL15-CAR T cells describes a state of low
differentiation. Comparison of select significantly differentially expressed genes between
expanded mIL15-CAR and persisting WD-mIL15-CAR T cells. The selected genes are
associated with long-lived central memory or short-lived effector T cells, which are
described as having low and high levels of differentiation, respectively. (A) Plots of
normalized mRNA counts for selected genes from the multiplexed digital gene profiling.
Lines connecting data points match donors. (B) Classification of the subset of genes in (A)
by function. Bars represent the mean fold change in gene expression of WD-mIL15-CAR T
cells relative to mIL15-CAR T cells. Asterisk indicates protein expression was verified by
flow cytometry.
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Figure 25. Molecular profiling of WD-mIL15-CAR T cells describes a state of low
differentiation
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Foxo3 was significantly up-regulated 2.1-fold (Fig. 24B), but its role in CD8 T cell
differentiation remains ill-defined.
Some transcription factors have been found to function in pairs with graded reciprocal
activity controlling effector and memory T cell differentiation. The ratio of T-bet and Eomes
is one such pairing, with the ratio lowest in early memory T cell differentiation states (16,
26). We observed that mIL15-CAR and WD-mIL15-CAR T cells indeed had altered mRNA
ratios of T-bet and Eomes (20:1–94:1 and 2:1–9:1, respectively), with WD-mIL15-CAR T
cells representative of the low ratio associated with memory stages. Together these data
suggest that in the absence of antigen WD-mIL15-CAR T cells exhibit an overall profile that
is characteristic of less differentiated T cells.
4.2.5

WD-mIL15-CAR T Cells Possess Phenotypic and Functional Characteristics

Associated with a Low Differentiation State
Protein expression of specific transcription factors and surface markers associated with
T cell differentiation status corroborated the observed low differentiation molecular profile of
WD-mIL15-CAR T cells. Memory-associated transcription factor TCF-1 (16) was increased
in WD-mIL15-CAR T cells whereas effector-associated transcription factors, T-BET and
BLIMP-1 (16), were concurrently decreased in these cells (Fig. 26A). Contrasting mIL15CAR T cells, WD-mIL15-CAR T cells showed significantly greater frequencies of the
memory-associated surface markers IL-7Rα (P = 0.0454), CD27 (P = 0.0148), and CCR7
(P = 0.0091) were observed (Fig. 26B,E).

This protein-level expression pattern of

transcription factors and surface markers corresponds with the molecular profile established
in section 4.3.4 (Fig. 25A,B). WD-IL15-CAR T cell expression of IL-7Rα ranged 4% - 34%,
CCR7 expression ranged 41% - 92%, and CD27 expression was greater than 99%.
Although at a diminished expression level relative to mIL15-CAR T cells, CD62L+ cells were
not absent but present at an average frequency of 18% (Fig. 26B,E). WD-mIL15-CAR T
cells re-expressed CD45RA to 76 ± 20%.
+

While the majority of cells were

+

CD45RA CD45RO a substantial population of CD45RA+CD45ROneg cells emerged within
the culture (31 ± 17%, mean ± SD, P = 0.0233; Fig. 26C,E). CD122 (IL-2Rβ) expression is
highly expressed on memory cells but has decreased expression on less differentiated T
cell subsets, such as in naïve or memory stem cells (17, 119, 169). CD122 MFI on mIL15CAR T cells (30 ± 8, mean ± SD) significantly differed from that found on WD-mIL15-CAR T
cells (15 ± 3, mean ± SD; P = 0.0040; Fig. 26D).
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Figure 26. WD-mIL15-CAR T cells possess phenotypic characteristics associated
with less differentiated T cells. Validation of select genes found to be differentially
expressed and phenotypic characterization of persisting WD-mIL15-CAR T cells compared
to mIL15-CAR T cells. (A) Representative histograms of transcription factor expression for
TCF-1, T-BET, and BLIMP-1. (B) Representative histograms of surface expressed
molecules associated with T cell differentiation status. (C) Representative flow plots
showing co-expression of CD45RA and CD45RO. Gate frequencies are displayed in the
top right corner of the plots. (D) Representative histogram of CD122 expression. (E)
Frequencies of respective markers from (B) and (C) represented as interleaved box and
whiskers bars with the horizontal bar denoting the median. All data are representative of
greater than five donors. *P < 0.05, ** P < 0.01, *** P < 0.001, paired t test.
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Figure 26. WD-mIL15-CAR T cells possess phenotypic characteristics associated
with less differentiated T cells
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T cell subsets were assessed to further describe the changes in differentiation and
memory potential. With the observed high co-expression of CD45RA and CD45RO, T cell
subsets were defined by CD45RO and CCR7 expression (18, 170, 171). In increasing
differentiation, the subsets are as follows: naïve or memory stem cell (TN or TSCM;
CD45ROnegCCR7+), central memory (TCM; CD45RO+CCR7+), effector memory (TEM;
CD45ROnegCCR7neg), and effector memory RA (TEMRA; CD45RO+CCR7neg).
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CD45RO CCR7 effector memory phenotype (P < 0.0001 for comparisons of within mIL15CAR T cell groups comparing memory subsets; Fig. 27A). After antigen withdrawal, the
memory composition shifted to favor CD45ROnegCCR7+ WD-mIL15-CAR T cells (P < 0.01)
and a sharp decline in the previously dominating CD45ROnegCCR7neg subset was observed
(P < 0.0001; Fig. 27A). The altered composition of CD45RO-CCR7 subsets at the end of
withdrawal was resultant of a significant increase in CD45ROnegCCR7+ cell number (up to
eight-fold) with concomitant decreases in cell number of CD45RO+CCR7+ and
CD45RO+CCR7neg subsets (P < 0.001, P < 0.001, and P < 0.0001, respectively).
Surprisingly, CD45ROnegCCR7neg T cells persisted long-term, albeit without increasing in
number (Fig. 27). With the increase in CD45ROnegCCR7+ T cells, further examination was
done to determine whether T cells in this subset were antigen-experienced as opposed to
naïve.

Further gating on the CD45ROnegCCR7+ subset of WD-mIL15-CAR T cells

confirmed CD45RA expression (95% ± 4, mean ± SD), which may be expressed by either
TN or TSCM. Assessing CD95 enabled differentiation between TN or TSCM subsets since TN
do not express CD95 (52).

Additional staining showed that CD45ROnegCCR7+ T cells

expressed CD95 similarly to the other antigen-experienced subsets (Fig. 27B). Together
these data suggest that subsets supported by mIL15 during antigen withdrawal represent
the least and most differentiated T cell subsets.
The net gain of this low differentiation subset corresponded with an acquired capacity
for IL-2 production (P < 0.0001), a hallmark feature of memory cells (18). It was observed
that merely 2-8% of mIL15-CAR produced IL-2 upon stimulation whereas 25-46% of WDmIL15-CAR T cells produced IL-2 (Fig. 28 A,B). In sum, within the heterogeneous mix of
WD-mIL15-CAR T cell subsets, T cells whose persistence was promoted or supported were
CD45ROnegCCR7+ and CD45ROnegCCR7neg, respectively.

Despite describing a bulk

population, a molecular and phenotypic profile emerged showing that within the persisting
subsets some T cells possessed traits associated with an early state of differentiation. The
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Figure 27. Long term in vitro populations of WD-mIL15-CAR T cells become enriched
with CD45RA+CCR7+ and CD45RA+CCR7neg subsets. (A) Memory subset (based on
CD45RO and CCR7) composition (top panel) and cell number (bottom panel) of mIL15CAR T cells before and after withdrawal assay conditions. Data are plotted as interleaved
box and whiskers with the horizontal bar denoting the median. Data is representative of
greater than five donors. ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns = not significant, n
> 5, two-way ANOVA (Bonferroni’s post-test). (B) Representative histogram of one of four
donors showing CD95 expression on WD-mIL15-CAR T cells amongst the memory subsets
from (A). Histograms are gated on each of the corresponding subsets. The vertical bar in
the plot denotes a reference line based on isotype staining.

74

Figure 27. Long term in vitro populations of WD-mIL15-CAR T cells become enriched
with CD45RA+CCR7+ and CD45RA+CCR7neg subsets
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Figure 28. WD-mIL15-CAR T cells acquire the capability to produce IL-2. (A)
Representative histograms of IL-2 intracellular staining of expanded mIL15-CAR T cells and
persisting WD-mIL15-CAR T cells after lymphocyte activation cocktail (LAC) or no
stimulation. (B) Frequency of LAC-stimulated T cells producing IL-2 from (A). ****P <
0.0001, n = 6, paired t test.
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presence of such a phenotype for WD-mIL15-CAR T cells remaining after long-term antigen
withdrawal strengthens its potential for clinical application.
4.2.6 mIL15 Supports CCR7+ T Cell Subset Viability
To determine whether the promotion of memory phenotype in our system was due
specifically to mIL15, a 65-day withdrawal assay was conducted comparing WD-mIL15CAR T cells to WD-CAR T cells cultured with soluble IL-2 or IL-15 complex (Fig. 29A). It
was observed that CD45RA expression was elevated amongst the treatment groups (P >
0.05; Fig. 27). In contrast, CCR7 expression was 21% - 35% on WD-CAR T cells receiving
IL-2, 17% - 31% on WD-CAR T cells receiving IL-15 complex, and 46% - 91% on WDmIL15-CAR T cells (Fig. 27C). CCR7 expression was significantly enhanced in WD-mIL15CAR T cells relative to CAR T cells supplemented with IL-2 or soluble IL-15 complex (both
P < 0.05). Viability of CCR7neg and CCR7+ subsets was assessed by Annexin V staining. It
was found that irrespective of the type of cytokine stimulation (IL-2, IL-15 complex, or
mIL15), CCR7neg T cells showed equal frequencies of live cells. In contrast, CCR7+ T cells
exposed to mIL15 had significantly higher viability than the CAR T cells receiving IL-2 or IL15 complex (both P < 0.05; Fig. 29D,E). These data suggest that mIL15 is sufficient to
support the CCR7+ phenotype which thus contributes to maintaining the less differentiated
CD45ROnegCCR7+ T cell subset.
4.2.7 mIL15-CAR T Cells Persisting In Vivo in the Absence of TAA Show the Emergence of
an Early Differentiated CD45ROnegCCR7+ Memory Subset
The mIL15-CAR T cells were, once again, tested in vivo to further investigate memory
subset maintenance and to determine whether the in vitro observations could be
recapitulated. The mIL15-CAR T cells were adoptively transferred into NSG mice with no
tumor or exogenous cytokine support and assessed after 50 days. T-cell expression of
CD45RO and CCR7 was observed in a tissue-specific manner. T cells highly expressed
CD45RO in the bone marrow, but CD45RO+ T cells were at low frequencies in peripheral
blood and spleen (Fig. 30A).

Interestingly CCR7+ T cell frequency was inversely

associated with CD45RO expression where higher expression was observed in the blood
and spleen (Fig. 30A). T cell differentiation, in the blood and spleen, recapitulated in vitro
observations of the preferential persistence of CD45ROnegCCR7+ and CD45ROnegCCR7neg
T cells (Fig. 30B).

Strikingly, the bone marrow contained the highest proportion of

CD45RO+CCR7- T cells and nearly all of the T cells in the bone marrow were found to be
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Figure 29. Tethered IL-15 supports survival of CCR7+ CAR-modified T cells. (A)
Schematic summarizing the withdrawal experiment comparing IL-2, IL-15 complex, and
mIL15 on CD45RA and CCR7 phenotype. During the 65-day antigen withdrawal, the
mIL15-CAR T cells received no exogenous cytokine supplementation while CAR T cell
control treatments received either IL-2 (50 U/ml) or IL-15 complex (5 ng/ml). T cells
persisting at the end of the assay are referred to as WD-T cells. (B) A representative
histogram of CD45RA expression and (C) CCR7 expression on WD-T cells. (D)
Representative histograms showing Annexin V levels in CCR7neg and CCR7+ WD-T cell
subsets. Histograms were gated on the lymphocyte population to avoid non-specific CCR7
staining. (E) Graph plotting frequencies of live (Annexin Vneg) WD-T cell treatment cohorts
in the CCR7neg and CCR7+ subsets. Data are represented as mean ± SD. *P < 0.05, ns =
not significant, two-way ANOVA (Tukey’s post-test). All data are representative of three
donors. Color legend: WD-CAR T cells supplemented with IL-2 (black), WD-CAR T cells
supplemented with IL-15 complex (grey), and WD-mIL15-CAR T cells (magenta).
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Figure 29. Tethered IL-15 supports survival of CCR7+ CAR-modified T cells

79

Figure 30. Long-term in vivo persisting mIL15-CAR T cells are maintained at diverse
levels of differentiation with different distribution patterns. NSG mice were i.v.
injected with 20 x 106 mIL15-CAR T cells. After 50 days analysis of peripheral blood,
spleen, and bone marrow was performed to assess differentiation of T cells persisting longterm in the absence of CAR activation. (A) Representative histograms of CD45RO (upper
panel) and CCR7 (lower panel) expression on in vivo mIL15-CAR T cells. (B) Memory
subset composition of the in vivo T cells in reference to in vitro WD-mIL15-CAR T cells.
Graphed data is represented as mean ± sem. *P < 0.05, **P < 0.01, *** P < 0.001, two-way
ANOVA (Tukey’s post-test).
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the

more

differentiated

subsets

(P

<

0.0001

for

CD45RO+CCR7neg

versus

CD45ROnegCCR7+ or CD45RO+CCR7+; P < 0.001 for CD45ROnegCCR7neg versus
CD45ROnegCCR7+ or CD45RO+CCR7+; Fig. 30B). Similar to in vitro observations, T cells
in the blood and organs expressed moderate levels of CAR and modest levels surfacedetected mIL15 (Fig. 31AB). After ex vivo numeric expansion, T cells derived from the
organs retained antigen-specific function by the production IFNγ in response to CD19+
targets (Fig. 31C). Together these data suggest that while mIL15-CAR T cells can persist
in vivo long-term as various memory subsets, they are also maintained as a substantial
subset of early differentiated cells, which are thought to be a desirable population for ACT.

4.3 Discussion
There is sparse information on the maturation fate of cytokine-modified T cells. It has
not been elucidated whether such cells can behave in a physiologically relevant manner
and modulate their activation to form or maintain memory; or, if they are merely dominated
by extrinsic input that generates over-activated T cells in perpetual overdrive. With IL-15’s
well-known effects on the homeostatic maintenance of TCM, we expected that persisting
mIL15-CAR T cells would be characterized primarily as TCM. Contrary to our hypothesis,
we did not observe a promotion of that subset. Rather, and most surprisingly, we found the
emergence of a low differentiation CD45ROnegCCR7+ subset with a memory-like molecular
profile and phenotype rarely observed in CAR T cell studies.
Transition from a higher to lower differentiation state of mIL15-CAR T cells after antigen
withdrawal was observed on a molecular level (Fig.25) and corroborated by phenotypic
assessment (Fig.26). The modulation of key transcription factors associated with T cell
differentiation state (i.e., TCF-1, LEF-1, T-bet, BLIMP-1, EOMES, and Bcl-6) supports the
important involvement of intrinsic elements in directing mIL15-CAR T cell fate after antigen
withdrawal. That we did not observe intrinsic differences between CAR T cells and mIL15CAR T cells after ex vivo expansion is not entirely surprising. In another study, T cells
derived from TCM and TEM subsets both displayed a similar effector phenotype prior to
infusion into primates, yet demonstrated differing in vivo fitness (50).

A plausible

explanation for this observation likely involves the dominance of extrinsic factor signaling
from CAR-triggering (mimicking TCR and CD28 signaling), costimulatory signaling (i.e.
CD27 and CD28), and cytokine signaling (i.e., IL-21 and mIL15 or IL-2) that converge upon
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Figure 31. Long-term in vivo persisting mIL15-CAR T cells express CAR and remain
responsive to TAA. (A) Representative histograms show expression of CAR and mIL15,
with CAR detection using the CAR idiotype antibody (clone 136.20.1) and (B) plotted
frequencies of marker expression from (A) represented as mean ± sem. Plots and graphs
(A,B) show T cell frequencies after gating on human CD3+ and mouse CD45- cells in the
peripheral blood (n = 5), spleen (n = 9), and bone marrow (n = 9). (C) Cells isolated from
spleen, liver, or bone marrow were ex vivo expanded on aAPC to generate sufficient cell
numbers for assessing intracellular IFNγ production in response to CD19- and CD19+
targets, n = 7 from three tissue sources and four mice. Histograms were gated on CD3.
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Figure 31. Long-term in vivo persisting mIL15-CAR T cells express CAR and remain
responsive to TAA
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the PI3K/Akt pathway to modify the cell’s molecular profile. In recent years, studies have
unraveled that the PI3K/Akt pathway is central to integrating such signaling and acts as a
rheostat in T cell differentiation (Fig. 2) (25, 27). It has been shown that strong induction of
Akt does not sustain CD8 T cell memory, but consequently induces terminal differentiation
(26, 27, 172). An additional consideration is the role of epigenetics in T cell memory. It has
been shown that knock-out mice of the methyltransferase Dnmt1 or methyl DNA binding
protein MBD2 yielded reduced memory T cells and aberrant memory differentiation (173,
174). In T cells, epigenetic changes have been shown to act on cytokine gene loci in
effector and memory subsets, and BLIMP-1 can regulate CD8 T cell memory via epigenetic
modifications (175-177). This additional level of regulation may offer explanation for our
observations regarding the lack of phenotypic differences noted in ex vivo expanded T
cells, and raises questions as to whether IL-15/mIL15 signaling may contribute to any
epigenetic programming.
The finding that Foxo1 did not increase in parallel with other related pro-memory
transcription factors in WD-mIL15-CAR T cells was unanticipated (Fig. 24). We found Il7ra,
Ccr7, Eomes, Bach2, Bcl-6, and Tcf7 to be significantly up-regulated in WD-mIL15-CAR T
cells, yet studies have described Foxo1 to directly or indirectly regulate these genes (127,
163, 167, 168, 178, 179).

A possible explanation to account for this paradoxical

observation involves Foxo3. It was found that Foxo3 was significantly up-regulated in the
WD-mIL15-CAR T cells. The study of FOXOs in T cell memory has been largely assessed
with FOXO1 while the role of FOXO3 in this context is not fully understood. Both FOXO1
and FOXO3 integrate into the PI3K/Akt axis of T cell memory regulation, as their activity is
inhibited by Akt (178). T cell-specific deletion of Foxo1 does not result in spontaneous T
cell activation, but rather plays a role in regulating genes critical for naïve T cell
homeostasis (168). Results from Foxo3-deficient mice have been somewhat conflicting,
but like Foxo1 they do not show lymphocytes with spontaneous activation (180). However,
it took conditional deletion of Foxo1, Foxo3, and Foxo4 in hematopoietic stem cells to
induce aberrant cell cycle and apoptosis features (181). These studies suggest that there
may be some level of redundancy amongst the FOXOs. The dominant Foxo3 transcription
over Foxo1 in our system was associated with an increased proportion of the less
differentiated CD45ROnegCCR7+ subset and is a novel observation. This model may be
useful in further examining the roles of FOXO1 and FOXO3 in mature T cells and their
regulation in the maintenance of memory.
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In this study, we observed modulation of

transcript levels of Foxo1 and Foxo3 that revealed intriguing results with much potential for
elucidating the incompletely defined relationships of this family of transcription factors in
mature T cell differentiation and homeostasis. Present understanding of FOXO regulatory
mechanisms and instituted gene expression programs indicate that the function of this
family of transcription factors is largely in response to alterations in environmental
conditions and cellular stress (ie., oxidative stress and AMP-activated protein kinase
activity) (182).

Moreover, FOXOs are regulated by cytoplasmic shuttling and post-

translational modifications (PTMs), including phosphorylation, methylation, ubiquitylation,
and acetylation (182).

Thus, future investigation into the context-dependent roles of

FOXOs in T cells must assess cellular/environmental status along with the various PTMs of
FOXOs in the different memory subsets of T cells. Determining whether FOXO3 is involved
in the generation or maintenance of the CD45ROnegCCR7+ subset would contribute to the
limited knowledge of this recently identified subset and, in general, to FOXO3 mechanisms
in mature T cell differentiation or homeostasis.
We observed that mIL15-CAR T cells persist in a spectrum of memory states, including
a substantial population exhibiting very low differentiation, delineated as CD45ROnegCCR7+
(Fig. 27). This subset also expressed high levels of CD45RA, CD27, TCF-1, and modest
frequency of cells also expressed IL-7Rα and CD62L. A study with IL-15-secreting CAR T
cells that evaluated the long-term in vivo phenotype of persisting T cells observed
increased CD45RA expression and a small subset (~6%) of CD45RA+CCR7+ cells in the
spleen (92). Though our long-term engraftment was not nearly as high as in the reported
study, we observed a 24% average frequency of the CD45ROnegCCR7+ subset in the
spleen. The caveat being that our T cell manufacture technique uses more rounds of aAPC
stimulation, thus likely decreasing memory potential in the cells. Additionally our in vivo
model was TAA-free whereas the other study assessed T cells from mice that survived
tumor challenge.

Contrasting our results, antigen-specific T cells modified to express

constitutively activate STAT5, and assayed after 20 days in vivo, demonstrated an effector
phenotype characterized by high levels of T-BET, effector molecule expression, and
diminished IL-2 production (183). Yet, other studies examining the mechanisms of STAT5
have shown constitutive STAT5 to promote greater memory populations or supported both
memory and effector T cells, which is more in line with our results (154, 184). Polyclonal
TCM-derived cells expressing chimeric cytokine receptors signaling through CD127 or
CD122 cytoplasmic domains activated STAT5 and resulted in moderate to low expression
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of memory associated molecules, respectively (120). However, CD45RA/RO staining was
not performed and thus memory subsets could not be defined. These data collectively
suggest that (i) providing only STAT5 activity may not necessarily recapitulate the signaling
networks that promote a low differentiation state or (ii) the STAT5 activity level was
inappropriate for early memory formation or maintenance. Our data showed that mIL15CAR T cells are representative of several memory subsets and indicated that some of these
cells received an appropriate level of mIL15 costimulation to maintain a low differentiation
state.
Our TSCM-like population of WD-mIL15-CAR T cells could be described as
CD45RA+CD45ROnegCCR7+CD122+CD95+ which was similar for the majority of markers to
other studies describing TSCM (52, 126) but for the expression level of CD62L and CD28,
which was at a lower frequency in our CD45ROnegCCR7+ WD-mIL15-CAR T cells. This
may indicate that the CD62LnegCD28neg cells within the CD45ROnegCCR7+ T cell subset are
further along in the differentiation spectrum than TSCM described by other groups (52, 126).
The generation of CD45ROnegCCR7+ that are CD62LnegCD28neg has, to our knowledge, not
been reported and the functional consequences of the lack of these markers in this putative
low differentiation subset is unknown. The down-modulation of CD28 may be due to IL-15
costimulation in the mIL15-CAR T cells. IL-15 has been shown to induce proliferation of
memory CD8 T cells which resulted in a loss of CD28 in actively dividing T cells in vitro
(164, 166). While these CD28neg CD8 memory T cells showed no proliferative defects to IL15 (166), it was also found that IL-21 countered the IL-15-induced down-modulation of
CD28 (185). Thus, the addition of IL-21, or a membrane-bound IL-21, could be considered
should the preservation of CD28 expression be desired in the mIL15-CAR T cells. CD62L
down-modulation was observed in WD-mIL15-CAR T cells, but not to the same extent as
CD28. Unlike with CD28, it is unknown whether IL-15 may play a role in this modulation.
This observed phenomenon may also be indicative of the complexity of memory T-cell
phenotypes and while the CCR7+CD62Lneg memory T cell subset is not one of the
archetypal memory subsets observed and discussed, this subset has been detected in mice
after viral infection (186).
Gattinoni et al. (2011) generated low differentiation TSCM (CD45RA+CD45ROnegCD62L+
CCR7+IL-7Rα+CD95+) from naïve T cells using a glycogen synthase kinase 3β (GSK-3β)
inhibitor to activate the Wnt pathway (52). In contrast, Cieri et al. (2013) generated similar
TSCM, albeit CD45RO+, using IL-7 and IL-15 (126). Our TSCM-like population of WD-mIL1586

CAR T cells (CD45RA+CD45ROnegCCR7+CD122+CD95+) only had access to IL-15-induced
signaling from mIL15. Cieri et al. (2013) reported that IL-15 alone could generate a small
population of TSCM, but far superior numbers were generated when IL-7 was used in
combination with IL-15 (126).

This, however, does support our observation of the

promotion of a low differentiation subset solely with IL-15-mediated signaling. Additionally,
the inclusion of IL-7-mediated signaling in some manner (i.e., membrane-bound IL-7
expressed on T cells) is a valid consideration for us to augment the development or
maintenance of this desirable population in our mIL15-CAR T cell cultures and potentially in
vivo. We also noted the up-regulated expression of genes related to the Wnt-signaling
pathway (Tcf 7, Lef1, and Axin2; Fig. 24), which are reported to be regulated by Akt (187).
Moreover, since Axin2 is a direct target of the Wnt pathway through TCF-1 and LEF-1
activity, its up-regulated status suggests that Wnt signaling is active in WD-mIL15-CAR T
cells.

Akt signal strength is involved with regulating the Wnt pathway where weaker

signaling sustains a memory phenotype (26). FOXOs have been shown to interact with βcatenin and could therefore be a contributor to modulating T cell differentiation (188), but
this still needs to be further investigated. There is still much to unravel with the cross-talk
between the PI3K/Akt and Wnt/β-catenin pathways. Delving into how Wnt signaling may be
active in some populations of mIL15-CAR T cells when they receive only IL-15-based
signaling instead of exogenous Wnt pathway agonists may help to elucidate this
connection. Moreover, the observation of putative Wnt pathway activation in our system
indirectly suggests that signaling induced by mIL15 only weakly signals the PI3K/Akt
pathway so as to not inhibit the Wnt pathway. Further validation of this observation would
contribute to knowledge on how the PI3K/Akt node acts as a rheostat to modulate T cell
differentiation. In order to be better able to modulate CAR T cell phenotype and in vivo
fitness, valuable information may be gained by further unravelling the specific pathway
stimulation that is achieved in the TSCM-like mIL15-CAR T cells.
Our data showed the presence of the CD45ROnegCCR7+ population in the peripheral
blood and spleen of NSG mice at 50 days after adoptive transfer (Fig. 30). In contrast,
Gattinoni et al. (2011) adoptively transferred polyclonal TSCM (generated by GSK3β inhibition) with CD8-depleted PBMC (for human cytokines and costimulation) into NSG
mice. At four weeks after transfer, cells that were found in the spleen uniformly showed an
effector phenotype (52). This is in contrast to Cieri et al. (2013) where polyclonal TSCM
adoptively transferred into a GVHD model maintained high CD62L and low IL-7Ra
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expression, but CD45RAneg, on T cells in the peripheral blood at two weeks in primary
recipients and one week in secondary recipients (126). It is an interesting observation that
TSCM generated via cytokine signaling persisted in vivo with a less differentiated phenotype
than TSCM produced by pharmacological methods. The mIL15-CAR T cells continued to
receive cytokine costimulation, thus it was anticipated that they retain some memory
potential in the absence of TAA. But, the TSCM having received IL-7 and IL-15 in vitro
appeared to carry with them some lasting effects that limited differentiation in comparison to
TSCM given GSK-3β inhibition.

Determining the mechanism for this disparity (i.e.,

epigenetics and post-translational modifications) could have clinical implications as
pharmacological methods of modulating T cell differentiation have been proposed for use in
the clinic, but other more robust approaches may be found. Moreover, if epigenetics or
some other post-translational regulatory mechanism is at play with IL-7 and IL-15 signaling,
understanding if such processes operate in mIL15-CAR T cells could assist in identifying
methods to further manipulate CAR T cell differentiation state.
Homeostatic proliferation, IL-7, and IL-15 have been shown to be integral in generating
CD45RA+CCR7+ early memory populations (126, 189). We uniquely showed that in vitro
mIL15, and not soluble IL-2 or IL-15, played a role in preserving the CCR7+ subset. It has
been demonstrated that differential signaling is induced between soluble IL-15 and
transpresented IL-15 (71), and thus it may plausible that the particular surface expression
level and specific signaling induced by the membrane-bound or transpresented nature of
mIL15 could be providing appropriate costimulatory signaling in CCR7+ subsets. Or, it may
be a phenomenon of mIL15 providing just the ‘right’ amount of signaling. Moreover, it is
likely that the soluble cytokines present in vitro are at supra-physiologic levels that induced
strong pathway activation, which is known to result in T cell differentiation (27).
This study assessed the bulk characteristics of cells and thus could not make
conclusions regarding lineage relationships between T cell subsets. Studies reporting on
the generation of TSCM have indicated their results to be consistent with a linear
differentiation model (17, 52, 126). In contrast, it has been reported that CD45RA+CCR7+
cells emerged from TCM after culture with IL-7 and IL-15 in the absence of antigenic
stimulation (189). In our withdrawal assay, we observed a decline in CD45RO+CCR7+ T
cell numbers with a concomitant increase of the CD45ROnegCCR7+ subset. This may be
due to cell death in the CD45RO+CCR7+ subset with proliferation in CD45ROnegCCR7+
subset. However, that seems like an unlikely outcome considering the numerous studies
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reporting that IL-15 is critical to supporting TCM (134, 190). Alternatively, observations by
Geginat et al. (2003) showed a proportion of sorted TCM de-differentiated to a
CD45ROnegCCR7+ in the presence of IL-7 and IL-15 in the absence of antigen (189).
Sorting the subpopulations prior to antigen withdrawal may identify which process is at work
in our model and contribute to knowledge on the model of T cell differentiation. Moreover,
identification of the source subset(s) for TSCM could then fold into methods for developing
clinically relevant methods to augment TSCM in the infusion product for CAR T cell therapies.
Sorting these subsets and individually testing their antitumor potency with in vivo models
would contribute knowledge to more clearly identify which T cell subset would possesses
the greatest therapeutic potential.
The characterization of mIL15-CAR T cells in this thesis was performed in the absence
of TAA. From this we have determined the memory potential of these cells and assembled
a profile of the intrinsic factors involved, which had been undefined for long-term persisting
CAR T cells. Future directions, though, should next assess mIL15-CAR T cells after tumor
challenge to determine how the T cell memory profile has changed and how their in vivo
fitness changes subsequent to tumor challenge. Much investigation has been conducted
on T cell differentiation during infection, but is much less studied in the context of tumor
challenge. As discussed in Chapter 3, mIL15 may have more optimal function with other
CAR configurations. Assessing how the different CAR configurations alter the mIL15-CAR
T cell molecular profile in response to tumor challenge may provide much needed
information

on

optimizing

CAR

T

cell

therapy

for

different

tumors

or

tumor

microenvironments (i.e., lack of CD80/86, tumor burden level, lack of CD4 help, and
immunosuppression by TREGs and TGF-β).
Nonetheless, while mechanisms for the generation of such early differentiated cells
remain to be fully elucidated, we showed that these subsets were promoted in our system
via costimulation from mIL15. While more differentiated subsets of WD-mIL15-CAR T cells
were found to persist long-term, their in vivo functional capacity is anticipated to be poor
(22). The preserved memory potential that we observed in our system is an important
factor as it has been demonstrated by numerous studies that the greatest therapeutic
potential is mediated by the least differentiated T cell subsets (52, 126). While it is currently
not feasible to treat patients with naturally occurring TSCM, due to their low circulating
frequency, identification of strategies to generate clinically relevant numbers of genetically
modified TSCM would greatly contribute to the advancement of CAR T cell-based therapies.
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The results presented herein showed that, in our system, mIL15 promoted a TSCM-like
population of CAR-modified T cells, and thus bolsters the rationale for using mIL15 in
further developing clinically-compliant strategies to augment this desirable T cell subset in
immunotherapy infusion products.
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CHAPTER 5
General Discussion and Future Directions

5.1 Dissertation Summary
Adoptive transfer of CAR T cells have demonstrated great potential in treating various
leukemias, however persistence of infused T cells remains an impediment to advancing
therapeutic outcome (43, 63, 77, 78) in the general field as well as with our focus on
treating low TAA in MRD. The primary aim of this dissertation was therefore to develop and
test a novel cellular immunotherapy approach to resolve this standing clinical issue. Our
strategy to address this deficit utilized the pleiotropic effects of IL-15 (85, 86, 191): (i) to
support initial survival of infused T cells that are a heterogeneous mixture of differentiation
states and (ii) for the long-term maintenance of subsets that remain responsive to IL-15,
which are typically less-differentiated and long-lived T cells.
We generated mIL15 to keep the cytokine targeted to responding CAR T cells and to
mimic the transpresentation mechanism by which IL-15 functions in vivo. Using clinically
compliant methods, we demonstrated the generation of mIL15-CAR T cells qualitatively
suitable for adoptive transfer.

The mIL15-CAR T cells showed enhanced STAT5

costimulation relative to cytokine unsupplemented CAR T cells.

Moreover, it was

demonstrated that mIL15 could mimic transpresentation and induce STAT5 signaling on
CAR T cells that did not express mIL15.
In immunocompromised NSG mice bearing a disseminated CD19+ leukemia, the
mIL15-CAR T cells demonstrated both persistence and an antitumor effect, whereas the
CAR T cell counterpart could not maintain significant persistence despite the presence of
TAA. In a preventative model where CAR and mIL15-CAR T cells were engrafted first
followed by the introduction of a disseminated CD19+ leukemia, only the mIL15-CAR T cells
were found to persist, eradicate tumor cells, and extend survival. It was also shown that
mIL15-CAR T cells were capable of persisting independently of TAA.
It is uncharted territory as to the differentiation status of persisting cytokine-modified
CAR T cells. It is unknown what role intrinsic factors may play in supporting these surviving
T cells.

Since IL-15 was selected, in part, for its critical role in supporting long-lived
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memory CD8 T cell subsets, it was hypothesized that TCM subsets would persist
preferentially. Characterization of the mIL15-CAR T cells that persisted long-term was in
the absence of TAA.

In vitro assays showed that surviving WD-mIL15-CAR T cells

maintained pSTAT5 activity and Bcl-2 levels whereas control CAR T cells showed
diminished levels of these molecules indicating that mIL15 was still functional. Comparing
the long-term persisting WD-mIL15-CAR T cells to the earlier ex vivo expanded mIL15-CAR
T cells, it was noted that WD-mIL15-CAR T cells significantly expressed genes associated
with a less differentiated state. This was validated by flow cytometry for specific memory
and differentiation-related transcription factors and cell-surface markers. Moreover, WDmIL15-CAR T cells acquired the capability to produce IL-2, a hallmark of less differentiated
memory cells. Assessing the subset composition, it was revealed that WD-mIL15-CAR T
cells persisted preferentially as the least differentiated (CD45ROnegCCR7+) and most
differentiated (CD45RO+CCR7neg) subsets.

The CD45ROnegCCR7+ subset would

classically be known as TN. However WD-mIL15-CAR T cells in that subset were found to
be CD95+ and CD122+, both markers associated with antigen-experienced T cells and TSCM.
Therefore, the molecular profile and phenotypic assessment of the bulk population
suggested that some cells within make up a TSCM-like subset that is less differentiated than
TCM. This in vitro WD-mIL15-CAR T cell subset composition was recapitulated in vivo, but
was tissue-dependent. It was found that WD-mIL15-CAR T cells persisting in the bone
marrow took on a more activated phenotype of CD45RO+CCR7neg whilst the peripheral
blood and spleen contained the highest frequencies of the CD45ROnegCCR7+ subset. This
capacity to sustain a less differentiated memory potential in vivo further reinforces their
suitability for use in the clinic. This also brings to light the importance of determining the
mechanism of generation and maintenance of such T cell subsets as this knowledge could
ultimately be harnessed for the generation of optimal T cell subsets for ACT. The results in
this dissertation provide pre-clinical data that can now be translated into a clinical trial to
evaluate mIL15-CAR T cell persistence and disease-free survival of post-HSCT patients
with MRD.

5.2 Treating MRD: A Focus on Forming Durable Immunologic Memory
At the genesis of this project, the primary aim was to achieve CAR T cell persistence
under low TAA so that it may translate to the clinic for treating patients with MRD or
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sequestered TAA.

We achieved this with the mIL15-CAR T cells (Figs. 15,19).

A

treatment approach was developed for a subset of patients that needed improved treatment
options. However, with results from clinical trials and observations from this study, we
propose that treating MRD may be a more desirable approach over treating bulky disease
for several reasons.
First, it may make T cell therapy safer. Clinical trials treating bulky disease, while
achieving some remarkable results with complete remissions, have also had severe
treatment related toxicities, including tumor lysis syndrome and cytokine storms (77, 145,
192). Such toxicities can be correlated to the level of tumor burden at time of infusion (78).
Hence, treating MRD would be anticipated to have a lower magnitude of toxicities.
Second, lower tumor burden may allow for the establishment of immunologic memory
and durable CAR T cell immunosurveillance for extended protection against relapse. In the
successful study by Kalos et al., T cells were detected persisting in patients after high tumor
burden was eradicated (77).

And while CD8 CARneg T cells displayed some markers

associated with memory, CD8 CAR+ T cells did not express any of these markers other
than low levels of CD27. In general, the CAR+ T cells displayed a highly differentiated
TEMRA phenotype (145). It is well accepted that repetitive antigen exposure and exposure to
strong stimuli, (i.e., strong TCR stimulation and inflammatory cytokines) leads to
progressive differentiation and loss of function (21, 22, 25, 193). Therefore, the low-TAA
environment associated with MRD may foster a more pro-memory environment, in the
sense of a lower magnitude of antigenic stimulation, less repetitive stimulation, and the
generation of lower levels of inflammatory cytokines. With mIL15-CAR T cells able to
persist under low TAA, there is potential for CAR T cells to reside as memory cells after
tumor is cleared and to maintain immunosurveillance for durable protection against relapse.

5.3 Application to Other CARs and Cell Therapies
The use of mIL15 is, by no means, limited to the CD19-specific CAR. Moving mIL15
into therapies treating solid tumors could provide assistance not only with persistence, but
also against tumor microenvironment suppressive factors, for which solid tumors are
notorious (194).

IL-15 has been shown to counter the immunosuppressive effects of

transforming growth factor-β (195, 196), as well as regulatory T cells (197, 198). Hence,
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mIL15 could be paired with most any other CAR targeting solid tumors, however the most
logical target to move to first may be melanoma. IL-15 has recently entered into the clinic
and its first implementation was in the treatment of melanoma, either as a monotherapy
(NCT01946789) or infused with autologous lymphocytes (NCT01369888). Murine models
with B16 revealed superior antitumor effect with the use of a soluble IL-15/IL-15Rα sushi
domain fusion protein (RLI) (199) or antibody fusion protein (98).

A CAR targeting

melanoma is toward the MAGE1 antigen (200). Preclinical data using RLI (a soluble IL15/IL-15Rα hyperagonist) also showed significantly enhanced antitumor activity against
colorectal cancer (199) and a targeted form specific for GD2 (201), which is found on
neuroblastoma. CARs targeting these tumors are in clinical trials (36) and could thus be
readily translated to trials including mIL15. The utility of mIL15 is diverse, but these solid
tumor targets are suggested to be the most promising.

5.4 Combination Therapies
5.4.1. Combining mIL15-CAR T Cells and Small Molecule Inhibitors
Cancer cells may overexpress anti-apoptotic proteins such as Bcl-2 or possess
persistently activated pathways (i.e., STAT5 and STAT3) that result in aberrantly high
resistance to natural apoptotic mediators or pharmacologic agents.

Combining the

approaches of drugs and immunotherapy to utilize more than one apoptotic pathway could
increase tumor cell death and decrease therapeutic resistance. The use of small molecule
inhibitors may shift the balance enough between the pro- and anti-apoptotic molecules
within tumor cells to sensitize them toward death or decrease resistance to killing during
encounter with tumor-specific T cells.
Elevated Bcl-2 expression has been found in hematologic malignancies [i.e., acute
myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL)] and solid tumors
(i.e., melanoma, breast and ovarian cancer) (202-206). Persistently activated STAT3 or
STAT5 has been observed in AML, CLL, chronic myelogenous leukemia, large granular
lymphocytic leukemia, and leukemia cell lines (207-210).

Small molecule inhibitors

targeting Bcl-2, STAT3, or STAT5 have shown efficacy in inducing apoptosis (207, 208,
211, 212). Moreover, the addition of a Bcl-2 inhibitor to CAR T cells in co-culture with
lymphoma and leukemia cells enhanced T cell-induced apoptosis (213). However, the
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inhibitor also caused T cells to undergo some level of apoptosis, which may pose a problem
for clinical application.
In our study, we showed that pSTAT5 and Bcl-2 levels were sustained by mIL15-CAR
T cells (Fig. 23). This would suggest that mIL15-CAR T cells may have some level of
resistance to the apoptotic-inducing effects of these small molecule inhibitors of this
pathway, and indeed they may.

The mIL15-CAR T cells were able to resist pSTAT5

abrogation by a STAT5 inhibitor that CAR T cells could not (L. Hurton, unpublished
observation). Thus, this may be a viable complementary approach that could be used to
boost antitumor activity by mIL15-CAR T cells.
5.4.2. Combining Cell Therapies
Single agent treatment of cancer is not always successful in the long run. The cancer
cells find a way to evade complete eradication and the patients relapse in time.

A

multipronged approach should be implemented, thus increasing therapeutic potential.
Physiologically, T cells and NK cells function coordinately in an orchestrated immune
response to eliminate the pathogen.

NK cell therapies are entering into the clinic for

various malignancies. Moreover, they can be reliably and significantly expanded ex vivo to
obtain sufficient numbers for adoptive transfer (214). Combining CAR T cells with NK cells
in adoptive immunotherapy may be advantageous to diversify the antitumor response.
Rather than targeting a single antigen, the innate activities of the NK cells may allow for
epitope spreading leading to a more well-rounded response that could plausibly decrease
the risk of tumor antigen escape (215). Another aspect of the combination therapy could be
NK-promoting effects from the T-cell transpresented mIL15.

Though a recent study

suggested that the homeostasis of human NK cells in not dependent on IL-15 (216), other
work on human NK cells indicates otherwise. Huntington et al. demonstrated that IL-15/IL15Rα complexes, but not monomeric IL-15, induced extensive human NK cell proliferation
(217). In a clinical trial, it was reported that after multiple doses of IL-15, NK cells were
found to increase 4 to 10 fold (218). Moreover, we observed massive expansions of NK
cells in cultures that only had mIL15 cytokine availability (Fig. 8).

Moreover, we

demonstrated that mIL15 can be transpresented and induce cytokine signaling in another
cell (Fig. 10). Together, this would suggest that a combination therapy using ex vivo NK
cells and mIL15-CAR T cells may mediate superior antitumor effects.
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5.5 Clinical Safety
In humans, dysregulated IL-15 production, elevated serum levels, or abnormal IL-15
signaling is associated with autoimmune diseases and may be involved in the pathogenesis
of T-cell LGL leukemia (219, 220). Moreover, transgenic mice engineered to maximally
overexpress IL-15 develop leukemia (221).

It has also been reported that one IL-15-

transduced T cell culture resulted in a clonal expansion, though the etiology was not
definitively identified (222). In contrast, constitutive STAT5 expression in lymphocytes did
not prompt transformational events (135, 154).

Similarly, our study demonstrated

enhanced engraftment of T cells without any overt dysregulated proliferation or activation in
vitro or in vivo.

The molecular profiling by NanoString showed the down-regulation of

activation genes (i.e., IL-2Rα and CD38; Fig. 24) and we did not observe any
splenomegaly in mIL15-CAR treated mice in the preventative or TAA-free mouse models
(L. Hurton, unpublished observations).

Despite the promising therapeutic potential of

mIL15-CAR T cells, concerns about the long-term safety of T cells receiving chronic IL-15
signaling are justified and must be addressed for clinical implementation. A clinically used
approach to conditionally ablate genetically-modified T cell is by additional co-modification
of the cells with an inducible caspase-9 suicide gene.

Exposure to a dimerizer drug

effectively induces apoptosis in the modified T cells (93, 223).

5.6 Clinical Implications
Clinical trials will now be addressing the targeting of minimal burdens of CD19+
malignancy as patients are enrolled earlier in their disease course and receive concomitant
chemotherapy. The intended goal of mIL15 was to enhance T-cell costimulation in situ to
support T-cell persistence independently of CAR activation, to sustain antitumor activity in a
low TAA environment, and preserve T cell memory potential. We have demonstrated that
mIL15-CAR T cells can stand up to the challenge of a TAA-poor environment. Their use in
the clinic should not require the use of exogenous IL-2, thereby improving the safety profile
in that regard.

In comparison to trials using CAR T cells to treat bulky disease, it is

anticipated that there will be fewer events of tumor lysis syndrome and cytokine storm since
mIL15-CAR T cells will be infused under low bio-burden conditions. Finally, mIL15-CAR T
cells were specifically generated to possess enhanced persistence after adoptive transfer.
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This should translate into establishing durable immunologic memory that would enable
extended immunosurveillance resulting in improved disease-free survival of MRD patients.
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CHAPTER 6
Materials and Methods

6.1 Plasmids
6.1.1 mIL15 (IL-15/IL15-Rα fusion) Transposon
The mIL15 construct fuses the IL-15 cDNA sequence (NM_000585.4) to the full-length
IL-15Ra

(NM_002189.3)

with

a

glycine-serine

linker

(SG3SG4SG4SG4SG3

SLQ) and has a C-terminal FLAG (x3) epitope tag (DYKDDDDK). In line with these reports,
the signal peptides for IL-15 and IL-15Rα were omitted and the IgE signal peptide
(gb|AAB59424.1) was used for the mIL15 fusion protein. This construct will produce an IL15 that is membrane-bound, but also presented in the context of IL-15Rα. Mortier et al.
created a similar IL-15 fusion protein, albeit in a secretable configuration, and demonstrated
that this fusion protein with a covalent linker was functional. Moreover, this construction
had increased potency over non-covalently linked IL-15 and soluble IL-15Rα (103). The
mIL15 DNA sequence was codon-optimized for expression in human cells and the DNA
plasmid, IL15-IL15Ra-FLAG_pMK-RQ, was synthesized by GeneArt (Regensburg,
Germany).

IL15-IL15Ra-FLAG_pMK-RQ and GlySer-EGFP-mIgG1/pSBSO underwent

digestion with Nhe and Xho restriction enzymes to obtain the mIL15 insert and pSBSO
vector backbone respectively.

The resulting fragments were excised and gel purified

(AIAquick Gel Extraction Kit, Quagen) and subsequently ligated using T4 DNA ligase
(Promega) yielding IL15-IL15Rα-Flag/pSBSO.

Transformation of C2925 bacteria

(Invitrogen) with the plasmid and selecting clones for amplification, both under kanamycin
drug selection, was followed by large-scale amplification plasmid DNA. The DNA was
purified with EndoFree Plasmid Maxi Kit (Quiagen). Prior to use in cell transfection, the
plasmid was validated by analytical digestion and had a spectrophotometer A260/A280 value
of 1.80 – 2.00.
6.1.2 CD19-specific CAR Transposons
Generation of the SB transposon encoding the second generation CD19-specific CAR
(CD19RCD28/pSBSO) under the human elongation factor-1α promoter has been
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previously described (224).

A CD19-specific CAR co-expressing an enhanced ffLuc,

designated CAR-ffLuc, (CD19RCD28-T2A-Flag-ffLuc/pT2SBSO) was used for in vivo
monitoring of T cells by BLI. Generation of the plasmid (produced by S. Olivares) is as
follows. Sleeping beauty plasmid CD19RCD28mz-T2A-Flag-FFluc (CoOp)/pT2SBSO, coexpressing the human codon optimized CD19-specific CAR and the luciferase reporter
gene from firefly (Photinus pyralis) via a self-cleaving 2A peptide from Thosea asigna virus,
was derived from the CD19RCD28mz-T2A-hΔTK (CoOp)/pΔSBSO plasmid. The sleeping
beauty inverted-direct repeats (IRs/DRs) T1 were replaced with the hyperactive IRs-DRs
T2, to improve transposition, and the firefly luciferase reporter gene replaced the hΔTK
transgene.

In the first step, plasmids CD19RCD28mz-T2A-hΔTK (CoOp)/pΔSBSO and

CD19RCD28mZ (CoOp)/pT2SBSO were digested with StuI-KpnI and ClaI-KpnI restriction
enzymes, respectively, with an extra blunting reaction after the ClaI digestion in order to
create compatible blunted ends. The resulting fragments were purified by gel
electrophoresis and ligated using T4 DNA ligase to create intermediate plasmid-I,
CD19RCD28mz-T2A-hΔTK (CoOp)/pT2SBSO. The second step consisted of replacing the
T2A-hΔTK transgene with a T2A-flag tag fusion and a more suitable multiple cloning site to
facilitate the cloning of the reporter gene. This T2A-flag-MCS was created by polymerase
chain reaction (PCR) primer annealing and TOPO-TA cloning for validation of the
sequence.

Once the sequence was validated, plasmids CD19RCD28mz-T2A-hΔTK

(CoOp)/pT2SBSO and T2A-Flag-MCS/TOPO were digested with BspE1 and SpeI
restriction enzymes.

The resulting fragments were purified by gel electrophoresis and

ligated using T4 DNA ligase to create intermediate plasmid-II, CD19RCD28mz-T2A-Flag
(CoOp)/pT2SBSO. The final step in the process was to introduce the firefly luciferase
transgene in-frame with the flag-tag. The firefly luciferase gene was digested out from the
previously made plasmid Flag-FFLuc-HyTK (CoOp)/pT2SBSO using SnaBI and EcoRV
restriction enzymes. The same restriction enzymes were used to digest the accepting
vector followed by a dephosphorylation reaction to prevent vector self-ligation due to the
resulting compatible blunt ends.

The resulting fragments were purified by gel

electrophoresis and ligated using T4 DNA ligase to create the final plasmid,
CD19RCD28mz-T2A-Flag-FFluc (CoOp)/pT2SBSO.
6.1.3 SB11 Transposase
The hyperactive transposase (SB11) is under the control of a cytomegalovirus (CMV)
promoter in the pKan-CMV-SB11 SB transposase as previously described (224).
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6.1.4 Truncated CD19 Transposon
A truncated CD19 plasmid (dCD19-F2A-Neo/pSBSO) was constructed by cloning the
extracellular and transmembrane domains of codon-optimized human CD19 (Accession:
M84371) from a GeneArt generated vector into a pSBSO plasmid linking with neomycin
resistance via a F2A self-cleavable peptide sequence (performed by S. Olivares).
6.1.5 rLuc-mKate Reporter
The rLuc-mKate reporter (rLuc8.6-535-T2A-mKateS158A/pLV430G) is a lentiviral
vector used for modifying tumor cell lines used for imaging tumor burden during in vivo
experiments. The sequences for rLuc8.6-535 and mKateS158A were derived previous
descriptions (225, 226), codon optimized as previously reported (227) and synthesized by
GeneArt (Regensburg, Germany) as a B1 rLuc8.6-535-T2A-mKateS158A B2 construct.
The B1 and B2 sites are lambda phage recombination sites used in Gateway
Recombination Cloning Technology (Invitrogen) synthesizing the construct via BP reaction
into

pDONR221.

Subsequently,

rLuc8.6-535-T2A-mKateS158A/

pDONR221

was

recombined into pLV430G (228), a self-inactivating lentivirus encoding an internal U3
promoter from murine stem cell virus (Performed by B. Rabinovich). Lentiviral particles
were

packaged

by

transfecting

293METR

cells

with

rLuc8.6-535-T2A-

mKateS158A/pLV430G using Lipofectamine 2000 (Invitrogen). Virus was harvested 48
hours post-transfection and concentrated using 100kDa NMWL filters (Millipore) to yield the
final viral particle supernatant used for transductions (performed by J. Krishnamurthy).

6.2 Cell Lines and Their Propagation
All cell lines in this study were maintained in complete media [RPMI 1640, 10% heatinactivated fetal bovine serum (Hyclone), and 1% Glutamax-100 (Gibco)] in humidified
conditions at 5% CO2 and 37˚C.
6.2.1 K562-derived aAPC (Clone 9)
K562-derived aAPC (Clone 9) were acquired from the University of Pennsylvania
courtesy of Dr. Carl June and were generated by retroviral transduction with CD64, CD86,
CD137L, and truncated CD19 as described previously (106). Validation of co-expression of
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antigen and co-stimulatory molecules (CD19, CD86, and CD137L) were performed before
addition to T-cell cultures.
6.2.2 NALM-6 and rLuc+mKate+NALM-6
NALM-6, a pre-B cell leukemia, was obtained from American Type Culture Collection
(Manassas, VA).

Generation of the rLuc+mKate+NALM-6 cells underwent lentiviral

transduction with viral particles encoding rLuc and mKate (from vector rLuc8.6-535-T2AmKateS158A/pLV430G) by plating NALM-6 cells with the viral particles and polybrene
(Millipore) followed by centrifuging plates at 2000rpm for 1.5 hours. After outgrowth of
transduced cells, mKate+ cells were subsequently FACS Aria (BD Biosciences) sorted
(performed by J. Krishnamurthy).
6.2.3 EL4 and dCD19+EL4
The EL4 cell line, a murine T-lymphoma, was acquired from ATCC. The dCD19+EL4
cells were generated by electro-transferring the dCD19 and SB11 plasmids into EL4 using
the Amaxa mouse T cell nucleofector kit (cat.no. VPA-1006; Lonza, Basel, Switzerland)
with subsequent selection under 0.8mg/ml G418 (InvivoGen, San Diego, CA) in culture
media (performed by T. Mi).

6.3 Generation and Ex Vivo Expansion of mIL15 and CAR-modified T Cells
Anonymized normal human donor blood bank buffy coats were obtained from the Gulf
Coast Regional Blood Center (Houston, TX) and mononuclear cells were isolated by FicollPaque density gradient centrifugation (GE Healthcare) followed by cryopreservation. The
mIL15+/-CAR+ T cells were generated and propagated based on modified standard
operating protocols used to generate clinical-grade CD19-specific T cells using the
Sleeping Beauty system (105, 229) and depicted in Figure 2. Cryopreserved PBMC were
thawed the day of electroporation (day 0) and rested for 2-3 hours in complete RPMI media.
Viable cells were enumerated based on Trypan blue exclusion using a Cellometer
automated cell counter (Auto T4 Cell Counter, Nexcelom Bioscience) with the
‘PBMC_human_frozen’ program. A total of 2 x 107 live PBMC were resuspended with
selected DNA plasmids in 100µl of human T cell nucleofector solution (Human T cell Kit,
Lonza) were used per electroporation reaction.
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Electroporation reactions for CAR-

modification of cells contained 15µg of CAR transposon (CD19RCD28/pSBSO) and 5 µg of
SB11 transposase (pKan-CMV-SB11) DNA. Electroporation reactions for mIL15 and CAR
co-modification of cells contained 7.5µg of mIL15 transposon (IL15-IL15Rα-Flag/pSBSO),
7.5µg of CAR transposon (CD19RCD28/pSBSO), and 5 µg of SB11 transposase (pKanCMV-SB11) DNA. PBMC that were modified for in vivo experiments instead used the CARffLuc (CD19RCD28-T2A-Flag-ffLuc/pT2SBSO) transposon in the same quantities that were
used for the CAR transposon. Each complete reaction was transferred to a single cuvette
and electroporated with program U-14 using Nucleofector II (Lonza). Transfected cells
were transferred to a 6-well plate containing phenol-free RPMI supplemented with 20%
FBS and 1x Glutamax-100. After resting the cells for 2-3 hours a half media change was
performed with fresh phenol-free media supplemented with 1x Glutamax-100 to achieve a
final supplementation of 10% FBS, in which the cells were cultured overnight. On day 1,
electroporated cells were phenotyped and stimulated with γ-irradiated (100Gy) K562 (Clone
9) aAPC based on their CAR expression with additional aAPC stimulations every 10 ± 2
days.

Co-cultures used a ratio of 1:2 CAR+ T cells to aAPC and were maintained in

complete media.

Co-cultures were supplemented with only human IL-21 (30ng/ml,

PeproTech) during the first week (given 3 times), after which mIL15-CAR T cell cultures
continued to receive only IL-21 while CAR T cells received IL-21 and either human IL-2
(50U/ml, Aldeleukin; Novartis, Switzerland) or a soluble IL-15/IL15-Ra-Fc complex (5ng/ml)
3 times per week. The IL-15/IL15-Rα-Fc complex, referred to as IL-15 complex, is a 2:1
molar ratio combination of human IL-15 (PeproTech) and human IL-15Rα-Fc chimera (R&D
Systems) containing 5ng/ml of IL-15, thus dosing of IL-15 is denoted by its IL-15 content
since not all of the cytokine is in complexed form. This formulation was used as it has been
reported that complexing IL-15 with IL-15Rα increases the potency of IL-15 (96, 97). Some
cytokine supplementation was modified for specific assays and conditions are defined in
other sections. The cultures were monitored for excessive outgrowth of CD3-CD56+ NK
cells, which if exceeding 15% were depleted from the cultures using CD56 microbeads
(Miltenyi Biotec) and LS columns (Miltenyi Biotec) per the manufacturer’s instructions.
Viable T cells were enumerated at the end of each aAPC stimulation cycle (Stim) based on
Trypan blue exclusion using a hemocytometer for the first Stim and Cellometer counts
(‘activated T cell’ program) for subsequent Stims. Inferred CAR+ T cell numbers were
calculated by multiplying the CD3+CAR+ cell fold expansion from the first Stim with the
relative starting cell number which would then be multiplied by the CAR-specific T cell
expansion from subsequent Stims.
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6.4 Immunophenotyping
Up to 1 x 106 were stained with fluorochrome-chrome conjugated antibodies:
fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein
conjugated to cyanine dye (PerCP-Cy5.5), allophycocyanin (APC), AlexaFluor-488, and
AlexaFluor-647, which unless otherwise stated, were obtained from BD Biosciences.
Unless otherwise stated, antibodies were used at 1:20, 1:40, 1:25, 1:33, 1:20, and 1:20
dilutions, respectively, in a 100µl volume of buffer. Staining for cell surface markers and
corresponding Isotype controls was conducted in FACS buffer [phosphate-buffered saline
(PBS), 2% fetal bovine serum (FBS), 0.1% sodium azide) for 30 minutes at 4˚C.
Intracellular staining was done following fixation and permeabilization for 20 minutes at 4˚C
with BD Cytofix/Cytoperm with antibodies diluted in 1x Perm/Wash buffer for 30 minutes at
4˚C (BD Biosciences). Annexin V staining was conducted in 1x annexin binding buffer (BD
biosciences). Antibodies used for immunostaining were against human: Bcl-2 (1:5 dilution,
clone Bcl-2/100), Fc (to detect CAR; clone H10104, Invitrogen), IL-15 (1:6.7 dilution for
APC; clone 34559, R&D Systems), BLIMP-1 (clone 646702, R&D Systems), CAR idiotype
(clone 136.20.1)(230), CD3 (clone SK7), CD4 (cloneRPA-T4), CD8 (clone SK1), CD25
(clone M-A251), CD27 (clone L128), CD28 (clone L293), CD19 (clone HIB19), CD45RA
(clone HI100), CD45RO (clone UCHL1), CD56 (clone B159), CD62L (clone DREG-56),
CD122 (clone Mik-β3), CD127 (1:8.3 dilution; clone 40131, R&D Systems), CCR7 (1:45
dilution for PerCP-Cy5.5; clone G043H7, BioLegend), IL-2 (clone MQ1-17H12), IFNγ (clone
B27), pSTAT5 (pY694) [1:5 dilution; clone 47/Stat5(pY694)], T-BET (1:20 for PerCP-Cy5.5;
clone 4B10, BioLegend), and unconjugated rabbit anti-TCF1 (1:20 dilution; clone C725.7,
Thermo Scientific).

Polyclonal goat anti-rabbit IgG-DyLight650 (1:100 dilution; Thermo

Scientific) was used as a secondary antibody to detect TCF1. Annexin V (1:20 dilution; BD
Bioscience) and anti-FLAG (1:200 dilution; Prozyme) were also used. Data acquisition was
on a FACSCalibur using Cell Quest version 3.3 (BD Biosciences). Analyses were with
FlowJo software (version 7.6.5, TreeStar).
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6.5 Validation of pSTAT5 Induction by mIL15
Ex vivo expanded T cells were assessed at > 10 days after the 4th aAPC stimulation.
Cells were washed in PBS to remove residual cytokines from culture media. The cells were
then transferred to fresh serum-free culture medium (RPMI supplemented with 1%
Glutamax) at a high density of 2 x 106/ml and serum and exogenous cytokine starved for 12
hours. Starved CAR T cells indicate baseline or control levels of pSTAT5 while CAR T cells
treated with 50-100 ng/ml IL-15 one hour prior to fixation served as the positive control.
The cells were pelleted to remove the supernatant, then immediately fixed with 6ml of 37˚C
1x PhosFlow Lyse/Fix Buffer (BD Biosciences), and further incubated in a water bath for 15
minutes at 37˚C.

The cells were pelleted again to remove the supernatant, then

permeabilized by adding 3ml of 4˚C BD PhosFlow Perm Buffer III (BD Biosciences) while
vortexing, incubated on ice for 20 minutes, and then washed with FACS buffer. Cells were
stained with pSTAT5 (pY694) antibody for 20 minutes at room temperature in the dark,
washed and resuspended in FACS buffer for flow cytometry analysis.

For assessing

transpresentation of mIL15, CAR and mIL15-CAR T cells were co-cultured at a 1:4 ratio for
16 hours in serum and exogenous cytokine free medium and then processed as previously
described.

6.6 Chromium Release Assay
The antigen-specific cytolytic activity of T cells was assessed in a standard 4-hour
CRA, as previously described (231). Genetically modified T cells were incubated with 2 x
105

51

Cr-labeled target cells (EL4, CD19+EL4, or NALM-6) in V-bottomed 96-well plates

(Costar). The percentage of specific lysis was calculated from the release of

51

Cr, as

previously described, using a TopCount NXT (Perkin-Elmer) (231).

6.7 Intracellular Cytokine Production
Production of cytokines was assessed by intracellular cytokine staining of T cells. T
cells were co-cultured with CD19+ or negative targets (EL4, CD19+EL4, or NALM-6) at an
effector to target ratio of 1:5 in 200µl of culture media in a round bottom, 96-well plate. T
cells were incubated alone as a negative control and with the addition of LAC [PMA
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(phorbol 12 myristate 13 acetate) and ionomycin; BD Biosciences) as a positive control.
Brefeldin-A (GolgiPlug, BD Biosciences) was added to all cultures to block exocytosis of
cytokines produced in response to antigenic stimulation. Cultures were incubated for 6
hours at 37˚C and then stained for surface markers followed by fixation and
permeabilization and staining for intracellular proteins.

6.8 In Vivo Experiments Assessing T Cell Persistence and Antitumor Activity
Human tumor xenograft models were performed under the approved protocol of the
Institutional Animal Care and Use Committee at MDACC. All in vivo murine experiments
used age and sex-matched humanized NSG mice (NOD.Cg-PrkdcscidIL2rγtm1Wjl/SzJ, The
Jackson Laboratory).
6.8.1 In Vivo Bioluminescence Imaging
Serial non-invasive bioluminescence imaging (BLI) was performed to measure
persistence of mIL15-CAR and CAR T cells co-expressing ffLuc. BLI for ffLuc activity was
acquired 10 minutes after subcutaneous administration of D-Luciferin potassium salt
(215µg/mouse, Caliper) as has been previously described (53, 232). Serial non-invasive
BLI was also done to monitor tumor burden of rLuc+NALM-6 cells. BLI for rLuc activity was
acquired 20 minutes after intraperitoneal injection of freshly diluted Enduren Live Cell
Substrate (68µg/mouse, Promega) as has been previously described (232). Imaging was
performed on anesthetized mice in an anterior posterior position using Xenogen IVIS 100
series system (Caliper Life Sciences). Imaging for T cells and tumor were performed on
alternate days.

T cell and tumor flux (measured as photons/s/cm2/steradian) were

quantified by measuring photon signal within a delineated region of interest (ROI) which
encompassed the entire mouse, except the tail. An addition ROI was established for T cell
flux, termed ‘femur ROI’ and encompassed the femur, tibia, and foot region of the mouse.
Living Image software (v2.50, Xenogen; Caliper Life Sciences) was used to process the BLI
data.
6.8.2 Tissue Preparation
At the end of some experiments, mice were euthanized by cervical dislocation and
peripheral blood and tissues were harvested (spleen and bone marrow). Spleens were
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manually homogenized in 2% FBS/PBS and passed through a 40µm cell strainer (BD
BioSciences). To obtain the bone marrow, the femurs were flushed with 2% fetal bovine
serum in phosphate buffered saline (FBS/PBS) using 30G needles (BD Biosciences). ACK
lysing buffer (Gibco-Invitrogen) was used to lyse red blood cells in all samples followed by
washes with 2% FBS/PBS. Cells were stained for the presence of T cells (CD3), tumor
(CD19), and murine lymphocytes (CD45).
6.8.3 Persistence of CAR and mIL15-CAR T Cells in a High Tumor Burden Model
On day -1, mice were intravenously (i.v.) injected via tail vein with 1 x 105 NALM-6 cells
to establish a disseminated leukemia model. On day 0, mice (n = 5/group) in two treatment
cohorts received mIL15+CAR+ffLuc+ T cells or CAR+ffLuc+ T cells (cultured with IL-2 and IL21) injected i.v. at 2 x 107 CAR+ T cells per mouse.

T cell persistence (ffLuc) was

longitudinally monitored by BLI until day 14 when mice were sacrificed and tissues were
harvested for analysis of CD3 by flow cytometry.
6.8.4 Persistence and Efficacy of CAR and mIL15-CAR T Cells in a Low Tumor Burden
Model
T cells were engrafted first in this preventative tumor model mimicking MRD, where on
day 0 two treatment cohorts (n = 5/group) were i.v. injected with 2 x 107 CAR+ T cells: (i)
mIL15+CAR+ffLuc+ T cells and (ii) CAR+ffLuc+ T cells. On day 6, 1 x 104 rLuc+NALM-6 were
i.v. injected. T cell and tumor BLI were monitored until death or sacrifice (day 36) when
tissues were harvested for analysis of CD3 and CD19 by flow cytometry.

To assess

survival over a longer duration, another experiment was conducted in a similar fashion with
survival as the experimental endpoint followed to 98 days and tested the following cohorts:
(i) mIL15+CAR+ffLuc+ T cells plus NALM-6 (n = 7), (ii) CAR+ffLuc+ T cells plus NALM-6 (n =
8, cultured with IL-2 and IL-21), and (iii) NALM-6 only. As in the previous experiment,
NALM-6 cells were i.v. injected after T cell engraftment at 1 x 104 cells per mouse. T cell
persistence was followed by BLI until mortality or euthanasia occurred.

Mice were

considered at the experimental endpoint if they developed hind-limb paralysis or were
otherwise moribund.
6.8.5 In Vivo Persistence of CAR and mIL15-CAR T Cells in the Absence of TAA
To test T cell persistence in the absence of antigen, 2 x 107 CAR+ T cells were i.v.
injected into mice in two treatment cohorts (n = 5/group): (i) mIL15+CAR+ffLuc+ T cells and
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(ii) CAR+ffLuc+ T cells. BLI was performed to monitor T cell persistence until sacrifice at
days 48. Tissues were harvested for analysis of CD3 and CD19 by flow cytometry. Some
spleen, liver, and bone marrow samples were ex vivo expanded on K562 (Clone 9) aAPCs
at an initial stimulation one isolated cell to 5 aAPCs with subsequent stimulations at 1:1.
Expanded cells were tested for antigen-specific function by assessing IFNγ production in
response to tumor cell targets, as described in section 6.7.

6.9 Assays Characterizing Long-term mIL15-CAR T Cell Persistence in the Absence
of TAA
6.9.1 In Vitro Phenotypic and Functional Characterization
Persistence and function of T cells after antigen and exogenous cytokine withdrawal
were tested using genetically-modified T cells that had undergone four aAPC stimulation
cycles. After the fourth Stim, the T cell cultures continued to be maintained with exogenous
cytokine supplementation, as described in section 6.3, for 10 days after which T cells were
enumerated and transferred to fresh complete RPMI to establish the following treatment
groups for the withdrawal assay: (i) mIL15-CAR T cells, (ii) CAR T cells, (iii) CAR T cells
supplemented with IL-15 complex (5ng/ml, 2x/week). Cells were enumerated at days 15,
30, 50, and 65. T cells persisting > 65 days after antigen withdrawal, referred to as ‘WD-T
cells’, were then assessed for mIL15 and CAR expression.

To verify that mIL15 was

functional, pSTAT5 and Bcl-2 levels were assessed in WD-T cells per phosflow and
intracellular staining described in sections 6.5 and 6.7, respectively. To test whether the
WD-T cells were still functional and responsive to antigen stimulation, they were challenged
with CD19+/- targets and IFNγ production was measured by intracellular cytokine staining as
previously described in section 6.7. IL-2 production was assessed upon stimulation with
LAC and the analysis of intracellular staining was performed by flow cytometry. WD-T cells
were enumerated and re-stimulated with aAPC at a ratio of 1:1 and supplemented with
exogenous cytokines as described for stimulations in section 6.3.
6.9.2 nCounter System Digital Gene Expression Analysis
The day 0 CAR and mIL15-CAR T cells, as well as WD-mIL15-CAR T cells persisting
at day 65 were phenotyped and pellets of > 5 x 105 cells were frozen at -80˚C for later gene
expression analysis by the nCounter System (NanoString Technologies). Gene expression
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was analyzed for mIL15-CAR and CAR T cells obtained from cultures after more than 8
days after the fourth aAPC stimulation. The WD-mIL15-CAR T cells were those persisting
long-term (>65 days after antigen withdrawal) in cultures from the antigen and exogenous
cytokine withdrawal assays. Cells used for analysis had been pelleted and frozen at -80˚C.
At the time of analysis, RLT buffer (Qiagen) was added to samples prior to thawing at a
ratio of 166ul of buffer per 1 x 106 cells. RNA lysates were immediately processed and
analyzed using nCounter Analysis System (NanoString Technologies) to detect genes of
interest (233) using a lymphocyte-specific CodeSet (Appendix 1).

This CodeSet was

generated from RefSeq accession numbers for chosen mRNA transcripts that were used to
generate the reporter and capture probe pairs constituting the lymphocyte gene panel.
Multiplexed target-specific color-coded reporter and biotinylated capture probes for mRNA
species of interest were hybridized for >12 hours at 65˚C in a thermocycler (Peltier Thermal
Cycler, Bio-Rad), processed in the cCounter PrepStation (NanoString Technologies), and
then analyzed using the nCounter Digital Analyzer (NanoString Technologies). Reference
genes (ACTB, G6PD, OAZ1, POLR1B, POLR2A, RPL27, RPS13, TBP), which together
span a dynamic range of RNA expression, were included in the CodeSet and were used to
normalize transcript levels to account for variation of transcript levels between samples and
in the amount of total RNA present in samples. The count data was positive-, negative-,
and housekeeping gene-normalized per nCounter guidelines using the nCounter RCC
Collector Worksheet (v1.6.0, NanoString Technologies) as previously described (234) and
filtered to remove genes with low counts of less than 10 in greater than 60% of samples.
Statistical analysis were performed by edgeR software (235) via RobiNA Java interface
(236). Statistical evaluation of differential gene expression was performed using edgeR
with implemented statistical methods based on a negative binomial dispersion (235, 237239).

Genes considered to be significantly differentially expressed demonstrated an

absolute fold change ≥ 2, a p-value cut-off of 0.01, and a FDR significance value (q) less
than 0.03 with the Benjamini-Hochberg method (240) used for multiple testing correction.
These significant differentially expressed genes were represented in a heatmap generated
using Qlucore Omics Explorer (v.2.3, Qlucore). Gene Ontology classification of significant
genes was examined by DAVID functional annotation (http://david.abcc.ncifcrf.gov/)(158,
159).
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6.9.3 In Vivo Characterization of Persisting mIL15-CAR T Cells
NSG mice were infused with 2 x 107 mIL15-CAR T cells (n = 9) that were allowed to
engraft at least 50 days. Peripheral blood, spleen, and bone marrow were harvested for
analysis by flow cytometry with staining for IL-15, CAR, CD45RA, CD45RO, IL-2Rα, IL7Ra, CD27, and CCR7.
6.10 Statistical Analysis
We performed statistical analyses using Prism (GraphPad Software, v.6.02).

Cell

count and flux values were log transformed for statistical analysis. Paired (in vitro data) and
unpaired (in vivo data) t tests were used to compare two groups. One-way ANOVA was
used to compare three groups. Two-way ANOVA was used for multiple comparisons of two
factors. Two-way RM ANOVA compared multiple groups over time. Survival was analyzed
with log-rank (Mantel-Cox).
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APPENDICIES
Appendix A. nCounter Analysis System Lymphocyte-specific CodeSet
Gene Name

Accession

Target
Region
39104010
285-385

ABCB1

NM_000927.3

ABCG2

NM_004827.2

ACTB

NM_001101.2

ADAM19

NM_023038.3

AGER

NM_001136.3

340-440

AHNAK

NM_001620.1

1542015520

AIF1

NM_032955.1

315-415

AIM2

NM_004833.1

607-707

AIMP2

NM_006303.3

507-607

AKIP1

NM_020642.3

570-670

AKT1

NM_005163.2

17721872

ALDH1A1

NM_000689.3

11-111

ANXA1

NM_000700.1

515-615

ANXA2P2

NR_003573.1

257-357

APAF1

NM_181869.1

11601260

ARG1

NM_000045.2

505-605

ARRB2

NM_004313.3

16521752

ATF3

NM_001030287.2

600-700

ATM

NM_000051.3

30-130

ATP2B4

NM_001684.3

AXIN2

NM_004655.3

B2M

NM_004048.2

25-125

B3GAT1

NM_018644.3

145-245

BACH2

NM_021813.2

33953495

BAD

NM_004322.2

195-295

BAG1

NM_004323.3

14901590

BATF

NM_006399.3

825-925

BAX

NM_138761.2

694-794

BCL10

NM_003921.2

BCL11B

NM_022898.1

BCL2

NM_000633.2

10101110
16901790

76407740
10351135

12501350
34203520
15251625

Target Sequence
TATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAGAAACAACGCATTGCC
ATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGC
AGGATTTAGGAACGCACCGTGCACATGCTTGGTGGTCTTGTTAAGTGGAAACTGCTGCTTTAG
AGTTTGTTTGGAAGGTCCGGGTGACTCATCCCAACAT
TGCAGAAGGAGATCACTGCCCTGGCACCCAGCACAATGAAGATCAAGATCATTGCTCCTCCTG
AGCGCAAGTACTCCGTGTGGATCGGCGGCTCCATCCT
GAGAAGGTGAATGTGGCAGGAGACACCTTTGGAAACTGTGGAAAGGACATGAATGGTGAACA
CAGGAAGTGCAACATGAGAGATGCGAAGTGTGGGAAGA
GAAAGGAGACCAAGTCCAACTACCGAGTCCGTGTCTACCAGATTCCTGGGAAGCCAGAAATTG
TAGATTCTGCCTCTGAACTCACGGCTGGTGTTCCCAA
GGATTTGACCTGAATGTTCCTGGGGGTGAAATTGATGCCAGCCTCAAGGCTCCGGATGTAGAT
GTCAACATCGCAGGGCCGGATGCTGCACTCAAAGTCG
AAAAGCGAGAGAAAAGGAAAAGCCAACAGGCCCCCCAGCCAAGAAAGCTATCTCTGAGTTGC
CCTGATTTGAAGGGAAAAGGGATGATGGGATTGAAGGG
ACGTGCTGCACCAAAAGTCTCTCCTCATGTTAAGCCTGAACAGAAACAGATGGTGGCCCAGCA
GGAATCTATCAGAGAAGGGTTTCAGAAGCGCTGTTTG
CCCTCTCCCTGCTTGTGCTGCACAGGCTGCTCTGTGAGCACTTCAGGGTCCTGTCCACGGTG
CACACGCACTCCTCGGTCAAGAGCGTGCCTGAAAACCT
GAACATCTCTAAGGACCTCTACATAGAAGTATATCCAGGGACCTATTCTGTCACTGTGGGCTCA
AATGACTTAACCAAGAAGACTCATGTGGTAGCAGTT
TTCTTTGCCGGTATCGTGTGGCAGCACGTGTACGAGAAGAAGCTCAGCCCACCCTTCAAGCC
CCAGGTCACGTCGGAGACTGACACCAGGTATTTTGATG
ATTGCTGAGCCAGTCACCTGTGTTCCAGGAGCCGAATCAGAAATGTCATCCTCAGGCACGCCA
GACTTACCTGTCCTACTCACCGATTTGAAGATTCAAT
GAAATCAGAGACATTAACAGGGTCTACAGAGAGGAACTGAAGAGAGATCTGGCCAAAGACATA
ACCTCAGACACATCTGGAGATTTTCGGAACGCTTTGC
ATATTGTCTTCTCCTACCAGAGAAGGACCAAAAAGGAACTTGCATCAGCACTGAAGTCAGCCTT
ATCTGGCCACCTGGAGACGGTGATTTTGGGCCTATT
TTCTGATGAAACTGCAGAATCTTTGCACACGGTTGGATCAGGATGAGAGTTTTTCCCAGAGGC
TTCCACTTAATATTGAAGAGGCTAAAGACCGTCTCCG
AAGGAACTAAAAGGAAAGATTCCCGATGTGCCAGGATTCTCCTGGGTGACTCCCTGTATATCT
GCCAAGGATATTGTGTATATTGGCTTGAGAGACGTGG
CATTAATTTTTTGACTGCAGCTCTGCTTCTCCAGCCCCGCCGTGGGTGGCAAGCTGTGTTCAT
ACCTAAATTTTCTGGAAGGGGACAGTGAAAAGAGGAG
GGCTCAGAATGGGAGGACTCCAGAAGATGAGAGAAACCTCTTTATCCAACAGATAAAAGAAGG
AACATTGCAGAGCTAAGCAGTCGTGGTATGGGGGCGA
ACGCTAAGTCGCTGGCCATTGGTGGACATGGCGCAGGCGCGTTTGCTCCGACGGGCCGAAT
GTTTTGGGGCAGTGTTTTGAGCGCGGAGACCGCGTGATA
CTTCCCATAGTATCATCTGTCCTCTGGAATGACTCTCCTGTCCCTAAAGGGGTTAAGAGAGAG
ATCACCTAGAAATCCCTCTGGACACTTGTGGGTTCTT
CTTGTCCAGCAAAACTCTGAGGGCCACGGCGAGTGTGAGGTCCACGGAAACTGTTGACAGTG
GATACAGGTCCTTCAAGAGGAGCGATCCTGTTAATCCT
CGGGCATTCCTGAAGCTGACAGCATTCGGGCCGAGATGTCTCGCTCCGTGGCCTTAGCTGTG
CTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTATCCA
CTGGACAGCGACCCCTTCTCAGACTCCAGTTGGGCCGGACTCTCCAAACCTGCTTCCGCAAT
GGGTGGGTTGTGAGTGCTGGTAATGAGGAGCCGTGGGT
TGTGGCACTGTTCATCTGCTGTCCCGAAGAAACCGAGAACACATTTGGTGCACACTACAGCGG
TCTTAGCAGCAATACTGTTCCGAAGTATCCTCTCCTC
CAGCTGTGCCTTGACTACGTAACATCTTGTCCTCACAGCCCAGAGCATGTTCCAGATCCCAGA
GTTTGAGCCGAGTGAGCAGGAAGACTCCAGCTCTGCA
CTCTTGTGATCGTGTAGTCCCATAGCTGTAAAACCAGAATCACCAGGAGGTTGCACCTAGTCA
GGAATATTGGGAATGGCCTAGAACAAGGTGTTTGGCA
CACTGTGGGTTGCAGGCCCAATGCAGAAGAGTATTAAGAAAGATGCTCAAGTCCCATGGCACA
GAGCAAGGCGGGCAGGGAACGGTTATTTTTCTAAATA
ATTTTTCTGGGAGGGGTGGGGATTGGGGGACATGGGCATTTTTCTTACTTTTGTAATTATTGG
GGGGTGTGGGGAAGAGTGGTCTTGAGGGGGTAATAAA
TGAAAATACCATCTTCTCTTCAACTACACTTCCCAGACCTGGGGACCCAGGGGCTCCTCCTTT
GCCACCAGATCTACAGTTAGAAGAAGAAGGAACTTGT
GAGATGTAGCACTCATGTCGTCCCGAGTCAAGCGGCCTTTTCTGTGTTGATTTCGGCTTTCATA
TTACATAAGGGAAACCTTGAGTGGTGGTGCTGGGGG
CCAAGCACCGCTTCGTGTGGCTCCACCTGGATGTTCTGTGCCTGTAAACATAGATTCGCTTTC
CATGTTGTTGGCCGGATCACCATCTGAAGAGCAGACG
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BCL2L1

NM_138578.1

15601660

BCL2L1

NM_001191.2

260-360

BCL2L11

NM_138621.2

28252925

BCL2L11

NM_138621.4

257-357

BCL6

NM_001706.2

675-775

BCL6B

NM_181844.3

21352235

BHLHE41

NM_030762.2

655-755

BID

NM_197966.1

BIRC2

NM_001166.3

BLK

NM_001715.2

990-1090

BMI1

NM_005180.5

11451245

BNIP3

NM_004052.2

325-425

BTLA

NM_001085357.1

890-990

C21orf33

NM_004649.5

13401440

CA2

NM_000067.2

575-675

CA9

NM_001216.2

960-1060

CARD9

NM_052813.2

18501950

CASP1

NM_033292.2

575-675

CAT

NM_001752.2

CBLB

NM_170662.3

CCBP2

NM_001296.3

CCL3

NM_002983.2

681-781

CCL4

NM_002984.2

35-135

CCL5

NM_002985.2

280-380

CCNB1

NM_031966.2

715-815

CCND1

NM_053056.2

690-790

CCR1

NM_001295.2

535-635

CCR2

NM_001123041.2

20-120

CCR4

NM_005508.4

35-135

CCR5

NM_000579.1

27302830

CCR6

NM_031409.2

935-1035

CCR7

NM_001838.2

16101710

CD160

NM_007053.2

500-600

CD19

NM_001770.4

17701870

CD19R-scfv

SCFV013.1

204-304

20952195
17601860

11301230
31953295
13451445

CTAAGAGCCATTTAGGGGCCACTTTTGACTAGGGATTCAGGCTGCTTGGGATAAAGATGCAAG
GACCAGGACTCCCTCCTCACCTCTGGACTGGCTAGAG
ATCTTGGCTTTGGATCTTAGAAGAGAATCACTAACCAGAGACGAGACTCAGTGAGTGAGCAGG
TGTTTTGGACAATGGACTGGTTGAGCCCATCCCTATT
TGTTGGCACCAGAACTTAAAGCGATGACTGGATGTCTCTGTACTGTATGTATCTGGTTATCAAG
ATGCCTCTGTGCAGAAAGTATGCCTCCCGTGGGTAT
CGGACTGAGAAACGCAAGAAAAAAAGACCAAATGGCAAAGCAACCTTCTGATGTAAGTTCTGA
GTGTGACCGAGAAGGTAGACAATTGCAGCCTGCGGAG
GTTGTGGACACTTGCCGGAAGTTTATTAAGGCCAGTGAAGCAGAGATGGTTTCTGCCATCAAG
CCTCCTCGTGAAGAGTTCCTCAACAGCCGGATGCTGA
CTTTATTTGTTCTAGGGCAGCTCTGGGAACATGCGGGATTGTGGAATTGGGTCAGGAACCCTC
TCTGGTATTCTGGATGTTGTAGGTTCTCTAGCAGTCT
CGCCCATTCAGTCCGACTTGGATGCGTTCCACTCGGGATTTCAAACATGCGCCAAAGAAGTCT
TGCAATACCTCTCCCGGTTTGAGAGCTGGACACCCAG
GCTTAGCTTTAGAAACAGTGCAACACTGGTCTGCTGTTCCAGTGGTAAGCTATGTCCCAGGAA
TCAGTTTAAAAGCACGACAGTGGATGCTGGGTCCATA
TGGGATCCACCTCTAAGAATACGTCTCCAATGAGAAACAGTTTTGCACATTCATTATCTCCCAC
CTTGGAACATAGTAGCTTGTTCAGTGGTTCTTACTC
AGCTTCTTGCTCCAATCAACAAGGCCGGCTCCTTTCTTATCAGAGAGAGTGAAACCAACAAAG
GTGCCTTCTCCCTGTCTGTGAAGGATGTCACCACCCA
CCTGGAGAAGGAATGGTCCACTTCCATTGAAATACAGAGTTCGACCTACTTGTAAAAGAATGA
AGATCAGTCACCAGAGAGATGGACTGACAAATGCTGG
CACCTCGCTCGCAGACACCACAAGATACCAACAGGGCTTCTGAAACAGATACCCATAGCATTG
GAGAGAAAAACAGCTCACAGTCTGAGGAAGATGATAT
GCACCAACAGAATATGCATCCATATGTGTGAGGAGTTAAGTCTGTTTCTGACTCCAACAGGGA
CCATTGAATGATCAGCATGTTGACATCATTGTCTGGG
TTGAGTTAATCAGCGTAAGGGGATTTCTAAAGCAGGCAATCCCTGTAGCCGCAGAGAATAAAC
GCCTTCCCAAAATGGCAACTTCCCACAGCCACATTTC
AGCTGTGCAGCAACCTGATGGACTGGCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAA
ACCGGGCCTTCAGAAAGTTGTTGATGTGCTGGATTCC
CAGGTCCCAGGACTGGACATATCTGCACTCCTGCCCTCTGACTTCAGCCGCTACTTCCAATAT
GAGGGGTCTCTGACTACACCGCCCTGTGCCCAGGGTG
CGCTGACTTGGCCTGGAACGAGGAATCTGGTGCCCTGAAAGGCCCAGCCGGACTGCCGGGC
ATTGGGGCCGTTTGTTAAGCGGCACTCATTTTGCGGAGG
ACAGGCATGACAATGCTGCTACAAAATCTGGGGTACAGCGTAGATGTGAAAAAAAATCTCACT
GCTTCGGACATGACTACAGAGCTGGAGGCATTTGCAC
ATGCTTCAGGGCCGCCTTTTTGCCTATCCTGACACTCACCGCCATCGCCTGGGACCCAATTAT
CTTCATATACCTGTGAACTGTCCCTACCGTGCTCGAG
TAATGTCGAAGTTGCCCGGAGCATCCTCCGAGAATTTGCCTTCCCTCCTCCAGTATCCCCACG
TCTAAATCTATAGCAGCCAGAACTGTAGACACCAAAA
GAACAGATGGGAACCAGCTCAATTGGGTGTCCACTCAAAGTGCTCTCTCCAGGGGCCTCAGT
GACTGTGTTGCTAAACCCAGTGGTCAGTTCTCAGTTCT
CTGTGTAGGCAGTCATGGCACCAAAGCCACCAGACTGACAAATGTGTATCGGATGCTTTTGTT
CAGGGCTGTGATCGGCCTGGGGAAATAATAAAGATGC
TTCTGCAGCCTCACCTCTGAGAAAACCTCTTTGCCACCAATACCATGAAGCTCTGCGTGACTG
TCCTGTCTCTCCTCATGCTAGTAGCTGCCTTCTGCTC
AGTGTGTGCCAACCCAGAGAAGAAATGGGTTCGGGAGTACATCAACTCTTTGGAGATGAGCTA
GGATGGAGAGTCCTTGAACCTGAACTTACACAAATTT
AACTTGAGGAAGAGCAAGCAGTCAGACCAAAATACCTACTGGGTCGGGAAGTCACTGGAAAC
ATGAGAGCCATCCTAATTGACTGGCTAGTACAGGTTCA
TTGAACACTTCCTCTCCAAAATGCCAGAGGCGGAGGAGAACAAACAGATCATCCGCAAACACG
CGCAGACCTTCGTTGCCCTCTGTGCCACAGATGTGAA
CATCATTTGGGCCCTGGCCATCTTGGCTTCCATGCCAGGCTTATACTTTTCCAAGACCCAATG
GGAATTCACTCACCACACCTGCAGCCTTCACTTTCCT
ACATTCTGTTGTGCTCATATCATGCAAATTATCACTAGTAGGAGAGCAGAGAGTGGAAATGTTC
CAGGTATAAAGACCCACAAGATAAAGAAGCTCAGAG
GGTCCTTCTTAGCATCGTGCTTCCTGAGCAAGCCTGGCATTGCCTCACAGACCTTCCTCAGAG
CCGCTTTCAGAAAAGCAAGCTGCTTCTGGTTGGGCCC
TAGGAACATACTTCAGCTCACACATGAGATCTAGGTGAGGATTGATTACCTAGTAGTCATTTCA
TGGGTTGTTGGGAGGATTCTATGAGGCAACCACAGG
CTTTAACTGCGGGATGCTGCTCCTGACTTGCATTAGCATGGACCGGTACATCGCCATTGTACA
GGCGACTAAGTCATTCCGGCTCCGATCCAGAACACTA
TTCCGAAAACCAGGCCTTATCTCCAAGACCAGAGATAGTGGGGAGACTTCTTGGCTTGGTGAG
GAAAAGCGGACATCAGCTGGTCAAACAAACTCTCTGA
TTGATGTTCACCATAAGCCAAGTCACACCGTTGCACAGTGGGACCTACCAGTGTTGTGCCAGA
AGCCAGAAGTCAGGTATCCGCCTTCAGGGCCATTTTT
AGATTCACACCTGACTCTGAAATCTGAAGACCTCGAGCAGATGATGCCAACCTCTGGAGCAAT
GTTGCTTAGGATGTGTGCATGTGTGTAAGTGTGTGTG
GGCACCGACTACAGCCTGACCATCTCCAACCTGGAGCAGGAGGACATCGCCACCTACTTTTG
CCAGCAGGGCAACACACTGCCCTACACCTTTGGCGGCG

111

CD19RCD28

MDA_00002.1

2-102

CD2

NM_001767.2

CD20-scfv
(rutuximab)

14001500

SCFV002.1

8-108

CD226

NM_006566.2

163-263

CD244

NM_016382.2

CD247

NM_198053.1

CD27

NM_001242.4

330-430

CD274

NM_014143.2

684-784

CD276

NM_001024736.1

21202220

CD28

NM_006139.1

305-405

CD300A

NM_007261.2

0-100

CD38

NM_001775.2

10351135

CD3D

NM_000732.4

110-210

CD3E

NM_000733.2

75-175

CD4

NM_000616.3

835-935

CD40LG

NM_000074.2

CD44

NM_000610.3

CD45R-scfv

SCFV006.1

222-322

CD47

NM_001777.3

897-997

CD56R-scfv

SCFV008.1

197-297

CD58

NM_001779.2

478-578

CD63

NM_001780.4

350-450

CD69

NM_001781.1

460-560

CD7

NM_006137.6

440-540

CD80

NM_005191.3

12881388

CD86

NM_006889.3

146-246

CD8A

NM_001768.5

CDH1

NM_004360.2

CDK2

NM_001798.2

CDK4

NM_000075.2

CDKN1A

NM_000389.2

CDKN1B

NM_004064.2

365-465

CDKN2A

NM_000077.3

975-1075

CDKN2C

NM_001262.2

CEBPA

NM_004364.2

11501250
14901590

12251325
24602560

13201420
12301330
220-320
10551155
19752075

12951395
13201420

CAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGTGCCAA
GCACTACTACTACGGCGGCAGCTACGCCATGGACTACT
TGGGTCTCACTACAAGCAGCCTATCTGCTTAAGAGACTCTGGAGTTTCTTATGTGCCCTGGTG
GACACTTGCCCACCATCCTGTGAGTAAAAGTGAAATA
GCTGTCCCAGAGCCCCGCCATCCTGAGCGCCAGCCCTGGCGAGAAGGTGACCATGACCTGC
CGGGCCAGCAGCTCTGTGAGCTACATGCACTGGTATCAG
TAAACAGGATACGATAAAAGTCCTTAACCAAGACGCAGATGGGAAGAAGCGTTAGAGCGAGCA
GCACTCACATCTCAAGAACCAGCCTTTCAAACAGTTT
AAGAGGAACCACAGCCCTTCCTTCAATAGCACTATCTATGAAGTGATTGGAAAGAGTCAACCTA
AAGCCCAGAACCCTGCTCGATTGAGCCGCAAAGAGC
TGGCAGGACAGGAAAAACCCGTCAATGTACTAGGATACTGCTGCGTCATTACAGGGCACAGG
CCATGGATGGAAAACGCTCTCTGCTCTGCTTTTTTTCT
CCAGATGTGTGAGCCAGGAACATTCCTCGTGAAGGACTGTGACCAGCATAGAAAGGCTGCTC
AGTGTGATCCTTGCATACCGGGGGTCTCCTTCTCTCCT
TAGGAGATTAGATCCTGAGGAAAACCATACAGCTGAATTGGTCATCCCAGAACTACCTCTGGC
ACATCCTCCAAATGAAAGGACTCACTTGGTAATTCTG
ACATTTCTTAGGGACACAGTACACTGACCACATCACCACCCTCTTCTTCCAGTGCTGCGTGGA
CCATCTGGCTGCCTTTTTTCTCCAAAAGATGCAATAT
GCTTGTAGCGTACGACAATGCGGTCAACCTTAGCTGCAAGTATTCCTACAATCTCTTCTCAAGG
GAGTTCCGGGCATCCCTTCACAAAGGACTGGATAGT
CGGGGAAGTGAGAGTCGGGGATCAGTCCTGCAAGCTACGGAGTCACTACAGGGAGAGGTCT
CATCACTAGAAATAGCCGAAGAACCTGCAGCCTCAACCA
CCTTGACTCCTTGTGGTTTATGTCATCATACATGACTCAGCATACCTGCTGGTGCAGAGCTGAA
GATTTTGGAGGGTCCTCCACAATAAGGTCAATGCCA
TATCTACTGGATGAGTTCCGCTGGGAGATGGAACATAGCACGTTTCTCTCTGGCCTGGTACTG
GCTACCCTTCTCTCGCAAGTGAGCCCCTTCAAGATAC
AAGTAACAGTCCCATGAAACAAAGATGCAGTCGGGCACTCACTGGAGAGTTCTGGGCCTCTG
CCTCTTATCAGTTGGCGTTTGGGGGCAAGATGGTAATG
AGACATCGTGGTGCTAGCTTTCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAAC
AGGTGGAGTTCTCCTTCCCACTCGCCTTTACAGTTGAA
GCATTTGATTTATCAGTGAAGATGCAGAAGGGAAATGGGGAGCCTCAGCTCACATTCAGTTAT
GGTTGACTCTGGGTTCCTATGGCCTTGTTGGAGGGGG
GTGGGCAGAAGAAAAAGCTAGTGATCAACAGTGGCAATGGAGCTGTGGAGGACAGAAAGCCA
AGTGGACTCAACGGAGAGGCCAGCAAGTCTCAGGAAAT
TTCACCCTGAACATCCACCCCGTGGAGGAAGAGGACGCCGCCACCTACTACTGCCAGCACAG
CAGAGAGCTGCCCTTCACCTTCGGCTCCGGCACCAAGC
GCCATATTGGTTATTCAGGTGATAGCCTATATCCTCGCTGTGGTTGGACTGAGTCTCTGTATTG
CGGCGTGTATACCAATGCATGGCCCTCTTCTGATTT
ATTCAGCGGCTCTGGCTCCGGCACCGACTTCACTCTGATGATCTCTCGGGTGGAGGCCGAGG
ACCTGGGCGTGTACTACTGCTTTCAGGGCAGCCACGTG
GTGCTTGAGTCTCTTCCATCTCCCACACTAACTTGTGCATTGACTAATGGAAGCATTGAAGTCC
AATGCATGATACCAGAGCATTACAACAGCCATCGAG
GTCATCATCGCAGTGGGTGTCTTCCTCTTCCTGGTGGCTTTTGTGGGCTGCTGCGGGGCCTG
CAAGGAGAACTATTGTCTTATGATCACGTTTGCCATCT
AGGACATGAACTTTCTAAAACGATACGCAGGTAGAGAGGAACACTGGGTTGGACTGAAAAAGG
AACCTGGTCACCCATGGAAGTGGTCAAATGGCAAAGA
CCTACACCTGCCAGGCCATCACGGAGGTCAATGTCTACGGCTCCGGCACCCTGGTCCTGGTG
ACAGAGGAACAGTCCCAAGGATGGCACAGATGCTCGGA
AAAGATCTGAAGGTCCCACCTCCATTTGCAATTGACCTCTTCTGGGAACTTCCTCAGATGGACA
AGATTACCCCACCTTGCCCTTTACGTATCTGCTCTT
TATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGGTGCTGCTCCTCTGAAG
ATTCAAGCTTATTTCAATGAGACTGCAGACCTGCCA
GCTCAGGGCTCTTTCCTCCACACCATTCAGGTCTTTCTTTCCGAGGCCCCTGTCTCAGGGTGA
GGTGCTTGAGTCTCCAACGGCAAGGGAACAAGTACTT
CGATAATCCTCCGATCTTCAATCCCACCACGTACAAGGGTCAGGTGCCTGAGAACGAGGCTAA
CGTCGTAATCACCACACTGAAAGTGACTGATGCTGAT
TCGCTGGCGCTTCATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAG
TTGTGTACAAAGCCAGAAACAAGTTGACGGGAGAGGTG
ACTTTTAACCCACACAAGCGAATCTCTGCCTTTCGAGCTCTGCAGCACTCTTATCTACATAAGG
ATGAAGGTAATCCGGAGTGAGCAATGGAGTGGCTGC
CATGTGTCCTGGTTCCCGTTTCTCCACCTAGACTGTAAACCTCTCGAGGGCAGGGACCACACC
CTGTACTGTTCTGTGTCTTTCACAGCTCCTCCCACAA
GCTTCCGAGAGGGGTTCGGGCCGCGTAGGGGCGCTTTGTTTTGTTCGGTTTTGTTTTTTTGAG
AGTGCGAGAGAGGCGGTCGTGCAGACCCGGGAGAAAG
AAGCGCACATTCATGTGGGCATTTCTTGCGAGCCTCGCAGCCTCCGGAAGCTGTCGACTTCAT
GACAAGCATTTTGTGAACTAGGGAAGCTCAGGGGGGT
ATAATGTAAACGTCAATGCACAAAATGGATTTGGAAGGACTGCGCTGCAGGTTATGAAACTTG
GAAATCCCGAGATTGCCAGGAGACTGCTACTTAGAGG
GAGCTGGGAGCCCGGCAACTCTAGTATTTAGGATAACCTTGTGCCTTGGAAATGCAAACTCAC
CGCTCCAATGCCTACTGAGTAGGGGGAGCAAATCGTG
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CFLAR

NM_003879.3

445-545

CFLAR

NM_001127183.1

653-753

CHPT1

NM_020244.2

13031403

CIITA

NM_000246.3

470-570

CITED2

NM_006079.3

965-1065

CLIC1

NM_001288.4

310-410

CLNK

NM_052964.2

11081208

c-MET-scfv

SCFV004.1

138-238

CREB1

NM_004379.3

48554955

CREM

NM_001881.2

260-360

CRIP1

NM_001311.4

269-369

CRLF2

NM_022148.2

14201520

CSAD

NM_015989.4

205-305

CSF2

NM_000758.2

475-575

CSNK2A1

NM_177559.2

CTGF

NM_001901.2

CTLA4

NM_005214.3

405-505

CTNNA1

NM_001903.2

75-175

CTNNB1

NM_001098210.1

18151915

CTNNBL1

NM_030877.3

855-955

CTSC

NM_001114173.1

260-360

CTSD

NM_001909.3

14951595

CX3CL1

NM_002996.3

140-240

CX3CR1

NM_001337.3

10401140

CXCL10

NM_001565.1

40-140

CXCL12

NM_199168.2

505-605

CXCL9

NM_002416.1

CXCR1

NM_000634.2

CXCR3

NM_001504.1

80-180

CXCR4

NM_001008540.1

135-235

DAPL1

NM_001017920.2

190-290

DEC1

NM_017418.2

190-290

DECTIN-1R

SCFV010.1

270-370

DGKA

NM_001345.4

13751475

DOCK5

NM_024940.6

630-730

19302030
11001200

19752075
19502050

CAAGACCCTTGTGAGCTTCCCTAGTCTAAGAGTAGGATGTCTGCTGAAGTCATCCATCAGGTT
GAAGAAGCACTTGATACAGATGAGAAGGAGATGCTGC
TAGAGTGCTGATGGCAGAGATTGGTGAGGATTTGGATAAATCTGATGTGTCCTCATTAATTTTC
CTCATGAAGGATTACATGGGCCGAGGCAAGATAAGC
GATATGGTGATATACTTTAGTGCTTTGTGCCTGCAAATTTCAAGACACCTTCATCTAAATATATT
CAAGACTGCATGTCATCAAGCACCTGAACAGGTTC
GCCTGAGCAAGGACATTTTCAAGCACATAGGACCAGATGAAGTGATCGGTGAGAGTATGGAG
ATGCCAGCAGAAGTTGGGCAGAAAAGTCAGAAAAGACC
AGGAGCTGCCCGAACTCTGGCTGGGGCAAAACGAGTTTGATTTTATGACGGACTTCGTGTGC
AAACAGCAGCCCAGCAGAGTGAGCTGTTGACTCGATCG
GTGATGGGGCCAAGATTGGGAACTGCCCATTCTCCCAGAGACTGTTCATGGTACTGTGGCTCA
AGGGAGTCACCTTCAATGTTACCACCGTTGACACCAA
GAAGGAGAACAAGGATGGTAGTTTCTTGGTCCGAGATTGTTCCACAAAATCCAAGGAAGAGCC
CTATGTTTTGGCTGTGTTTTATGAGAACAAAGTCTAC
CTGATCTACGCCGCCAGCAGCCTGAAGAGCGGCGTGCCCAGCCGGTTTAGCGGCTCTGGCT
CTGGCGCCGACTTCACCCTGACCATCAGCAGCCTGCAGC
TTTGATGGTAGGTCAGCAGCAGTGCTAGTCTCTGAAAGCACAATACCAGTCAGGCAGCCTATC
CCATCAGATGTCATCTGGCTGAAGTTTATCTCTGTCT
CTCCACCTCCTCGCGTCCGTAATCAGTGACGAGGTCCGCTACGTAAATCCCTTTGCGGCGGA
CAAATGACCATGGAAACAGTTGAATCCCAGCATGATGG
CAACCACCCCTGCTACGCAGCCATGTTTGGGCCTAAAGGCTTTGGGCGGGGCGGAGCCGAG
AGCCACACTTTCAAGTAAACCAGGTGGTGGAGACCCCAT
CAAGGCAGCACGTCCAAAATGCTGTAAAACCATCTTCCCACTCTGTGAGTCCCCAGTTCCGTC
CATGTACCTGTTCCATAGCATTGGATTCTCGGAGGAT
TCAAATTCTTCTGCCTAGCCTTAGCCATTAGAGAGAGGTCCTGCTAAAGATGGACTGCAAATG
CGCTTGATGGAAGGAGATGTCAATTCCACTGAAGTCC
AGATGAGGCTGGCCAAGCCGGGGAGCTGCTCTCTCATGAAACAAGAGCTAGAAACTCAGGAT
GGTCATCTTGGAGGGACCAAGGGGTGGGCCACAGCCAT
CCATTCCCACCATTGTTCCTCCACCGTCCCACACTTTAGGGGGTTGGTATCTCGTGCTCTTCTC
CAGAGATTACAAAAATGTAGCTTCTCAGGGGAGGCA
ACCACCCTGCCGGTGGAGTTCAAGTGCCCTGACGGCGAGGTCATGAAGAAGAACATGATGTT
CATCAAGACCTGTGCCTGCCATTACAACTGTCCCGGAG
AGTCTGTGCGGCAACCTACATGATGGGGAATGAGTTGACCTTCCTAGATGATTCCATCTGCAC
GGGCACCTCCAGTGGAAATCAAGTGAACCTCACTATC
TCGCCCAGCTAGCCGCAGAAATGACTGCTGTCCATGCAGGCAACATAAACTTCAAGTGGGATC
CTAAAAGTCTAGAGATCAGGACTCTGGCAGTTGAGAG
TCTTGCCCTTTGTCCCGCAAATCATGCACCTTTGCGTGAGCAGGGTGCCATTCCACGACTAGT
TCAGTTGCTTGTTCGTGCACATCAGGATACCCAGCGC
TGATGCCAACAAACTGTATTGCAGTGAAGTGCTGGCCATATTGCTCCAGGACAATGATGAAAA
CAGGGAATTGCTTGGGGAGCTGGATGGAATCGATGTG
TGCTCGGTTATGGGACCACAAGAAAAAAAAGTAGTGGTGTACCTTCAGAAGCTGGATACAGCA
TATGATGACCTTGGCAATTCTGGCCATTTCACCATCA
GAAGCCGGCGGCCCAAGCCCGACTTGCTGTTTTGTTCTGTGGTTTTCCCCTCCCTGGGTTCAG
AAATGCTGCCTGCCTGTCTGTCTCTCCATCTGTTTGG
AGCACCACGGTGTGACGAAATGCAACATCACGTGCAGCAAGATGACATCAAAGATACCTGTAG
CTTTGCTCATCCACTATCAACAGAACCAGGCATCATG
GGGCGCTCAGTCCACGTTGATTTCTCCTCATCTGAATCACAAAGGAGCAGGCATGGAAGTGTT
CTGAGCAGCAATTTTACTTACCACACGAGTGATGGAG
GCAGAGGAACCTCCAGTCTCAGCACCATGAATCAAACTGCGATTCTGATTTGCTGCCTTATCTT
TCTGACTCTAAGTGGCATTCAAGGAGTACCTCTCTC
GGGCCTGAGGTTTGCCAGCATTTAGACCCTGCATTTATAGCATACGGTATGATATTGCAGCTTA
TATTCATCCATGCCCTGTACCTGTGCACGTTGGAAC
CACCATCTCCCATGAAGAAAGGGAACGGTGAAGTACTAAGCGCTAGAGGAAGCAGCCAAGTC
GGTTAGTGGAAGCATGATTGGTGCCCAGTTAGCCTCTG
GCAGCCACCAGTCCATTGGGCAGGCAGATGTTCCTAATAAAGCTTCTGTTCCGTGCTTGTCCC
TGTGGAAGTATCTTGGTTGTGACAGAGTCAAGGGTGT
GTGAGTGACCACCAAGTGCTAAATGACGCCGAGGTTGCCGCCCTCCTGGAGAACTTCAGCTC
TTCCTATGACTATGGAGAAAACGAGAGTGACTCGTGCT
GTCACTATGGGAAAAGATGGGGAGGAGAGTTGTAGGATTCTACATTAATTCTCTTGTGCCCTT
AGCCCACTACTTCAGAATTTCCTGAAGAAAGCAAGCC
CGAGAAAACAAGTGCCATTGCAAATGTTGCCAAAATACAGACACTGGATGCCCTGAATGACGC
ACTGGAGAAGCTCAACTATAAATTTCCAGCAACAGTG
AGGCCTTACTTTCCAGATCCAGATCCTTGTGCATACAACTGACTTGTGTGGGTGAGGCTTGCA
GAAAAAATCAGCTAGAACAGCCTTGGGGGTAGTGGCA
CTGAAGATCGACAGCAGCAACGAGCTGGGCTTCATCGTGAAGCAGGTGTCCAGCCAGCCCGA
CAACTCCTTCTGGATCGGCCTGAGCAGGCCCCAGACCG
TTCCTAACACCCACCCACTTCTCGTCTTTGTCAATCCTAAGAGTGGCGGGAAGCAGGGGCAAA
GGGTGCTCTGGAAGTTCCAGTATATATTAAACCCTCG
TGCGAGATGACAATGGGAACATCCTAGACCCTGACGAAACCAGCACCATTGCCCTCTTCAAGG
CCCATGAGGTGGCCTCCAAAAGGATTGAGGAAAAGAT
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DOK2

NM_003974.2

650-750

DPP4

NM_001935.3

27002800

DUSP16

NM_030640.2

615-715

EGFR-scfv_
(NIMO CAR)

SCFV015.1

7-107

EGLN1

NM_022051.1

39754075

EGLN3

NM_022073.3

800-900

EIF1

NM_005801.3

869-969

ELF4

NM_001421.3

335-435

ELOF1

NM_032377.3

125-225

ENTPD1

NM_001776.4

225-325

EOMES

NM_005442.2

EPHA2

NM_004431.2

EPHA4

NM_004438.3

20-120

EPHB2

NM_017449.2

785-885

ETV6

NM_001987.4

FADD

NM_003824.2

FAM129A

NM_052966.2

FANCC

NM_000136.2

FAS

NM_000043.3

90-190

FASLG

NM_000639.1

625-725

FCGR3B

NM_000570.3

73-173

FGL2

NM_006682.2

250-350

FLT1

NM_002019.2

56155715

FLT3LG

NM_001459.2

927-1027

FOS

NM_005252.2

FOXO1

NM_002015.3

FOXO3

NM_001455.2

FOXP1

NM_032682.5

FOXP3

NM_014009.3

FYN

NM_002037.3

FZD1

NM_003505.1

G6PD

NM_000402.2

GABPA

NM_002040.3

GADD45A

NM_001924.2

865-965

GADD45B

NM_015675.2

365-465

16701770
15251625

38403940
15601660
35263626
21302230

14751575
15261626
18601960
67586858
12301330
765-865
24302530
11551255
11601260

GCCAGGGACCCAGCTGTACGACTGGCCCTACAGGTTTCTGCGGCGCTTTGGGCGGGACAAG
GTAACCTTTTCCTTTGAGGCAGGCCGTCGCTGCGTCTCT
CAGCAGTCAGCTCAGATCTCCAAAGCCCTGGTCGATGTTGGAGTGGATTTCCAGGCAATGTG
GTATACTGATGAAGACCATGGAATAGCTAGCAGCACAG
ATGGGTTTAACTCTCCTTTTGCCAGTCACCACCAGCCTGACCTCATACACTTTTAGTACAATGG
AGTGGCTGAGCCTTTGAGCACACCACCATTACATCA
AGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGCGACAGAGTGACCATCACCTG
CCGGTCCAGCCAGAACATCGTGCACAGCAACGGCAACAC
AGCAGCATGGACGACCTGATACGCCACTGTAACGGGAAGCTGGGCAGCTACAAAATCAATGG
CCGGACGAAAGCCATGGT
AAGCTACATGGTGGGATCCTGCGGATATTTCCAGAGGGGAAATCATTCATAGCAGATGTGGAG
CCCATTTTTGACAGACTCCTGTTCTTCTGGTCAGATC
CCTGAACAGTCCTCGGTGAATCTGAGAGGAGAGGATGGGGTAAGGCAGAAGCACCAGCTGTA
CTACTAGAAGGGAGCTTTTGGTGGTAGATCCCCTGGTG
AGCTCTGGAGGGCTCTGATAATCCCGTTGTCAGCTCTCTGAAAAGACAGCATGGCTATTACCC
TACAGCCCAGTGACCTGATCTTTGAGTTCGCAAGCAA
AGACCCAGTTCACCTGCCCCTTCTGCAACCACGAGAAATCCTGTGATGTGAAAATGGACCGTG
CCCGCAACACCGGAGTCATCTCTTGTACCGTGTGCCT
TTCGAGTAACTTTAGGAAAATGAGCTGCTGGACTCCTCAGTCAATCTGTCCTTTCTAGTCAATG
AAAAAGACAGGGTTTGAGGTTCCTTCCGAAACGGGG
ATCCCATGCCCTGGGGTATTACCCAGACCCAACCTTTCCTGCAATGGCAGGGTGGGGAGGTC
GAGGTTCTTACCAGAGGAAGATGGCAGCTGGACTACCA
GAGCCGAGTGTGGAAGTACGAGGTCACTTACCGCAAGAAGGGAGACTCCAACAGCTACAATG
TGCGCCGCACCGAGGGTTTCTCCGTGACCCTGGACGAC
GCAGCGTTGGCACCGGCGAACCATGGCTGGGATTTTCTATTTCGCCCTATTTTCGTGTCTCTT
CGGGATTTGCGACGCTGTCACAGGTTCCAGGGTATAC
CAAAGCAGGCTTCGAGGCCGTTGAGAATGGCACCGTCTGCCGAGGTTGTCCATCTGGGACTT
TCAAGGCCAACCAAGGGGATGAGGCCTGTACCCACTGT
GTATGAATATGAAATCAGAGACCAGGGCATGATGTTGCTAGGATTAGAGCCTCTCAGTCTGGC
CTCTTCACCCAAGTGCAAGAACTCAGTCTCTTACTGT
TGAGACTGCTAAGTAGGGGCAGTGATGGTTGCCAGGACGAATTGAGATAATATCTGTGAGGT
GCTGATGAGTGATTGACACACAGCACTCTCTAAATCTT
TGCCCAATAGATTCAAGAGAAGCTAAGCGGAAATGGAGGGTGGAAGGTGTGATCTGTGGGAC
TGTCTGGGCCTGTTACTCATCCTGCTATCAATTTCTTA
GACTCAGTCAGACATGTTCACTAATGACTCAAGTGAGCCTTCGGTACTCCTGGTGCCCGCCCG
GCCAGACCGTCAGCTTGATAATTACTAAAGCAAAGGC
CACCGGGGCTTTTCGTGAGCTCGTCTCTGATCTCGCGCAAGAGTGACACACAGGTGTTCAAA
GACGCTTCTGGGGAGTGAGGGAAGCGGTTTACGAGTGA
TCCATGCCTCTGGAATGGGAAGACACCTATGGAATTGTCCTGCTTTCTGGAGTGAAGTATAAG
AAGGGTGGCCTTGTGATCAATGAAACTGGGCTGTACT
CCTATTCCTGTTCTATGGTGGGGCTCCATTGCGAGACTTCAGATTGAGAAATCAGATGAAGTTT
CAAGAAAAGGAAACTGGCAGGTGACAGAGATGGGTG
CAATTCAGCAGGATCGAGGAGGTGTTCAAAGAAGTCCAAAACCTCAAGGAAATCGTAAATAGT
CTAAAGAAATCTTGCCAAGACTGCAAGCTGCAGGCTG
TTCAACTGCTTTGAAACTTGCCTGGGGTCTGAGCATGATGGGAATAGGGAGACAGGGTAGGA
AAGGGCGCCTACTCTTCAGGGTCTAAAGATCAAGTGGG
CCTCCCCAGAATGGAGGCAACGCCAGAATCCAGCACCGGCCCCATTTACCCAACTCTGTACA
AAGCCCTTGTCCCCATGAAATTGTATATAAATCATCCT
ACTCAAGTCCTTACCTCTTCCGGAGATGTAGCAAAACGCATGGAGTGTGTATTGTTCCCAGTG
ACACTTCAGAGAGCTGGTAGTTAGTAGCATGTTGAGC
TCTCATCACCAACATCATTAACTGTTTCGACCCAGTCCTCACCTGGCACCATGATGCAGCAGA
CGCCGTGCTACTCGTTTGCGCCACCAAACACCAGTTT
CCGGAACGTGATGCTTCGCAATGATCCGATGATGTCCTTTGCTGCCCAGCCTAACCAGGGAA
GTTTGGTCAATCAGAACTTGCTCCACCACCAGCACCAA
CCTGAAAATCAGATTTACAATGCTGAAGGCATTTCTTGGGCCCAGTGTAGCTCACGCAATCTCT
GCTACCCATAAGCCTTGATGAAGATGATACAGTCCG
GGGCCATCCTGGAGGCTCCAGAGAAGCAGCGGACACTCAATGAGATCTACCACTGGTTCACA
CGCATGTTTGCCTTCTTCAGAAACCATCCTGCCACCTG
GTCTTTGGAGGTGTGAACTCTTCGTCTCATACGGGGACCTTGCGTACGAGAGGAGGAACAGG
AGTGACACTCTTTGTGGCCCTTTATGACTATGAAGCAC
GTGCCAATCCTGACATCTCGAGGTTTCCTCACTAGACAACTCTCTTTCGCAGGCTCCTTTGAAC
AACTCAGCTCCTGCAAAAGCTTCCGTCCCTGAGGCA
ACAACATCGCCTGCGTTATCCTCACCTTCAAGGAGCCCTTTGGCACTGAGGGTCGCGGGGGC
TATTTCGATGAATTTGGGATCATCCGGGACGTGATGCA
GACCAAGTCCTGCATTGGGTGGTTTGGGTAATGAAGGAATTCAGCATGACCGATATAGACCTC
ACCACACTCAACATTTCGGGGAGAGAATTATGTAGTC
GTTACTCCCTACACTGATGCAAGGATTACAGAAACTGATGCCAAGGGGCTGAGTGAGTTCAAC
TACATGTTCTGGGGGCCCGGAGATAGATGACTTTGCA
TGTGGACCCAGACAGCGTGGTCCTCTGCCTCTTGGCCATTGACGAGGAGGAGGAGGATGACA
TCGCCCTGCAAATCCACTTCACGCTCATCCAGTCCTTC
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GAL3ST4

NM_024637.4

11401240

GAS2

NM_005256.3

915-1015

GATA2

NM_032638.3

GATA3

NM_001002295.1

gBAD-1R-scfv

SCFV001.1

1-101

GEMIN2

NM_001009182.1

537-637

GFI1

NM_005263.2

22352335

GLIPR1

NM_006851.2

255-355

GLO1

NM_006708.1

12401340

GNLY

NM_006433.2

305-405

GSK3B

NM_002093.2

925-1025

GZMA

NM_006144.2

155-255

GZMB

NM_004131.3

540-640

GZMH

NM_033423.3

705-805

HCST

NM_001007469.1

132-232

HDAC1

NM_004964.2

785-885

HDAC2

NM_001527.1

930-1030

HER2-scfv

SCFV014.1

64-164

HERV-K
6H5-scfv

SCFV012.1

137-237

HLA-A

NM_002116.5

10001100

HMGB2

NM_001130688.1

14951595
28352935

125-225
11171217
15031603
10151115

HOPX

NM_001145460.1

HOXA10

NM_018951.3

HOXA9

NM_152739.3

HOXB3

NM_002146.4

60-160

HOXB4

NM_024015.4

13401440

HPRT1

NM_000194.1

240-340

HRH1

NM_000861.2

30553155

HRH2

NM_022304.1

600-700

Human CD19Rscfv

SCFV009.1

215-315

ICOS

NM_012092.2

640-740

ICOSLG

NM_015259.4

11901290

ID2

NM_002166.4

505-605

ID3

NM_002167.3

195-295

IDO1

NM_002164.3

50-150

CGAGCCCAAACCCTCAATCCCAATGCCCTCATCCATCCTGTTTCCACTGTTACTGATCATCGCA
GCCAGATATCAAGCCCTGCCTCTTTCGATTTGGGGT
GATCTCCCGTGTGGATGGCAAAACATCCCCTATCCAAAGCAAATCTCCAACTCTAAAGGACAT
GAATCCAGATAACTACTTGGTGGTCTCTGCCAGTTAT
GAAGAAGGAAGGGATCCAGACTCGGAACCGGAAGATGTCCAACAAGTCCAAGAAGAGCAAGA
AAGGGGCGGAGTGCTTCGAGGAGCTGTCAAAGTGCATG
AAGAGTCCGGCGGCATCTGTCTTGTCCCTATTCCTGCAGCCTGTGCTGAGGGTAGCAGTGTAT
GAGCTACCAGCGTGCATGTCAGCGACCCTGGCCCGAC
AGACAGACACCCTGCTCCTCTGGGTGTCCGGCACCTGTGGCGACATCGTGATGAGCAGAAGC
CCCAGCAGCCTGGCCGTGTCCGTGGGCGAGAAAGTGAC
ACAAGCAACAGTAACTAGTGTCTTGGAATATCTGAGTAATTGGTTTGGAGAAAGAGACTTTACT
CCAGAATTGGGAAGATGGCTTTATGCTTTATTGGCT
TCATCACTGGAGGTAAAAGCACAAGCAATGCCTGTGGACAAGATGTCATTCATTCACTCAGCA
AATGTTCATGGATCACCGGCTACCAAGGTACCAGGCA
CTGCGTTCGAATCCATAACAAGTTCCGATCAGAGGTGAAACCAACAGCCAGTGATATGCTATA
CATGACTTGGGACCCAGCACTAGCCCAAATTGCAAAA
GGAAATGATATGGTACCCAGACACTGGGCTAGGCTGCAACTTTATCTCATTTAATACTCCCAGC
TGTCATGTGAGAAAGAAAGCAGGCTAGGCATGTGAA
CAGGAGCTGGGCCGTGACTACAGGACCTGTCTGACGATAGTCCAAAAACTGAAGAAGATGGT
GGATAAGCCCACCCAGAGAAGTGTTTCCAATGCTGCGA
ACTGATTATACCTCTAGTATAGATGTATGGTCTGCTGGCTGTGTGTTGGCTGAGCTGTTACTAG
GACAACCAATATTTCCAGGGGATAGTGGTGTGGATC
AGACCCTACATGGTCCTACTTAGTCTTGACAGAAAAACCATCTGTGCTGGGGCTTTGATTGCAA
AAGACTGGGTGTTGACTGCAGCTCACTGTAACTTGA
ACACTACAAGAGGTGAAGATGACAGTGCAGGAAGATCGAAAGTGCGAATCTGACTTACGCCAT
TATTACGACAGTACCATTGAGTTGTGCGTGGGGGACC
AAAAAAGGGACACCTCCAGGAGTCTACATCAAGGTCTCACACTTCCTGCCCTGGATAAAGAGA
ACAATGAAGCGCCTCTAACAGCAGGCATGAGACTAAC
ATCCTCTTCCTGCTTTTGCTCCCAGTGGCTGCAGCTCAGACGACTCCAGGAGAGAGATCATCA
CTCCCTGCCTTTTACCCTGGCACTTCAGGCTCTTGTT
CAAGCCGGTCATGTCCAAAGTAATGGAGATGTTCCAGCCTAGTGCGGTGGTCTTACAGTGTG
GCTCAGACTCCCTATCTGGGGATCGGTTAGGTTGCTTC
AAGCCTATTATCTCAAAGGTGATGGAGATGTATCAACCTAGTGCTGTGGTATTACAGTGTGGT
GCAGACTCATTATCTGGTGATAGACTGGGTTGTTTCA
CCTGCAGCGCCAGCAGCAGCGTGTCCTACATGCACTGGTATCAGCAGAAGTCCGGCACTAGC
CCCAAGCGGTGGATCTACGACACCTACAAGCTCGCCAG
CGGCGGCACCAGCTACAACCAGAAGTTCAAGGACAAGGCCATCCTGACCGTGGACAAGAGCA
GCAGCACCGCCTACATGGAACTGCGGAGCCTGACCAGC
GGAAGAGCTCAGATAGAAAAGGAGGGAGTTACACTCAGGCTGCAAGCAGTGACAGTGCCCAG
GGCTCTGATGTGTCCCTCACAGCTTGTAAAGTGTGAGA
CTGTCAACATGGGTAAAGGAGACCCCAACAAGCCGCGGGGCAAAATGTCCTCGTACGCCTTC
TTCGTGCAGACCTGCCGGGAAGAGCACAAGAAGAAACA
AACAATAGGAAGCTATGTGTATCTTCTGTGTAAAGCAGTGGCTTCACTGGAAAAATGGTGTGG
CTAGCATTTCCCTTTGAGTCATGATGACAGATGGTGT
TTCTATAGAGATAGATATTGTCCTAAGTGTCAAGTCCTGACTGGGCTGGGTTTGCTGTCTTGGG
GTCCCACTGCTCGAAATGGCCCCTGTCTTCGGCCGA
GGCTCTAAACCTCAGGCCACATCTTTTCCAAGGCAAACCCTGTTCAGGCTGGCTCGTAGGCCT
GCCGCTTTGATGGAGGAGGTATTGTAAGCTTTCCATT
TGTCCGTTTAAATGCTGCTGGGAGACTCGTAAAAAAATCATCGTGGACCTGGAGGATGAGAGG
GGCGAGCTTTATTTCGGTCGGATTGCGGTGTGGTGGT
CCTTTCTTTGTCCCCCACTCCCGATACCCAGCGAAAGCACCCTCTGACTGCCAGATAGTGCAG
TGTTTTGGTCACGGTAACACACACACACTCTCCCTCA
TGTGATGAAGGAGATGGGAGGCCATCACATTGTAGCCCTCTGTGTGCTCAAGGGGGGCTATA
AATTCTTTGCTGACCTGCTGGATTACATCAAAGCACTG
GTGGCAGCTCAAAATGATATGTTTGAGTAGACGAACAGCTGACATGGAGTTCCCGTGCACCTA
CGGAAGGGGACGCTTTGAAGGAACCAAGTGCATTTTT
GCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCGTGGGCTTGAA
CCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGT
CTTCACCATCAGCAGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCAGCAGTACCAGA
GCCTGCCCTACACCTTCGGCCAGGGCACCAAGCTGCAG
AACTCTGGCACCCAGGCATGAAGCACGTTGGCCAGTTTTCCTCAACTTGAAGTGCAAGATTCT
CTTATTTCCGGGACCACGGAGAGTCTGACTTAACTAC
CTGCTGGCGTTGGCTGTGATCCTGGAATGAGGCCCTTTCAAAAGCGTCATCCACACCAAAGG
CAAATGTCCCCAAGTGAGTGGGCTCCCCGCTGTCACTG
CGGATATCAGCATCCTGTCCTTGCAGGCTTCTGAATTCCCTTCTGAGTTAATGTCAAATGACAG
CAAAGCACTGTGTGGCTGAATAAGCGGTGTTCATGA
AGGAAGCCTGTTTGCAATTTAAGCGGGCTGTGAACGCCCAGGGCCGGCGGGGGCAGGGCCG
AGGCGGGCCATTTTGAATAAAGAGGCGTGCCTTCCAGGC
CTATTATAAGATGCTCTGAAAACTCTTCAGACACTGAGGGGCACCAGAGGAGCAGACTACAAG
AATGGCACACGCTATGGAAAACTCCTGGACAATCAGT
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IFNGR1
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IGF1R
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IL10
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IL12A
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16851785
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39-139
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240-340
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30203120
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48-148
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840-940
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319-419

IL23A

NM_016584.2

411-511

IL23R

NM_144701.2

710-810

IL27
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143-243

IL2RA
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ATCCCTCTCTTTATCAACAAACTTGCAAGAAAGATTAAGGAGGAAGGAATAACATCTGGTCCAA
CATGAAAACAATTCTTATTGACTCATACACCAGGTC
ATACTATCCAGTTACTGCCGGTTTGAAAATATGCCTGCAATCTGAGCCAGTGCTTTAATGGCAT
GTCAGACAGAACTTGAATGTGTCAGGTGACCCTGAT
CCCGGGCAGCCATCTGACTCCAATAGAGAGAGAGAGTTCTTCACCTTTAAGTAGTAACCAGTC
TGAACCTGGCAGCATCGCTTTAAACTCGTATCACTCC
TCGGGGGGCCATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTC
CCTGATCCTGGATGCGGTGTCCAATAACTACATTGTG
CCGCTGTGTACTACTGTGTGCCTAGATTCCATGCACTCTCGTTGTGTTTGAAGTAAATATTGGA
GACCGGAGGGTAACAGGTTGGCCTGTTGATTACAGC
CCATGTACCTCCTATGGAAGATTGTAAGGAACAAGAGCCTATTATGGACAACAATATTTCTCTG
GTGCCTTTTGAGAGACCTGCTGTCATAGAGAAGCTC
AAGGATCAGCTGGACAACTTGTTGTTAAAGGAGTCCTTGCTGGAGGACTTTAAGGGTTACCTG
GGTTGCCAAGCCTTGTCTGAGATGATCCAGTTTTACC
TGCCCAGCCCTCCGTCTGTGTGGTTTGAAGCAGAATTTTTCCACCACATCCTCCACTGGACAC
CCATCCCAAATCAGTCTGAAAGTACCTGCTATGAAGT
CTTTCTAGATCAAAACATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGT
GAGACTGTGCCACAAAAATCCTCCCTTGAAGAACCG
GCAAGGCTGCAAGTACATCAGTTTTATGACAATCAGGAAGAATGCAGTGTTCTGATACCAGTG
CCATCATACACTTGTGATGGATGGGAACGCAAGAGAT
AGGAAAAGTGTTACTACATTACCATCTTTGCCTCTGCGCACCCCGAGAAGCTCACCTTGTGGT
CTACGGTCCTGTCCACCTACCACTTTGGGGGCAATGC
CCTCCGTGGGACATTAGAATCAAATTTCAAAAGGCTTCTGTGAGCAGATGTACCCTTTATTGGA
GAGATGAGGGACTGGTACTGCTTAATCGACTCAGAT
TTTCTTTCTGATGTCAAAAATGTCTTGGGTAGGCGGGAAGGAGGGTTAGGGAGGGGTAAAATT
CCTTAGCTTAGACCTCAGCCTGTGCTGCCCGTCTTCA
AGGGTGATAGTCAAATTATGTATTGGTGGGGCTGGGTACCAATGCTGCAGGTCAACAGCTATG
CTGGTAGGCTCCTGCCAGTGTGGAACCACTGACTACT
CGCTCGCCCGGGGAGTCCAGCGGTGTCCTGTGGAGCTGCCGCCATGGCCCCGCGGCGGGC
GCGCGGCTGCCGGACCCTCGGTCTCCCGGCGCTGCTACTG
TACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATATCCC
TCTGTGATCTGGGAGGCAAAGTGCCGCCACTTGGGCT
GCCCGCCTGTGCCAGGAGGTAGTATGAAGCTTGACATTGGCATCATCAATGAAAACCAGCGC
GTTTCCATGTCACGTAACATCGAGAGCCGCTCCACCTC
CTACTATGTGGCGGGCATTTGGGATACCAAGATAAATTGCATGCGGCATGGCCCCAGCCATGA
AGGAACTTAACCGCTAGTGCCGAGGACACGTTAAACG
GACAGTCAGCAAGGAATTGTCTCCCAGTGCATTTTGCCCTCCTGGCTGCCAACTCTGGCTGCT
AAAGCGGCTGCCACCTGCTGCAGTCTACACAGCTTCG
GAATGAGGGGATTTTAAGTGTCTGAAGAGGCATTTTCTAGGGACCAGTGGGTGACTGAGTAAC
TGAAATGCTGCTTTCACTCCCTAACACCATGGATCTG
GCTTGATGGACAATGGAGTGGGATTGAGACTGTGGTTTAGAGCCTTTGATTTCCTGGACTGGA
CTGACGGCGAGTGAATTCTCTAGACCTTGGGTACTTT
ACTCCATGAAGGCTGCATGGATCAATCTGTGTCTCTGAGTATCTCTGAAACCTCTAAAACATCC
AAGCTTACCTTCAAGGAGAGCATGGTGGTAGTAGCA
GGGACCAAAGGCGGCCAGGATATAACTGACTTCACCATGCAATTTGTGTCTTCCTAAAGAGAG
CTGTACCCAGAGAGTCCTGTGCTGAATGTGGACTCAA
AGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACAAACAGTGCACCTACTT
CAAGTTCTACAAAGAAAACACAGCTACAACTGGAGC
CGTGTTTGTGGTCAACAGATGACAACAGCCGTCCTCCCTCCTAGGGTCTTGTGTTGCAAGTTG
GTCCACAGCATCTCCGGGGCTTTGTGGGATCAGGGCA
CTATCTGATGAAGCAGGTGCTGAACTTCACCCTTGAAGAAGTGCTGTTCCCTCAATCTGATAG
GTTCCAGCCTTATATGCAGGAGGTGGTGCCCTTCCTG
CAGGGACAACAGTCAGTTCTGCTTGCAAAGGATCCACCAGGGTCTGATTTTTTATGAGAAGCT
GCTAGGATCGGATATTTTCACAGGGGAGCCTTCTCTG
AACTGCAAATTCACCTGGATGATATAGTGATACCTTCTGCAGCCGTCATTTCCAGGGCTGAGA
CTATAAATGCTACAGTGCCCAAGACCATAATTTATTG
CAGGAGCTGCGGAGGGAGTTCACAGTCAGCCTGCATCTCGCCAGGAAGCTGCTCTCCGAGGT
TCGGGGCCAGGCCCACCGCTTTGCGGAATCTCACCTGC
CTTGGTAAGAAGCCGGGAACAGACAACAGAAGTCATGAAGCCCAAGTGAAATCAAAGGTGCT
AAATGGTCGCCCAGGAGACATCCGTTGTGCTTGCCTGC
GTCCTGCTGCCCGAGCCAGGAACTGTGTGTGTTGCAGGGGGGCAGTAACTCCCCAACTCCCT
CGTTAATCACAGGATCCCACGAATTTAGGCTCAGAAGC
CCACAGCTGGACTGAACAATCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGG
GCAGAAACGCTACACGTTTCGTGTTCGGAGCCGCTTT
GACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCACAAGCAGCTGATCCGATT
CCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGG
ATCATCTCACCTATGCAGTCAACATTTGGAGTGAAAACGACCCGGCAGATTTCAGAATCTATAA
CGTGACCTACCTAGAACCCTCCCTCCGCATCGCAGC
CCACAGAAATTCCCACAAGTGCATTGGTGAAAGAGACCTTGGCACTGCTTTCTACTCATCGAA
CTCTGCTGATAGCCAATGAGACTCTGAGGATTCCTGT
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TGACAAACAAATTCGGTACATCCTCGACGGCATCTCAGCCCTGAGAAAGGAGACATGTAACAA
GAGTAACATGTGTGAAAGCAGCAAAGAGGCACTGGCA
CTTTCTACATAGTGTCCATGTGCGTCGCCAGTAGTGTCGGGAGCAAGTTCAGCAAAACTCAAA
CCTTTCAGGGTTGTGGAATCTTGCAGCCTGATCCGCC
TTGCTTTGACCACTCTTCCTGAGTTCAGTGGCACTCAACATGAGTCAAGAGCATCCTGCTTCTA
CCATGTGGATTTGGTCACAAGGTTTAAGGTGACCCA
AAGTACTAAAGAACAACAAGTGTCCATATTTTTCCTGTGAACAGCCATGCAACCAAACCACGGC
AGGCAACGCGCTGACATTTCTGAAGAGTCTTCTGGA
CTGTGCGAGTGTACCGGATGCTTCCACCTCTCACCAAGAACCAGAGAAAAGAAAGAAAGTCGA
AGTCCAGCCGAGATGCTAAGAGCAAGGCCAAGAGGAA
CAGTACCTGGAGCTTCTCTTTAACTCAGGACTCCAGCCCATTGGTAGACGTGTGTTTCTAGAG
CCTGCTGGATCTCCCAGGGCTACTCACTCAAGTTCAA
GGGCACTGTTTAAAGGAAAGTTCCGAGAAGGCATCGACAAGCCGGACCCTCCCACCTGGAAG
ACGCGCCTGCGGTGCGCTTTGAACAAGAGCAATGACTT
ACTGTGAGAACTTCAGGTTTTCCAACCTATTGGTGGTATGTCTGACAGTGGATCACAACTTGGT
TCAATGGGTAGCCTCACCATGAAATCACAGCTTCAG
AAGTGGCAAGACTATAAGGAAAGAGTATGCACAACGTATTCCATCAGGTGGGGATGGTAAGAC
ACTGAAATTTTTTGGCCAGTCTATCCACGGAGAAATG
GCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCCGGGGCGATTTACAGATGCA
GGATCGGAAAGAATCCCGGCCAGACGTGCGAACAGCTC
AGAAGACTTTGTTGCTGGTGTGCCCAAAGGGAACCTCACTTACGGCTATGTCACCATCCTTAA
TGGCTCAGACATTCGATCCCTCTACAACTTCTCAGGG
GTGAGGGCTTGTCATTACCAGACGGTTCACCAGCCTCTCTTGGTTTCCTTCCTTGGAAGAGAA
TGTCTGATCTAAATGTGGAGAAACTGTAGTCTCAGGA
GCCCTCCGAGGGTGTCCTCAAGAGGATAGTGACATTGCCTTCTTGATTGATGGCTCTGGTAGC
ATCATCCCACATGACTTTCGGCGGATGAAGGAGTTTG
CCCCTCAGCCTGTTGGCTTCTGTTCACCAGCTGCAAGGGTTTACATACACGGCCACCGCCATC
CAAAATGTCGTGCACCGATTGTTCCATGCCTCATATG
TTTTAACATTACCAAGGTAGAAAGTCGGGACAAATTACCCCAGCCGGTCCAACCTGATCCTGT
GTCCCATTGTAAGGAGAAGGATGTTGACGACTGTTGG
CAACGTGGTACAGCTCATCATGGATGCTTATAATAGCCTGTCTTCCACCGTGACCCTTGAACA
CTCTTCACTCCCTCCTGGGGTCCACATTTCTTACGAA
GCCAGTAAAGAAGTCAGTATAGAACCACTAGCGAATAGTGTTGCTCTGGCACAGACCACTGTG
GTTGATGGCATGGCCCTCCAACTTGGAATAGGATTTT
GAGAACACCAAGCTCTGGTATGCTCCAAATCGCACCATCACCGTTGATGACAAGATGTCCCTC
CGGCTCCACTACCGGATGAGGTTCTATTTCACCAATT
CTCCTCCCGCGACGGCAAATGTTCTGAAAAAGACTCTGCATGGGAATGGCCTGCCTTACGATG
ACAGAAATGGAGGGAACATCCACCTCTTCTATATATC
GTGCTGCTGAAGGTCATGGATGCCAAGCACAAGAACTGCATGGAGTCATTCCTGGAAGCAGC
GAGCTTGATGAGCCAAGTGTCGTACCGGCATCTCGTGC
ACACAGCCAGCCAGCCAGGTCGGCAGTATAGTCCGAACTGCAAATCTTATTTTCTTTTCACCTT
CTCTCTAACTGCCCAGAGCTAGCGCCTGTGGCTCCC
GCGCGCCTGGAGGACAAGGTGAAGACGCTCAAGGCCGAGAACGCGGGGCTGTCGAGTACCG
CCGGCCTCCTCCGGGAGCAGGTGGCCCAGCTCAAACAGA
GCAGGAAACAGAACAGCGAATAGCGAGGACTCTGATGAACAAGACCCTCAGGAGGTGACATA
CACACAGTTGAATCACTGCGTTTTCACACAGAGAAAAA
TCTCCTTCATCGCTGGTGCTCCAACAAAAAAAATGCTGCGGTAATGGACCAAGAGTCTGCAGG
GAACAGAACAGCGAATAGCGAGGACTCTGATGAACAA
CTCCGAAACCGGTAACCCCAGACACCTGCATGTTCTGATTGGGACCTCAGTGGTCATCATCCT
CTTCATCCTCCTCCTCTTCTTTCTCCTTCATCGCTGG
GCGTCCTGGCAGCAGAAGCTGCACCATGTCCATGTCACCCACGGTCATCATCCTGGCATGTC
TTGGGTTCTTCTTGGACCAGAGTGTGTGGGCACACGTG
GACACGTGCTGTTCCACCTTCCCTCATGCTGTTTCACCTTTCCTCAGACTATTTTCCAGCCTTC
TGTCAGTCAGCAGTGAAACTTATAAAATTTTTTGTG
CTTCACCCACTGAACCAAGCTCCGAAACCGGTAACCCCAGACACCTACATGTTCTGATTGGGA
CCTCAGTGGTCAAAATCCCTTTCACCATCCTCCTCTT
CAAGAGCCTGCAGGGAACAGAACAGTGAACAGCGAGGATTCTGATGAACAAGACCATCAGGA
GGTGTCATACGCATAATTGGATCACTGTGTTTTCACAC
GGCCTTCACCCACTGAACCAAGCTCCAAAACCGGTAACCCCAGACACCTACACGTTCTGATTG
GGACCTCAGTGGTCAAACTCCCTTTCACCATCCTCCT
ACATACAAGAGGCTGCCTCTTAACACAGCACTTAGACACGTGCTGTTCCACCTCCCTTCAGAC
TATCTTTCAGCCTTCTGCCAGCAGTAAAACTTATAAA
CTTCCTTCTGCACAGAGAGGGGACGTTTAACCACACTTTGCGCCTCATTGGAGAGCACATTGA
TGGGGTCTCCAAGGGCAACTTCTCCATCGGTCGCATG
CCAAATCTGGTAACCCCAGACACCTGCACATTCTGATTGGGACCTCAGTGGTCATCATCCTCT
TCATCCTCCTCCTCTTCTTTCTCCTTCATCTCTGGTG
TGCCACCCACGGAGGGACCTACAGATGCTTCGGCTCTTTCCGTGCCCTGCCCTGCGTGTGGT
CAAACTCAAGTGACCCACTGCTTGTTTCTGTCACAGGA
CCTTGCGCCTCGTTGGACAGCTCCACGATGCGGGTTCCCAGGTCAACTATTCCATGGGTCCC
ATGACACCTGCCCTTGCAGGGACCTACAGATGCTTTGG
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CTCCAAATCTGGTAACCTCAGACACCTGCACATTCTGATTGGGACCTCAGTGGTCAAAATCCC
TTTCACCATCCTCCTCTTCTTTCTCCTTCATCGCTGG
CATCGCAGCTACCGCGATGAGAGGCGCTCGCGGCGCCTGGGATTTTCTCTGCGTTCTGCTCC
TACTGCTTCGCGTCCAGACAGGCTCTTCTCAACCATCT
GCTCAGGCAACAAGTGTGATTCGTCATACAGCTGATGCCCAGCTATGTAACCACCAGACCTGC
CCAATGAAAGCAGCCAGCATCCTCAACTATCAGAACA
GGAAGTTTGCGCGCTCAGACGAGCTCACGCGCCACTACCGAAAGCACACGGGCCACCGGCC
ATTCCAGTGCCATCTGTGCGATCGTGCCTTCTCGCGCTC
CGAGCATTTTCCAGGTCGGACCACCTCGCCTTACACATGAAGAGGCATTTTTAAATCCCAGAC
AGTGGATATGACCCACACTGCCAGAAGAGAATTCAGT
GGGATGCGTGTTCCAGCCAAAGCATGCCGTTCTGCACCCTACCCAGTTGCCTCCAGGGCCTC
TCCTTGGAAGGTCTTTTGAGGGCTAAAAAGGTCCTGTA
GTACTATTGAGATCTTTCGCGTCGATCCCAACGGCCTTAGCGGCGGCAGACTGGAATAACACC
TTACACCTTTCTGGCCTGCATTTCTGTAGACTTCACT
CCTTCAGAGTCACAGAATAGATTAAGGCCTGATGATACTCAAAGGCCTGGGAAAACTGATGAC
AAAGAATTTTCAGTGCCCTGGCACCTCATTGCAGTGA
TGAGTTAAACTTACCCACAGACTCAGGCCCAGAAAGTTCTTCACCTTCATCTCTTCCTCGGGAT
GTCTGTCAGGGTTCACCTTGGCATCAATTTGCCCTG
ACCTATCACTGCAAAGATTTACCATCAGCTCCAGAGAAGCTCATTGTTGGGATCCTGGGAATTA
TCTGTCTTATCTTAATGGCCTCTGTGGTAACGATAG
TATGTGAGTCAGCTTATAGGAAGTACCAAGAACAGTCAAACCCATGGAGACAGAAAGTAGAAT
AGTGGTTGCCAATGTCTCAGGGAGGTTGAAATAGGAG
ACTCCTGAGCTCAAGAAATCAACACATCTTGGCCTCCCAAGTTGCTGGGATTACTGACACAAG
CCACCGCCCCTGAGTGCTCATGTACCATTTAGCTTGT
TTATATTGGTCAACAGCAAAATGAACATTACTACTCAGCCTCCAACACATGCAGTTTGCCTATA
CCAGGGATCCTGTCAAAATATACACCACTTATAGCT
AGCCTGCTTCAGCTTCAAAACACAGATGAACTGGATTTTATGAGCTCCAGTCAACAATTTTACT
GGATTGGACTCTCTTACAGTGAGGAGCACACCGCCT
AAAAAGGAAGTTGTTCAAATGCCACTCAGTATGAGGACACTGGAGATCTAAAAGTGAATAATG
GCACAAGAAGAAATATAAGTAATAAGGACCTTTGTGC
TGCCTACGGCAACCCAAGCCCAGAATGACTATGGACCACAGCAAAAATCTTCCTCTTCCAGGC
CTTCTTGTTCTTGCCTTGTGGCAATAGCTTTGGGGCT
GGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACATTCCAACA
AATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTC
CTTTTGGTGACTGGAGCCTTTGGCTTTCACCTTTGGAGAAGACAGTGGCGACCAAGACGATTT
TCTGCCTTAGAGCAAGGGATTCACCCTCCGCAGGCTC
GCACCTGAGGGTAGAAAGTCACTCTAGGAAAAGCCTGAAGCAGCCATTTGGAAGGCTTCCTG
TTGGATTCCTCTTCATCTAGAAAGCCAGCCAGGCAGCT
TGTGTAATAGAATAAAGGCCTGCGTGTGTCTGTGTTGAGCGTGCGTCTGTGTGTGCCTGTGTG
CGAGTCTGAGTCAGAGATTTGGAGATGTCTCTGTGTG
TGCAGAGCTGATTAAACAGTGTTGTGACTGTCTCATGGGAAGAGCTGGGGCCCAGAGGGACC
TTGAGTCAGAAATGTTGCCAGAAAAAGTATCTCCTCCA
ATTAAGTGGACAGCGCCAGAAGCCATTAACTACGGGACATTCACCATCAAGTCAGATGTGTGG
TCTTTTGGGATCCTGCTGACGGAAATTGTCACCCACG
CAGAATGGAATCTCAGACCTTGTGAAGGTGACTCTGACTTCTGAGGAAGAGGCCCGTTTGAAG
AAGAGTGCAGATACACTTTGGGGGATCCAAAAGGAGC
CCGTCACACATCCCATCAGATGTCAACTCCAAACAAGGCATGTCCAGACATCCTCCAGCTCCT
GATATCCCTACTTTTTATCCCTTGTCTCCGGGTGGTG
GGTGCGCCTGCCCGGGAACATCCTCCTGGACTCAATCATGGCTTGTGGTCTGGTCGCCAGCA
ACCTGAATCTCAAACCTGGAGAGTGCCTTCGAGTGCGA
CAGCCGTCCGGAGCCAGCCAACGAGCGGAAAATGGCAGACAATTTTTCGCTCCATGATGCGT
TATCTGGGTCTGGAAACCCAAACCCTCAAGGATGGCCT
CCTATTGTCCACCCATCATTGAGGAAGAAATACCAAACCCAGCCGCAGATGAAGCTGGAGGGA
CTGCACAGGTTATTTACATTGATGTTCAGTCGATGTA
AGCTGAGAAAACTAAGTCAGAAAGTGCATTAAACTGAATCACAATGTAAATATTACACATCAAG
CGATGAAACTGGAAAACTACAAGCCACGAATGAATG
TGATCACATTCTACCTGGCATTATTTCATCTGAGTCCCTGTCCTAGCCCTTCTGCCCATTAGAC
TGTAACCTTGTTTAGGGAAAGACCTGTGTCTTACTC
TGGACACCAACATGATCGAGTCGTCCAACATGCTGGGTCAGGAGCGGGTCGTGATTGCCGAC
GATCTCCCGCACCCGTTCGGTCTGACGCAGTACAGCGA
CTTAGATTATCCAGAAGGCATGGCAGTAGACTGGCTTGGGAAGAACTTGTACTGGGCAGACAC
AGGAACGAATCGAATTGAGGTGTCAAAGTTGGATGGG
CACCCTGGTGTGGGTTCTCCTGTTCTCTCTGTGCTCTTGCATTCTCTCATTCCCTTTTCCTCTAT
TGAGCAGAGCCTGGAGTTTGAGACTATGGAATCCA
CTGATCAAGTCACCGGAGCTTTCAAAGAAGGAATTCTAGGCATCCCAGGGGACCACACCTCCC
TGAACCATCCCTGATGTCTGTCTGGCTGAGGATTTCA
CTAACAGGGGCCCAAGGAACCAATTTATCACCCATGACTGACGGAGTCTGAGAAAAGGCAGA
AGAAGGGGGGCACAAGGGCACTTTCTCCCTTGAGGCTG
TCCTGAAGAGCGATGAAGGTGGCAAAGTGCTGCTTCCAAAGCTCATTGACTTTTCTGCTCAGA
TTGCAGAGGGAATGGCATACATCGAGCGGAAGAACTA

118

MAD1L1

NM_003550.2

306-406

MAP2K1

NM_002755.2

970-1070

MAPK14

NM_001315.1

450-550

MAPK3

NM_002746.2

580-680

MAPK8

NM_139049.1

945-1045

MBD2

NM_003927.3

MCL1

NM_021960.3

MIF

NM_002415.1

319-419

MMP14

NM_004995.2

14701570

MPL

NM_005373.2

895-995

MTOR

NM_004958.2

50955195

MXD1

NM_002357.2

880-980

MYB

NM_005375.2

MYC

NM_002467.3

MYO6

NM_004999.3

NANOG

NM_024865.2

NBEA

NM_015678.3

NCAM1

NM_000615.5

NCL

NM_005381.2

NCR1

NM_001145457.1

145-245

NCR2

NM_004828.3

798-898

NCR3

NM_147130.1

50-150

NCRNA00185

NR_001544.2

143-243

NEIL1

NM_024608.2

NEIL2

NM_145043.2

NFAT5

NM_173214.1

NFATC1

NM_172390.1

NFATC2

NM_012340.3

NFATC3

NM_004555.2

NFKB1

NM_001165412.1

NOS2

NM_000625.4

605-705

NOTCH1

NM_017617.3

735-835

NR3C1

NM_001018077.1

16651765

NR4A1

NM_002135.3

155-255

NREP

NM_001142474.1

990-1090

20152115
12601360

31453245
16101710
66556755
11001200
86458745
16201720
14921592

16751775
25702670
32903390
25102610
18151915
21902290
23052405

GAAGACCTGGGGGAAAACACCATGGTTTTATCCACCCTGAGATCTTTGAACAACTTCATCTCTC
AGCGTGTGGAGGGAGGCTCTGGACTGGATATTTCTA
ACGGAATGGACAGCCGACCTCCCATGGCAATTTTTGAGTTGTTGGATTACATAGTCAACGAGC
CTCCTCCAAAACTGCCCAGTGGAGTGTTCAGTCTGGA
TGGGCTCTGGCGCCTATGGCTCTGTGTGTGCTGCTTTTGACACAAAAACGGGGTTACGTGTG
GCAGTGAAGAAGCTCTCCAGACCATTTCAGTCCATCAT
AACGTGCTCCACCGAGATCTAAAGCCCTCCAACCTGCTCATCAACACCACCTGCGACCTTAAG
ATTTGTGATTTCGGCCTGGCCCGGATTGCCGATCCTG
TCTCTGTAGATGAAGCTCTCCAACACCCGTACATCAATGTCTGGTATGATCCTTCTGAAGCAGA
AGCTCCACCACCAAAGATCCCTGACAAGCAGTTAGA
ATTTACATTCAACTCTGATCCCTGGGCCTTAGGTTTGACATGGAGGTGGAGGAAGATAGCGCA
TATATTTGCAGTATGAACTATTGCCTCTGGACGTTGT
GCTGTAACTTCCTAGAGTTGCACCCTAGCAACCTAGCCAGAAAAGCAAGTGGCAAGAGGATTA
TGGCTAACAAGAATAAATACATGGGAAGAGTGCTCCC
TCCTACAGCAAGCTGCTGTGCGGCCTGCTGGCCGAGCGCCTGCGCATCAGCCCGGACAGGG
TCTACATCAACTATTACGACATGAACGCGGCCAATGTGG
GACAAGATTGATGCTGCTCTCTTCTGGATGCCCAATGGAAAGACCTACTTCTTCCGTGGAAAC
AAGTACTACCGTTTCAACGAAGAGCTCAGGGCAGTGG
CAGTGGCACTTGGACTGCAATGCTTTACCTTGGACCTGAAGAATGTTACCTGTCAATGGCAGC
AACAGGACCATGCTAGCTCCCAAGGCTTCTTCTACCA
TTAGTGTTGCTCCTGGGAGTTGATCCGTCTCGGCAACTTGACCATCCTCTGCCAACAGTTCAC
CCTCAGGTGACCTATGCCTACATGAAAAACATGTGGA
GAGAATAAAGCTGCAGGACAGTCACAAGGCGTGTCTTGGTCTCTAAGAGAGTGGGCACTGCG
GCTGTCTCCTTGAAGGTTCTCCCTGTTGGTTCTGATTA
AACTGTTGCATGGATCCTGTGTTTGCAACTGGGGAGACAGAAACTGTGGTTGATAGCCAGTCA
CTGCCTTAAGAACATTTGATGCAAGATGGCCAGCACT
TCGGACACCGAGGAGAATGTCAAGAGGCGAACACACAACGTCTTGGAGCGCCAGAGGAGGA
ACGAGCTAAAACGGAGCTTTTTTGCCCTGCGTGACCAGA
AAGTTGGGGAGATGGCACCTTCTCAGAGGATTGTGAAAATATGAGGAAGAAACAAAACAGTGC
ATGTAGGAGCACAGGGCCACACAAAGGCATTCTATTG
CTACTCCATGAACATGCAACCTGAAGACGTGTGAAGATGAGTGAAACTGATATTACTCAATTTC
AGTCTGGACACTGGCTGAATCCTTCCTCTCCCCTCC
CTGAGAGCCCTTGAAGGACCAGAAAACTGCTTATTCCCACGCTTGATATCTGTCTCCAGCGAA
GGCCACTGTATCATATACTATGAACGAGGGCGATTCA
GGTATTTGCCTATCCCAGTGCCACGATCTCATGGTTTCGGGATGGCCAGCTGCTGCCAAGCTC
CAATTACAGCAATATCAAGATCTACAACACCCCCTCT
GAACAGAGATCGATGGGCGATCTATTTCCCTGTACTATACTGGAGAGAAAGGTCAAAATCAAG
ACTATAGAGGTGGAAAGAATAGCACTTGGAGTGGTGA
TTTCATGGTTCCAAAGGAAAAGCAAGTGACCATCTGTTGCCAGGGAAATTATGGGGCTGTTGA
ATACCAGCTGCACTTTGAAGGAAGCCTTTTTGCCGTG
CTTCAACAGGTCACGGACCTTCCCTGGACCTCAGTTTCCTCACCTGTAGAGAGAGAAATATTAT
ATCACACTGTTGCAAGGACTAAGATAAGCGATGATG
GCATCTGTCCTCTCTCCTCAGGGAGGCAAGCATTTGATGCTCGAGGTCCCTGGCAGTTGTGGT
CCTTGGCAAGTGATGTGTGAGTCCCGTGTGTCATAGG
GAGGCTGTCTGCCAACATCTTTCATCACTCTGCCTGCAACTATGAAAAATTTAGTTCTAAAAAAT
GCAACCTTGCTAAATTGAGTACTAATAGGATTGGT
TTAGCAGGAGGCTCTCCTTGCTTGCACTCACCCTTTCTTATTGTCTTGCCCTGCATCTGGGGG
TCTGAATTTTTGGGAGCAGGCAATATCTGAAGGTGCA
GCCCGGTGGTGTGTAGAGAAAAGCTGCTTGTTTACTCCTTAAGTCAATGTATTGGTGACTGTT
GATTTGTTGAACAATTCAGGAATCAAGGGCTGTGGAG
CCCTGACAACTATTCAAACCCAGGACATCTCACAGCCTGGTACTTTTCCAGCAGTTTCTGCTTC
TAGTCAGCTGCCCAACAGCGATGCACTATTGCAGCA
CCAGTACCAGCGTTTCACCTACCTTCCCGCCAACGGTAACGCCATCTTTCTAACCGTAAGCCG
TGAACATGAGCGCGTGGGGTGCTTTTTCTAAAGACGC
GACGGACATTGGAAGAAAGAACACGCGGGTGAGACTGGTTTTCCGAGTTCACATCCCAGAGT
CCAGTGGCAGAATCGTCTCTTTACAGACTGCATCTAAC
GTCCTTGAAGTTCCTCCATATCATAACCCAGCAGTTACAGCTGCAGTGCAGGTGCACTTTTATC
TTTGCAATGGCAAGAGGAAAAAAAGCCAGTCTCAAC
CTTGGGTAACTCTGTTTTGCACCTAGCTGCCAAAGAAGGACATGATAAAGTTCTCAGTATCTTA
CTCAAGCACAAAAAGGCAGCACTACTTCTTGACCAC
TTGCCTGGGGTCCATTATGACTCCCAAAAGTTTGACCAGAGGACCCAGGGACAAGCCTACCC
CTCCAGATGAGCTTCTACCTCAAGCTATCGAATTTGTC
CTGCCAGGCTTCACCGGCCAGAACTGTGAGGAAAATATCGACGATTGTCCAGGAAACAACTG
CAAGAACGGGGGTGCCTGTGTGGACGGCGTGAACACCT
GCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAACTCGAATGAGGACTG
CAAGCCTCTCATTTTACCGGACACTAAACCCAAAATT
CGGCCGGGTAGGGTGCAGCCTGAGGCTTGTTCAGCAGAACAGGTGCAAGCCACATTGTTGCC
AAGACCTGCCTGAAGCCGGATTCTCCCCACTGCCTCCT
AAACTCATTGTTTCCTTGTGGTAAGTGACCGAGATGCTGCCACAGGACCTGAGACACTGATGA
ATGGTGCTATTTTGGACTTTCAACATGCTCCTTGGCG
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335-435

NRP1
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TGACTCATGGAGAAGAGCTTGGCTCTGATGTGCACCAGGATTCTATTGTTTTAACTTACCTAGA
AGGATTACTAATGCATCAGGCAGCAGGGGGATCAGG
GCCTCGCTGCTTTCTTTTCTCCAAGACGGGCTGAGGATTGTACAGCTCTAGGCGGAGTTGGG
GCTCTTCGGATCGCTTAGATTCTCCTCTTTGCTGCATT
ATTCGGGTTTTGAAATGGATAAACTCATCGCTCAGAAAGTGAGGGGTGTGGACGTCGTGGTG
GGAGGACACTCCAACACATTTCTTTACACAGGCAATCC
GGTGGGCGAGGGAATAGTCAGAGGGATCACAATCTTTCAGCTAACTTATTCTACTCCGATGAT
CGGCTGAATGTAACAGAGGAACTAACGTCCAACGACA
TGAAGCTAAATAATCAAGCCATGAAAGGGAGATTTGAGGAGCTTTCGGCCTGGACAGAGAAAC
AGAAGGAAGAACGCCAGTTTTTTGAGATACAGAGCAA
AGTTGGTGCACAGTGTCTTTGACACCGCAGACTACACCTTCCCTTTGCAGGGGAACTCTTTCT
TCGTGATGACAAACTTTCTCAAAACAGAAGGCCAAGA
CTCCAAGAGGAGCACACTTTGGGGAGATGTCCTGGTTTCCTGCCTCCATTTCTCTGGGACCGA
TGCAGTATCAGCAGCTCTTTTCCAGATCAAAGAACTC
CTTCTTCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCT
CCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGC
TGTGGAGCTGTGGCAAGTCCTCATATCAAATACAGAACATGATCTTCCTCCTGCTAATGTTGAG
CCTGGAATTGCAGCTTCACCAGATAGCAGCTTTATT
CTGGCCAACCTTCAGGAATCCTTCATCTCTCACATTGTGGGGCCTCTGTGCAACTCCTATGATT
CAGCAGGACTAATGCCTGGAAAATGGGTGGAAGACA
AATAATGGTGTATACCCTCATTCTCATTCCTGGGCAGCCCTTCCTTCCACCCTGGCACCAAAAT
AATTTCTCCTCCATCCGTACCTTGCCTAGCCTCTCC
GTAGCTCAACAAGGAATAGAGGGAGGAGTGTAATTTTGGTAGCTGGTGTTGAATAGGGCCTTT
GAGAATCAGACTGAACACAGTGAAATATGTGCCCAAA
TGGATTGCCCATATCACGTCTTTACGCACAATACTTCCAAGGAGACCTGAAGCTGTATTCCCTA
GAGGGTTACGGGACAGATGCAGTTATCTACATTAAG
TCCCGGAGGACCTCCTTCCCGTCTACAAAGAAAAAGTGGTGCCGCTTGCAGACATTATCACGC
CCAACCAGTTTGAGGCCGAGTTACTGAGTGGCCGGAA
ATCTGCACTGCAGGTATTGACAAAGTGGTCAAGAAAAGCAACACAGTCCAGATAGTCGTATGT
GAAATGCTCTCCCAGCCCAGGATTTCTTATGATGCCC
GGCAGAATGCCACTCTACCCTCAGGTCAATTTTATGGTATATGAAAATGCCAGTAATATTTGTG
CCACTTGCCAACTCGGGGGAGGAGGGGCTTTTCCCT
ATACAGCTCCACCTACACCGGAATTACATGGCATCAACCCTGTGTTCCTGTCCAGTAATCCCA
GCCGTTGGAGTGTAGAGGAGGTGTACGAGTTTATTGC
GGAGAACTCGGCCTTAGAATACTTTGGTGAGATGTTAAAGGCTGCTGGCTACAATTTCTATGG
CACCGAGAGGTTATATAGTGGCATCAGTGGGCTAGAA
TTCCAAGAAGCCAAAGACTCCTTCGCTTACTGTCTTCCTGTTGGGCCAGTCCGCTCGAGATGC
TGAGAGAGCCAAGGATATTCTGTGCCGTCTGGAGCAT
GCTTCAGGCCCACTTGTTGAACAGAACAATCTGGGTAGCAACAGCATCTTCCACAGTTTTCCA
AACTGGATAGCTGCCAACCAGCAGACATTACCCACTT
AAGTTCTTCATTCACTAAGGAAGGAATTGGGAACACAAAGGGTGGGGGCAGGGGAGTTTGGG
GCAACTGGTTGGAGGGAAGGTGAAGTTCAATGATGCTC
GGGTGTGTTTGCTATACGAACATAATGGACGTGAAGTGGGGCAGAAACCCAGAACTCAGCATT
CAAGGATGCCCAGGAGAGCTGTCCCTGTTTTAAAGAG
AACTTAACTCCTTGTGCATGGCCTGGCTTGTGGATCATGTATATGCCATCCGCGAGGCAGCCA
CCAGCAACCTGAAGAAGCTAGTGGAAAAGTTTGGGAA
CATCCCTGCCAACCAGGAACTTCTTGTGTGGTATTGTCGGGACTTTGCAGAAAGGCTTCACTA
CCCTTATCCCGGAGAGCTGACAATGATGAATCTCACA
ACTGTTTTTCAGGGAGGTGGCTGGGTTTACACGCTAATCCCGATTCACCCTGTCCAAACTGCC
TAAGCCCTCCGCCATTCTCAAGCCCTGCAGTCACAGC
ATAGTGGTGACCCTCAAGACCAGCTTGCAGTGGCTTATCATCTTATCATTGACAATCGGAGAAT
AATGAACCAAGCCAGTGAGTTCTACCTCGCCTCTAG
GATGGACGATGATGTTGAGTGCACGATGGTAGAGAAGAGAGTTCTTTCCTTGGCCTGGGAGC
ATCCGTTTCTGACGCACATGTTTTGTACATTCCAGACC
AGCCTGCGGTCATCTCTCAATGACCCTCTGTGCTTGGTGCATCCATCAAGTGAAACCTGCAAC
AGCATCAGATTGTCTCTAAGCCAGCTGAATAGCAACC
GTCAGAAGGAGCTACAAAACCTACCCTCAGTGAGCATGGTACTTGGCCTTTGGAGGAACAATC
GGCTGCATTGAAGATCCAGCTGCCTATTGATTTAAGC
GGTTCAAGCTGGATTATTTCAGTGGAACTGGCAATCGGCCCAGAAGAAGGAATCAGTTACCTA
ACGGACAAGGGCTGCAATCCCACACATCTTGCTGACT
TAGTCCCTAGGTTGCTACGGCTTATCATGTGCTTGGTAAAAGGTGATCGCAGGTTCTCAGACG
AGTTTACTTTACATGAGATGGAATCAGGCAGAGAGGC
TCGAGGCTTTTTTTCTCCAGCCGAGAGGACGCGGCTGTGATATACGAAGACTTTGTGTGGACA
GTAATGACCTCACGTTTCCGATTGCCTGCTGGCAGAA
TGGTGCAGACGGAGGCGCAGTACAAGTTCATCTACGTGGCCATCGCCCAGTTCATTGAAACC
ACTAAGAAGAAGCTGGAGGTCCTGCAGTCGCAGAAGGG
GTGATCAACCGGATTTTTAGGATATGCAATCTAACAAGACCACAGGAAGGTTATCTGATGGTG
CAACAGTTTCAGTACCTAGGATGGGCTTCTCATCGAG
TTTTGTAAAGAGCTTCCATCTGGGCTGGACCCAGTTCTTGCACATACAAGACACCGCTGCAGT
CAGCTAGGACCTTTCCGCCATGTATTCTATTCTGTAG
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RAC2
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RAF1
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S100A4

NM_002961.2
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SH2B3
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SKAP1
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SLAMF1
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NM_005359.3
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AAAGACCTTCGTCTTTGAGAAGACGGTAGCTTCTGCAGTTAGGAGGTGCAGACACTTGCTCTC
CTATGTAGTTCTCAGATGCGTAAAGCAGAACAGCCTC
GCTGCCACAACTTGTGTACCTTCAGGGATGGGGCTCTTACTCCCTCCTGAGGCCAGCTGCTCT
AATATCGATGGTCCTGCTTGCCAGAGAGTTCCTCTAC
CCTATGGCATCGTATTGTATGAACTGATGACGGGGGAGCTTCCTTATTCTCACATCAACAACC
GAGATCAGATCATCTTCATGGTGGGCCGAGGATATGC
CCCACGGCTGGAAAGAGGCCTGTACGTTCTGGACGCGTTTTGTTGGCTGGGCTTCTGGAGGC
ACTGGCAAGGTCAAACTGCATTTCTTTAAGAACAGTTG
AGCCACCTAGCTGGGGCCCATCTAGGAGTGGCATCTTTTTTGGTGCCCTGAAGGCCAGCTCT
GGACCTTCCCAGGAAAAGTGCCAGCTCACAGAACTGCT
AAACAGCCTGTAGGTTTTGTCAGTTTTGACAGTCGCTCAGAAGCAGAGGCTGCAAAGAATGCT
TTGAATGGCATCCGCTTCGATCCTGAAATTCCGCAAA
GGTACTCTGGTGAGTCACCACTTCAGGGCTTTACTCCGTAACAGATTTTGTTGGCATAGCTCT
GGGGTGGGCAGTTTTTTGAAAATGGGCTCAACCAGAA
GCAAGGTGTGTATGTCCCTTTTGTCAGAGGGAACTGTATGAAGACAGCTTGCTGGATCATTGT
ATTACTCATCACAGATCGGAACGGAGGCCTGTGTTCT
AAAATTAACCGAGACACTTTATATGGCCCTGCACAGACCTGGAGCGCCACACACTGCACATCT
TTTGGTGATCGGGGTCAGGCAAAGGAGGGGAAACAAT
CTCATCAATGCCCATCGGCCAGGGCTCCAAGAGAAAAGGAAAGTAGAACAGCTGCAGTACAAT
CTGGAGCTGGCCTTTCATCATCATCTCTGCAAGACTC
GGGCCGGGTGGTTGCTGCCGAAATGGGCAAGTTCATGAAACCTGGGAAGGTGGTGCTTGTCC
TGGCTGGACGCTACTCCGGACGCAAAGCTGTCATCGTG
GCATCTTGAGAGGAACAGAAAGGATAAGGATGCTAAATTCCGTCTGATTCTAATAGAGAGCCG
GATTCACCGTTTGGCTCGATATTATAAGACCAAGCGA
CAGCCATGAAGAACCAGGTTGCAAGATTTAATGACCTCAGGTTTGTCGGTCGAAGTGGAAGAG
GGAAAAGCTTCACTCTGACCATCACTGTCTTCACAAA
GAAGCCACAGCAGTTCCCCAACTGTTTTGAATTCTAGTGGCAGAATGGATGAATCTGTTTGGC
GACCATATTGAAATTCCTCAGCAGTGGCCCAGTGGTA
GTGGTCTCATAATTCCATTTGTGGAGAGAACAGGAGGGCCAGATAGATAGGTCCTAGCAGAAG
GCATTGAGGTGAGGGATCATTTTGGGTCAGACATCAA
CAGGGACAACGAGGTGGACTTCCAAGAGTACTGTGTCTTCCTGTCCTGCATCGCCATGATGTG
TAACGAATTCTTTGAAGGCTTCCCAGATAAGCAGCCC
TTCCTGGGGGCCTTGGCTTTGATCTACAATGAAGCCCTCAAGGGCTGAAAATAAATAGGGAAG
ATGGAGACACCCTCTGGGGGTCCTCTCTGAGTCAAAT
TTCCGAAATCTACCAGTGGGTACGCGATGAACTGAAACGAGCAGGAATCTCCCAGGCGGTATT
TGCACGTGTGGCTTTTAACAGAACTCAGGGCTTGCTT
GCAACGTATGGTTCTTCTTCAGGGCTCTGCCTTGGCAACCCTCGGGCTGACAGCATCCACAAC
ACTTACTCAACTGACCATGCTTCTGCAGCACCACCTT
ATTGGAAGCCCGTGACCCTCGCAATGCCACTTCAGTATGTATTGCTACGGTTATTGGAATTACT
GGGGCCAGGTTACGGTTACGACTGGATGGTAGTGAC
GGGCAATCTAATAGCCCACATGGTTTTGGGTTACAGATACTGGGCTGGCATCGGCGTCCTCCA
GAGTTGTGAATCTGCCCTGACTCACTATCGTCTTGTT
CTCCCTTTGGGCAAGGACCTGAGACCCTTGTGCTAAGTCAAGAGGCTCAATGGGCTGCAGAA
GAACTAGAGAAGGACCAAGCAAAGCCATGATATTTCCA
CATGGGCTGTTAGGTTGACTTCAGTTTTGCCTCTTGGACAACAGGGGGTCTTGTACATCCTTG
GGTGACCAGGAAAAGTTCAGGCTATGGGGGGCCAAAG
CGCTGCCTTCCATCTGCTCCCACTTCAATCCTCTGTCTCTCGAGGAACTAGGCTCCAACACGG
GGATCCAGGTTTTCAATCAGATTGTGAAGTCGAGGCC
CCTCCAGCCAGAAGTTAAACATCTGGGATATGACGTCTTCATGCCAGGGGCACTCATTTCTTA
GCAGCCTCTCTACATACATCTCTCAGGTGGTGCCAAG
TGCTGGAGCCCAAGCCTCAGGGGTGCTACTTGGTGCGGTTCAGCGAGAGCGCGGTGACCTT
CGTGCTGACTTACAGGAGCCGGACTTGCTGCCGCCACTT
GCCCCAGCCCCCCGTAGCAGGGGCATGACTGTTTCCCAACCAGCACCCAAAGACGGGCGCC
ATTGCCAAGTCACAGGATGTGATCTACCCCGGACTTCCT
AAGTGGGAAGAGGCACGTTCATCAAACCTGTTACTAAACCAGCCTAGTCATAGCTCATCCCCA
TCTCTAAATGTGTCCACACAACCACATCTGCCTTTTC
TTTTACAGTTAATCCAGGAGAGGGAGTCCTTTGCCAACTGATGACCAACAGTTCCAAGCCAGA
TAGTCTCGTGAACAGTGACAATACAGAAATAAGGTGT
AAAGGAAAGCTGAGATGATGTCTTACCGTAGCAGCAGATCTTGGATGGTCCAGGCTCTATGTG
ACCTCCAGAGCAAAGAGAAAGACTTCGGACAGTCTAG
GTGTCTCTTGATCCATCCGAAGCAGGCCCTCCACGTTATCTAGGAGATCGCTACAAGTTTTATC
TGGAGAATCTCACCCTGGGGATACGGGAAAGCAGGA
GGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCAGATGGAGGCTA
CTCCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCA
AGGCTCCATTAGGATTTGCCCCTTCCCATCTCTTCCTACCCAACCACTCAAATTAATCTTTCTTT
ACCTGAGACCAGTTGGGAGCACTGGAGTGCAGGGA
TTAAAGGACAGTTGAAAAGGGCAAGAGGAAACCAGGGCAGTTCTAGAGGAGTGCTGGTGACT
GGATAGCAGTTTTAAGTGGCGTTCACCTAGTCAACACG
AGGTTGCACATAGGCAAAGGTGTGCAGTTGGAATGTAAAGGTGAAGGTGATGTTTGGGTCAG
GTGCCTTAGTGACCACGCGGTCTTTGTACAGAGTTACT
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GACCACTATGCCGCGCTCTTTCCTCGTCAGGAAGCCCTCCGACCCCAATCGGAAGCCTAACTA
CAGCGAGCTGCAGGACTCTAATCCAGAGTTTACCTTC
TTAACTGTATCTGGAGCCAGGACCTGAACTCGCACCTCCTACCTCTTCATGTTTACATATACCC
AGTATCTTTGCACAAACCAGGGGTTGGGGGAGGGTC
GGAGGATGGAGGAGACGGGACATCTTTCACCTCAGGCTCCTGGTAGAGAAGACAGGGGATTC
TACTCTGTGCCTCCTGACTATGTCTGGCTAAGAGATTC
GCCTATAAAGTAGTCGCGGAGACGGGGTGCTGGTTTGCGTCGTAGTCTCCTGCAGCGTCTGG
GGTTTCCGTTGCAGTCCTCGGAACCAGGACCTCGGCGT
ATTTATTGAGTGCCCACTACGTGCCAGGCACTGTTGCTGAGTTCCTGTGGGTGTGTCTCTCGA
TGCCACTCCTGCTTCTCTGGGGGCCTCTTTCTGTGCT
CTTAAGCCTTTCCAAAAAATAATAATAACAATCATCGGCGGCGGCAGGATCGGCCAGAGGAGG
AGGGAAGCGCTTTTTTTGATCCTGATTCCAGTTTGCC
GTTCACGGTCAAACTGAAATGGATTTGCACGTTGGGGAGCTGGCGGCGGCGGCTGCTGGGC
CTCCGCCTTCTTTTCTACGTGAAATCAGTGAGGTGAGAC
TAGCCATGCAATGATGGATTTCAATCTGAGTGGAGATTCTGATGGAAGTGCTGGAGTCTCAGA
GTCAAGAATTTATAGGGAATCCCGAGGGCGTGGTAGC
CTCCGCAGCGGCGACATGAAGGACAGCATCTGGTGGGTGGACAAGGACAAGGGCACCTTCC
AGTTCTCGTCCAAGCACAAGGAGGCGCTGGCGCACCGCT
AAGCCAGGCTTCATGGAAAGATCGTATGTGTGACCCAAATATGAGTTCTTCAGCTCAGCCATG
GTAATCCCTTCCTTGAAGTCTCCATTTCTGCAGTACA
AAAGAGGAAATACTCCGCGTGCGCTTGTAGAAGGGGAGTCGTCTCCAGCTCCGAACCCCGGA
GTGTTCATCAGCGGGGAATCTGGCTCCGAATTCTCTTT
TTTGCTGTATGCCATCCTCGAGAGCTGTCTAGGTTAACGTTCGCACTCTGTGTATATAACCTCG
ACAGTCTTGGCACCTAACGTGCTGTGCGTAGCTGCT
AGACTTGGGCTTACCATTGGGTTTAAATCATAGGGACCTAGGGCGAGGGTTCAGGGCTTCTCT
GGAGCAGATATTGTCAAGTTCATGGCCTTAGGTAGCA
AGACAATGGATCAGAGTGACAAGAATAGTGCCATGGTGAATCAGGAAGTTTTGACACTGCAGG
AAATGCTTAACAGCCTCGATTTCAAGAGAAAGGAGGC
GAGACAGAGAGAGAGAAAGAGAGAGTGTGTGGGTCTATGTAAATGCATCTGTCCTCATGTGTT
GATGTAACCGATTCATCTCTCAGAAGGGAGGCTGGGG
AAGGAGAAGCCCTTCATCAGATGCAAGCGTTATATGGCCAGCATTTTCCCATTGAGGTGCGGC
ATTATTTATCCCAGTGGATTGAAAGCCAAGCATGGGA
AGAACATCCAGCCATTCTCTGCCAAAGACCTGTCCATTCGCTCACTGGGGGACCGAATCCGG
GATCTTGCTCAGCTCAAAAATCTCTATCCCAAGAAGCC
CGTGGGTGGCGGCAGGACTTTCCTTATCCCAGTTGATTGTGCAGAATACACTGCCTGTCGCTT
GTCTTCTATTCACCATGGCTTCTTCTGATATCCAGGT
CGGACTCTCCAAAGCACTGCGTGCTGATGAAAACTACTACAAGGCCCAGACCCATGGAAAGT
GGCCTGTCAAGTGGTACGCTCCGGAATGCATCAACTAC
ACAGCATCTGTAGTCAGCCGACAACTATTTCGGCCTTTTGGGGGTGGGTCTGGCCGTACTTGT
GATTTCGATGGTACGTGACCCTCTGCTGAAGACTTGC
CGCCGGCTGTTTAACTTCGCTTCCGCTGGCCCATAGTGATCTTTGCAGTGACCCAGCAGCATC
ACTGTTTCTTGGCGTGTGAAGATAACCCAAGGAATTG
ACACAGGAGCGCACTGGATGCGCCAGGAAGTTTCATTTGGGAAACTAAAGCTCACAAACAACA
AGGGGGCGTCCAACAATGTGACCCAGATGATTGTGCT
CACACGCGCTCCTCCTTCCTCACCTTCCTCTGCGGCCTCGTCCTCACCGACTTCCTGGGGCT
GCTGGTGACCGGTACCATCGTGGTGTCCCAGCACGCCG
CACATGACCGCTTGAGTTATCCTCCACACTCAGTTTCACCAACAGACATAAACACGAGTCTTCC
ACCAATGTCCAGCTTTCATCGCGGCAGTACCAGCAG
ATACGTGTCAACACAGCTGGCTGGATGATTGGGACTTTAAAACGACCCTCTTTCAGGTGGATT
CAGAGACCTGTCCTGTATATAACAGCACTGTAGCAAT
ATTCCATTTCCAGTTCATCTATGGCAGTCCAGCCAGCTCCTGGGCAGCTTGAGAGGGCAAACC
CAAAACCTCATGACAGCCAGAGCCTGTCTTTCAGCAT
AAGGAAAGAAAACATCTTTAAGGGGAGGAACCAGAGTGCTGAAGGAATGGAAGTCCATCTGC
GTGTGTGCAGGGAGACTGGGTAGGAAAGAGGAAGCAAA
AAGGTCAATGATAGCATCTGCCTAGAGTCAAACCTCCGTGCTTCTCAGACAGTGCCTTTTCAC
CATGAGTGGGTGCCCATTTTTAGGAAACAACTTTGGA
CGAGTTCGAGGAGAGGCAATCAGGATACGAACCATGAAGATGCGTCAACAAGCTTCCTTCCTA
CCAGCTACTTTAACTATGACTGTGGACAAGGGAGATA
CTGAAAGCAGAATACCTGTTTCAAAGAGTCAGCCGGTAACTCCTGAAAAACATCGAGCTAGAA
AAAGACAGGCATGGCTTTGGGAAGAAGACAAGAATTT
GGCTTCAAGGCTGGGAGGAACATGCGTCGCAAACTCTTTGGGGTCTTGCGGCTGAAGTGTCA
CAGCCTGTTTCTGGATTTGCAGGTGAACAGCCTCCAGA
CTGCTCCACCCTTAACCAATACTTCGGCTACTCGGGAGCCTTCAAGTGTCTGAAGGATGGTGC
TGGGGATGTGGCCTTTGTCAAGCACTCGACTATATTT
CAGTTTCCACCATCTCGGTCATCAGGATTGCCTAATATACCTGTCCAGACAATCTCCAGAGCTG
CTGCAGAAAAGCTGTTTGGGAATATGGAAGGAGACT
TGCCACAGACCTTCCTACTTGGCCTGTAATCACCTGTGCAGCCTTTTGTGGGCCTTCAAAACT
CTGTCAAGAACTCCGTCTGCTTGGGGTTATTCAGTGT
TATATGTTCTTCAACACATCAGAGCTCCGAGAAGCGGTACCTGAACCCGTGTTGCTCTCCCGG
GCAGAGCTGCGTCTGCTGAGGCTCAAGTTAAAAGTGG
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NM_000594.2

TNFRSF14

NM_003820.2

916-1016

TNFRSF18

NM_004195.2

445-545

TNFRSF1B

NM_001066.2

835-935

TNFRSF4

NM_003327.2

200-300

TNFRSF9

NM_001561.4

255-355

TNFSF10

NM_003810.2

115-215

TNFSF11

NM_003701.2

490-590

TNFSF14

NM_003807.2

270-370

TOX

NM_014729.2

TP53

NM_000546.2

TRAF1

NM_005658.3

TRAF2

NM_021138.3

TRAF3

NM_145725.1

TSC22D3

NM_198057.2

TSLP

NM_033035.3

395-495

TXK

NM_003328.1

800-900

TYK2

NM_003331.3

485-585

TYROBP

NM_003332.2

457-557

UBASH3A

NM_001001895.1

19702070

VAX2

NM_012476.2

871-971

VEGFA

NM_001025366.1

13251425

WEE1

NM_003390.2

5-105

XBP1

NM_005080.2

440-540

XBP1

NM_001079539.1

935-1035

YY1AP1

NM_139118.2

755-855

ZAP70

NM_001079.3

ZBTB16

NM_006006.4

ZC2HC1A

NM_016010.2

27952895
10101110

39504050
13301430
37353835
13251425
17951895
14001500

11751275
15851685
665-765

AAGCCAGAGTGCCTGAACAACGGATTGAGCTATATCAGATTCTCAAGTCCAAAGATTTAACATC
TCCAACCCAGCGCTACATCGACAGCAAAGTTGTGAA
GGGGAAATACGACTTAGTGAGGCATAGACATCCCTGGTCCATCCTTTCTGTCTCCAGCTGTTT
CTTGGAACCTGCTCTCCTGCTTGCTGGTCCCTGACGC
TCTACGTACCCGAGCCGATGACTTACTGGCAGGTGCTGGGGGCTTCCGAGACAATCGCGAAC
ATCTACACCACACAACACCGCCTCGACCAGGGTGAGAT
CATCGGGGAGGGGAACTTCGGCCAGGTCATCCGGGCCATGATCAAGAAGGACGGGCTGAAG
ATGAACGCAGCCATCAAAATGCTGAAAGAGTATGCCTCT
CTGCTTTCAACTGGTAGTTGTGGGTTGAAGCACTGGACAATGCCACATACTTTGTGGATGGTG
TGGGTCTTGGGGGTCATCATCAGCCTCTCCAAGGAAG
GACAAAAACGTTCTCCTTTGTCTAGAGGAGAGGGATTGGGATCCGGGATTGGCCATCATCGAC
AACCTCATGCAGAGCATCAACCAAAGCAAGAAAACAG
AGCAACAAGACCACCACTTCGAAACCTGGGATTCAGGAATGTGTGGCCTGCACAGTGAAGTG
CTGGCAACCACTAAGAATTCAAACTGGGGCCTCCAGAA
CTCAGGGAGCCTCGTCATCGTCATTGTTTGCTCCACAGTTGGCCTAATCATATGTGTGAAAAG
AAGAAAGCCAAGGGGTGATGTAGTCAAGGTGATCGTC
AGGGGAAATTCAGTTTTGGCTTCCAGTGTATCGACTGTGCCTCGGGGACCTTCTCCGGGGGC
CACGAAGGCCACTGCAAACCTTGGACAGACTGCACCCA
CCCAGCTGAAGGGAGCACTGGCGACTTCGCTCTTCCAGTTGGACTGATTGTGGGTGTGACAG
CCTTGGGTCTACTAATAATAGGAGTGGTGAACTGTGTC
CCGTGCGGGCCGGGCTTCTACAACGACGTGGTCAGCTCCAAGCCGTGCAAGCCCTGCACGT
GGTGTAACCTCAGAAGTGGGAGTGAGCGGAAGCAGCTGT
AGATTTGCAGTCCCTGTCCTCCAAATAGTTTCTCCAGCGCAGGTGGACAAAGGACCTGTGACA
TATGCAGGCAGTGTAAAGGTGTTTTCAGGACCAGGAA
GGGGGGACCCAGCCTGGGACAGACCTGCGTGCTGATCGTGATCTTCACAGTGCTCCTGCAGT
CTCTCTGTGTGGCTGTAACTTACGTGTACTTTACCAAC
TACCTGATTCATGTAGGAGAATTAAACAGGCCTTTCAAGGAGCTGTGCAAAAGGAATTACAACA
TATCGTTGGATCACAGCACATCAGAGCAGAGAAAGC
ATTTTCAGAAGCCTCTGGAAAGTCGTGCACAGCCCAGGAGTGTTGAGCAATTTCGGTTTCCTC
TGAGGTTGAAGGACCCAGGCGTGTCAGCCCTGCTCCA
AATGAGCAGCTTTGACTTTGACAGGCGGTTTGTGCAGGAAAGCACAGTGCCGTGTTGTTTACA
GCTTTTCTAGAGCAGCTGTGCGACCAGGGTAGAGAGT
GGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATA
AAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGAC
CGAGTGATGGGTCTAGGCCCTGAAACTGATGTCCTAGCAATAACCTCTTGATCCCTACTCACC
GAGTGTTGAGCCCAAGGGGGGATTTGTAGAACAAGCC
GTGGCCCTTCAACCAGAAGGTGACCTTAATGCTGCTCGACCAGAATAACCGGGAGCACGTGA
TTGACGCCTTCAGGCCCGACGTGACTTCATCCTCTTTT
ATATGATGCCCTGCTTCCTTGGCCGTTTAAGCAGAAAGTGACACTCATGCTGATGGATCAGGG
GTCCTCTCGACGTCATTTGGGAGATGCATTCAAGCCC
TTAAGCAGAGGCAACCTCTCTCTTCTCCTCTGTTTCGTGAAGGCAGGGGACACAGATGGGAGA
GATTGAGCCAAGTCAGCCTTCTGTTGGTTAATATGGT
CCGTCTCTTGTAGCAATCGGCCACATTGCCTTACTGAAATCCAGAGCCTAACCTTCAATCCCAC
CGCCGGCTGCGCGTCGCTCGCCAAAGAAATGTTCGC
ATGACTCGTCTCCGATATCCAGTTGGGCTGATGGGCAGTTGTTTACCAGCCACAGCTGGGTTT
AGCTACGAAAAGTGGGAGATAGATCCATCTGAGTTGG
TCATCGCTGACAGCTGAGGAAGTCTGCATCCACATTGCACATAAAGTTGGTATCACTCCTCCTT
GCTTCAATCTCTTTGCCCTCTTCGATGCTCAGGCCC
CTGCACCTCATTCCAACTCCTACCGCGATACAGACCCACAGAGTGCCATCCCTGAGAGACCAG
ACCGCTCCCCAATACTCTCCTAAAATAAACATGAAGC
GAGATGCTGCTGTTTCCAGAGGCGTCTTAGTCTCACCCAATGTGATTTGTAGAAGCACGAGAC
GCACTTTTATATCCCGGAATATTTCCCTCCGGCTTTC
CAGCGCCAGCAGCTGCAAGAAAGCTAACACTTAAGACTCCCACCCTGTGACACTGAGTCCCG
AGCACAGCACCTTCCCAGTCTCCTGTGCCCCAGCGGAC
GAGTCCAACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGCACATAGGAGAG
ATGAGCTTCCTACAGCACAACAAATGTGAATGCAGAC
TGCGTTTGAGTTTGCCGCGAGCCGGGCCAATCGGTTTTGCCAACGCATGCCCACGTGCTGGC
GAACAAATGTAAACACGGAGATCGTGTGCCGGGCACTT
GGAGTTAAGACAGCGCTTGGGGATGGATGCCCTGGTTGCTGAAGAGGAGGCGGAAGCCAAG
GGGAATGAAGTGAGGCCAGTGGCCGGGTCTGCTGAGTCC
ATTCATTGTCTCAGTGAAGGAAGAACCTGTAGAAGATGACCTCGTTCCGGAGCTGGGTATCTC
AAATCTGCTTTCATCCAGCCACTGCCCAAAGCCATCT
ATGGGAGCTATGCAGCTGATTGAAGACTTCAGCACACATGTCAGCATTGACTGCAGCCCTCAT
AAAACTGTCAAGAAGACTGCCAATGAATTTCCCTGTT
GGAGCTCAAGGACAAGAAGCTCTTCCTGAAGCGCGATAACCTCCTCATAGCTGACATTGAACT
TGGCTGCGGCAACTTTGGCTCAGTGCGCCAGGGCGTG
TCCTGGATAGTTTGCGGCTGAGAATGCACTTACTGGCTCATTCAGCGGGTGCCAAAGCCTTTG
TCTGTGATCAGTGCGGTGCACAGTTTTCGAAGGAGGA
ACGATTACCGCAGCCAAGTGGCGCTGGCAAAACTGTTGTAGGTGTTCCTTCAGGTAAAGTGTC
TTCAAGTAGCAGCTCTTTGGGAAACAAACTTCAGACC
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ZEB2

NM_014795.2

20-120

ZNF516

NM_014643.2

48304930

TCCCAGAGAGAAACTTGGCGATCACGTTTTCACATGATGCTCACGCTCAGGGCGCTTCAATTA
TCCCTCCCCACAAAGATAGGTGGCGCGTGTTTCAGGG
GGTGGGGGACGGCTTCATATACCTCTTCCTCAGTAATGCAAATGCGAGTTTTTGTGGTGGGGG
TTAAGGCCCATAACAAAGGATCTTAAACCATGCAGTG
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Appendix B. Fold change in mRNA abundance of mIL15-CAR T cells relative to CAR
T cells
GENE

IL7RA
NRP1
DAP12
CD4
TNFRSF4
TIE1
HRH2
CPT1
PDCD1
ICOSLG
CMRF35H
CCR4
RORC
GILZ
CD86
TSLPR
BCL6
PAX5
IL23R
KIR2DS2
CD40LG
IKZF2
BCL2
SOX5
SOX13
BNIP3
GZMH
CD11B
LEF1
SMAD3
FLT1
KLRB1
CCL5
C5ORF13
KLF2
CD276
LRP5
P2RX7
NCAM1
ATF3
ANXA1
EOMES
NFATC1
MMP14
PHACTR2
GATA3
CD44
AIM2
AGER
TGFBR1

logFC

PValue

FDR

-2.4
-2.7
1.9
-1.9
-1.7
-1.9
1.6
-1.6
-1.6
-1.3
-1.7
-1.4
1.4
-1.1
-1.3
-1.5
-1.1
1.1
1.1
1.1
-1.1
-1.0
0.8
1.3
-0.9
-0.8
0.7
-0.8
0.9
-0.7
0.7
-0.7
-0.6
-0.8
-0.6
-0.9
0.7
-0.7
0.6
0.8
-0.7
-0.8
-0.6
-0.8
-0.7
-0.7
-0.6
-0.6
-0.6
0.6

1.9E-05
1.6E-04
3.1E-04
5.5E-04
2.5E-03
2.6E-03
4.6E-03
5.0E-03
8.6E-03
1.3E-02
1.4E-02
1.4E-02
2.5E-02
2.6E-02
2.7E-02
3.1E-02
3.8E-02
4.2E-02
4.8E-02
5.2E-02
6.3E-02
7.6E-02
9.2E-02
1.1E-01
1.4E-01
1.5E-01
1.5E-01
1.6E-01
1.6E-01
1.6E-01
1.6E-01
1.7E-01
1.7E-01
1.8E-01
2.0E-01
2.0E-01
2.0E-01
2.1E-01
2.1E-01
2.2E-01
2.2E-01
2.3E-01
2.3E-01
2.5E-01
2.6E-01
2.6E-01
2.6E-01
2.7E-01
2.7E-01
2.8E-01

6.7E-03
2.9E-02
3.7E-02
4.9E-02
1.5E-01
1.5E-01
2.2E-01
2.2E-01
3.4E-01
4.2E-01
4.2E-01
4.2E-01
6.4E-01
6.4E-01
6.4E-01
6.8E-01
7.9E-01
8.3E-01
8.9E-01
9.2E-01
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00

CSF2
CD80
IL10
FGL2
MYC
PHC1
LOC282997
ITGA5
SIP1
ITGA1
KIR3DL2
TBXA2R
CCR7
RNF125
ITGA4
IL17RA
NOTCH1
CD28
BIM
STMN1
LYN
KIR2DS1
NKp30
TNFRSF18
RUNX1
SH2D2A
PDK1
SELL
POU5F1
EGLN1
TRAF1
SOCS1
KIR2DL1
IL23p19
LNK
SKAP1
BIRC2
STAT1
LAIR1
TNFRSF9
MYB
CDK4
XBP1
TFRC
SLA2
CD69
FAS
CCL3
EGLN3
TNF
IGF1R
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-0.7
-0.6
0.4
-0.6
-0.5
-0.6
-0.5
-0.6
-0.5
-0.5
-0.8
0.6
-0.5
-0.5
-0.4
0.4
0.4
-0.4
-0.5
-0.4
0.4
0.4
0.4
-0.5
0.4
0.4
-0.4
-0.4
-0.5
-0.4
-0.4
0.4
-0.7
0.4
0.3
-0.4
-0.3
-0.2
-0.3
-0.5
-0.4
0.4
0.4
-0.4
0.4
0.3
-0.4
0.2
-0.3
0.2
-0.3

2.9E-01
3.0E-01
3.2E-01
3.3E-01
3.4E-01
3.5E-01
3.5E-01
3.6E-01
3.7E-01
3.7E-01
3.7E-01
3.8E-01
3.9E-01
3.9E-01
4.1E-01
4.1E-01
4.1E-01
4.2E-01
4.2E-01
4.3E-01
4.3E-01
4.3E-01
4.4E-01
4.4E-01
4.4E-01
4.5E-01
4.5E-01
4.6E-01
4.7E-01
4.7E-01
4.7E-01
4.7E-01
4.8E-01
4.8E-01
4.9E-01
4.9E-01
4.9E-01
5.0E-01
5.0E-01
5.0E-01
5.0E-01
5.0E-01
5.0E-01
5.0E-01
5.1E-01
5.1E-01
5.1E-01
5.1E-01
5.1E-01
5.2E-01
5.2E-01

1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00

BACH2
CD94
BCL2L1
TXK
IL10RA
RARA
XBP1
IL12RB2
DPP4
RUNX3
HVEM
FLT3LG
ITGAL
EPHA4
IL2RA
PTGER2
ID2
DNAM1
CD7
SLAMF1
BCLXL
SATB1
TP53
MAD1L1
FOS
NKG2D
CDK2
GZMB
IFNGR1
CTNNA1
ICOS
SNAI1
KIR2DL3
LAG3
HES1
CD85
PRF1
CDH1
VEGFA
mTOR
AKT1
CD38
TRAF3
GLIPR1
Dock5
BCL2L11
LAT2
ANXA2P2
p38
ETV6
ATM
KIR3DL3
CBLB
IL15RA
CATHEPSINC
MAPK8

0.3
-0.4
0.3
0.3
-0.3
-0.4
0.3
0.4
0.3
0.4
-0.3
-0.3
-0.3
-0.3
-0.4
-0.3
0.3
-0.2
0.3
-0.4
0.2
0.3
0.2
0.3
0.3
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0.2
0.2
0.4
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-0.2
-0.3
0.2
0.2
-0.3
-0.3
0.2
-0.3
-0.2
0.3
0.2
-0.2
0.3
-0.2
0.2
-0.3
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0.2
0.3
-0.2
0.3
0.3
-0.3
-0.2
0.2
-0.2

5.2E-01
5.2E-01
5.2E-01
5.2E-01
5.3E-01
5.3E-01
5.3E-01
5.3E-01
5.3E-01
5.4E-01
5.4E-01
5.4E-01
5.5E-01
5.5E-01
5.5E-01
5.6E-01
5.6E-01
5.7E-01
5.7E-01
5.7E-01
5.9E-01
5.9E-01
5.9E-01
6.0E-01
6.0E-01
6.0E-01
6.0E-01
6.0E-01
6.0E-01
6.1E-01
6.2E-01
6.2E-01
6.2E-01
6.2E-01
6.2E-01
6.3E-01
6.4E-01
6.5E-01
6.5E-01
6.6E-01
6.6E-01
6.6E-01
6.6E-01
6.6E-01
6.6E-01
6.6E-01
6.6E-01
6.7E-01
6.7E-01
6.7E-01
6.7E-01
6.8E-01
6.8E-01
6.9E-01
6.9E-01
6.9E-01

1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00

FYN
ITGB1
RUNX2
CCR1
PTPN4
FASLG
CD19Rscfv
PDE4
STAT5A
SHP2
E2A
CREM
LTA
FOXO3
CASP1
SHP1
BATF
MAD
SOCS3
NKG2F
IRF4
RAC2
NFATC2
STAT6
GNLY
CCL4
CD11C
CSAD
ABCB1
CD8A
BMI1
RAC1
LAT
PNK
AP1
STAT5B

CD19RCD28CAR

CITED2
DGKA
CD274
YAP
IL2RG
POP5
TRF
SLC2A1
NFATC3
CFLIP
SERPINE2
PDCD1LG2
CTLA4
SLAMF7
HOPX
TERT
NFAT5
SCAP2
TNFRSF1B
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-0.2
-0.3
-0.2
0.1
-0.2
0.2
-0.3
-0.2
-0.2
0.2
-0.2
0.2
-0.3
-0.2
0.2
0.2
0.2
-0.1
-0.2
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0.2
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0.2
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-0.1
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7.5E-01
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7.6E-01
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7.6E-01
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7.8E-01
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APAF1
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B2M
LDHA
CD43
KLRC1
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CDKN2C
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CAT
HPRT1
IKZF1
JAK2
NEIL2
NFkB
CXCR4
KLF10
DUSP16
MAP2K1
IL21R
RAF1
FOXO1
MIF
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GADD45beta
FOXP1
HLAA
NR3C1
PRKCQ
TCF12
NR4A1
BCL10
ITGB7
MAPK14
HDAC2
CD244
IL18R1
S100A4
HOXB4
CSNK2A1
BCL11B
CTNNBL1
NCL
ELF1
MBD2

0.1
0.1
-0.1
-0.2
0.1
0.2
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8.5E-01
8.5E-01
8.6E-01
8.6E-01
8.6E-01
8.6E-01
8.6E-01
8.6E-01
8.6E-01
8.7E-01
8.7E-01
8.7E-01
8.8E-01
8.8E-01
8.8E-01
8.8E-01
8.8E-01
8.8E-01
8.8E-01
8.9E-01
8.9E-01
8.9E-01
8.9E-01
8.9E-01
9.0E-01
9.0E-01
9.0E-01
9.0E-01
9.0E-01

1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00

DAP10
ELF4
GSK3B
IRF1
CDKN1A
CREB1
TDO2
STAT3
AHNAK
CD63
LCK
KLF6
IL2RB
NKp46
EIF1
TRAF2
DOK2
ADAM19
GFI1
NKG2E
AIF1
HMGB2
HDAC1
CTNNB1
TYK2
IAP
C80RF70
PPARA
PRDM1
ITCH
CLA
LGALS3
CATHEPSIND
IL18RAP
IL4R
TNFSF10
CD58
BID
JAK1
CD247
SOD1
CIITA
CRIP1
BetaArrestin
NEIL1
SMAD4
SELL
C11ORF17
TNFSF14
RHOA
CCR5
NKG2C
S100A6
SIT1
KIR2DL4
CD3E
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-0.1
0.1
-0.1
0.0
-0.1
0.0
0.1
-0.1
0.1
0.0
0.0
0.1
0.0
0.0
0.1
0.1
0.1
-0.1
0.0
-0.1
0.0
0.0
0.1
0.0
0.1
0.1
0.2
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.1
0.1
0.1
-0.1
0.0
0.0
0.0
0.0
0.0
-0.1
-0.1
0.0
0.0
-0.1
0.0

9.0E-01
9.0E-01
9.1E-01
9.1E-01
9.1E-01
9.1E-01
9.1E-01
9.1E-01
9.1E-01
9.1E-01
9.1E-01
9.2E-01
9.2E-01
9.2E-01
9.2E-01
9.2E-01
9.2E-01
9.2E-01
9.2E-01
9.3E-01
9.3E-01
9.3E-01
9.3E-01
9.3E-01
9.3E-01
9.3E-01
9.3E-01
9.3E-01
9.4E-01
9.4E-01
9.4E-01
9.4E-01
9.4E-01
9.4E-01
9.5E-01
9.5E-01
9.5E-01
9.5E-01
9.5E-01
9.5E-01
9.6E-01
9.6E-01
9.6E-01
9.6E-01
9.6E-01
9.6E-01
9.6E-01
9.6E-01
9.6E-01
9.6E-01
9.6E-01
9.7E-01
9.7E-01
9.7E-01
9.7E-01
9.7E-01

1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00

GZMA
TBX21
GLO1
IFNG
IL12RB1
CCNB1
IRF2
PDE7
TNFRSF7
CLIC1
JAK3
OPTN
MAPK3
RORA
KLF7
CDKN1B

0.0
0.0
0.1
-0.1
0.0
-0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0

9.7E-01
9.7E-01
9.7E-01
9.7E-01
9.7E-01
9.7E-01
9.7E-01
9.7E-01
9.8E-01
9.8E-01
9.8E-01
9.8E-01
9.8E-01
9.8E-01
9.9E-01
9.9E-01

1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00

PPP2R1A
ATP2B4
CD2
CXCR3
C10RF24
TGFB1
STAT4
ZAP70
CD3D
GABPa
CCR10
PECAM1
SOX4
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0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-0.1
-0.1
0.1

9.9E-01
9.9E-01
9.9E-01
9.9E-01
9.9E-01
9.9E-01
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00

1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00
1.0E+00

BIBLIOGRAPHY
1.

Hunger, S. P., X. Lu, M. Devidas, B. M. Camitta, P. S. Gaynon, N. J. Winick, G. H.
Reaman, and W. L. Carroll. 2012. Improved survival for children and adolescents
with acute lymphoblastic leukemia between 1990 and 2005: a report from the
children's oncology group. J Clin Oncol 30:1663-1669.

2.

Bassan, R., and D. Hoelzer. 2011. Modern therapy of acute lymphoblastic leukemia.
J Clin Oncol 29:532-543.

3.

Cobaleda, C., and I. Sanchez-Garcia. 2009. B-cell acute lymphoblastic leukaemia:
towards understanding its cellular origin. Bioessays 31:600-609.

4.

Gokbuget, N., R. Arnold, A. Bohme, R. Fietkau, M. Freund, A. Ganser, M. Kneba, T.
Lipp, W. D. Ludwig, G. Maschmeyer, D. Messerer, H. Rieder, E. Thiel, and D.
Hoelzer. 2007. Improved outcome in high risk and very high risk ALL by risk
adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL
patients treated according to the prospective GMALL study 07/2003. Blood 110:11a12a.

5.

Gadner, H., O. A. Haas, G. Masera, C. H. Pui, and M. Schrappe. 2003. 'Ponte di
Legno' Working Group--report on the Fifth International Childhood Acute
Lymphoblastic Leukemia Workshop: Vienna, Austria, 29 April - 1 May 2002.
Leukemia 17:798-803.

6.

Verma, A., and W. Stock. 2001. Management of adult acute lymphoblastic leukemia:
moving toward a risk-adapted approach. Curr Opin Oncol 13:14-20.

7.

Pui, C. H., and W. E. Evans. 2006. Treatment of acute lymphoblastic leukemia. N
Engl J Med 354:166-178.

8.

Bartram, C. R., A. Schrauder, R. Kohler, and M. Schrappe. 2012. Acute
lymphoblastic leukemia in children: treatment planning via minimal residual disease
assessment. Dtsch Arztebl Int 109:652-658.

9.

Rollison, D. E., N. Howlader, M. T. Smith, S. S. Strom, W. D. Merritt, L. A. Ries, B.
K. Edwards, and A. F. List. 2008. Epidemiology of myelodysplastic syndromes and
chronic myeloproliferative disorders in the United States, 2001-2004, using data
from the NAACCR and SEER programs. Blood 112:45-52.

10.

Gaynon, P. S., R. P. Qu, R. J. Chappell, M. L. Willoughby, D. G. Tubergen, P. G.
Steinherz, and M. E. Trigg. 1998. Survival after relapse in childhood acute

129

lymphoblastic leukemia: impact of site and time to first relapse--the Children's
Cancer Group Experience. Cancer 82:1387-1395.
11.

Jain, S., and G. Kapoor. 2013. How to Treat Relapsed Acute Lymphoblastic
Leukemia: Transplant vs. Conventional Chemotherapy. Indian J Pediatr 80:846-852.

12.

Oeffinger, K. C., A. C. Mertens, C. A. Sklar, T. Kawashima, M. M. Hudson, A. T.
Meadows, D. L. Friedman, N. Marina, W. Hobbie, N. S. Kadan-Lottick, C. L.
Schwartz, W. Leisenring, and L. L. Robison. 2006. Chronic health conditions in adult
survivors of childhood cancer. N Engl J Med 355:1572-1582.

13.

Eapen, M., E. Raetz, M. J. Zhang, C. Muehlenbein, M. Devidas, T. Abshire, A.
Billett, A. Homans, B. Camitta, W. L. Carroll, and S. M. Davies. 2006. Outcomes
after HLA-matched sibling transplantation or chemotherapy in children with Bprecursor acute lymphoblastic leukemia in a second remission: a collaborative study
of the Children's Oncology Group and the Center for International Blood and Marrow
Transplant Research. Blood 107:4961-4967.

14.

Woolfrey, A. E., C. Anasetti, B. Storer, K. Doney, L. A. Milner, E. L. Sievers, P.
Carpenter, P. Martin, E. Petersdorf, F. R. Appelbaum, J. A. Hansen, and J. E.
Sanders. 2002. Factors associated with outcome after unrelated marrow
transplantation for treatment of acute lymphoblastic leukemia in children. Blood
99:2002-2008.

15.

De Rosa, S. C., L. A. Herzenberg, and M. Roederer. 2001. 11-color, 13-parameter
flow cytometry: identification of human naive T cells by phenotype, function, and Tcell receptor diversity. Nat Med 7:245-248.

16.

Kaech, S. M., and W. Cui. 2012. Transcriptional control of effector and memory
CD8+ T cell differentiation. Nat Rev Immunol 12:749-761.

17.

Gattinoni, L., C. A. Klebanoff, and N. P. Restifo. 2012. Paths to stemness: building
the ultimate antitumour T cell. Nat Rev Cancer 12:671-684.

18.

Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets
of memory T lymphocytes with distinct homing potentials and effector functions.
Nature 401:708-712.

19.

Oberdoerffer, S., L. F. Moita, D. Neems, R. P. Freitas, N. Hacohen, and A. Rao.
2008. Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein,
hnRNPLL. Science 321:686-691.

20.

Weninger, W., M. A. Crowley, N. Manjunath, and U. H. von Andrian. 2001. Migratory
properties of naive, effector, and memory CD8(+) T cells. J Exp Med 194:953-966.
130

21.

Wirth, T. C., H. H. Xue, D. Rai, J. T. Sabel, T. Bair, J. T. Harty, and V. P. Badovinac.
2010. Repetitive antigen stimulation induces stepwise transcriptome diversification
but preserves a core signature of memory CD8(+) T cell differentiation. Immunity
33:128-140.

22.

Klebanoff, C. A., L. Gattinoni, and N. P. Restifo. 2006. CD8+ T-cell memory in tumor
immunology and immunotherapy. Immunol Rev 211:214-224.

23.

Kaech, S. M., and E. J. Wherry. 2007. Heterogeneity and cell-fate decisions in
effector and memory CD8+ T cell differentiation during viral infection. Immunity
27:393-405.

24.

Amsen, D., R. A. Backer, and C. Helbig. 2013. Decisions on the road to memory.
Adv Exp Med Biol 785:107-120.

25.

Kim, E. H., and M. Suresh. 2013. Role of PI3K/Akt signaling in memory CD8 T cell
differentiation. Front Immunol 4:20.

26.

Kim, E. H., J. A. Sullivan, E. H. Plisch, M. M. Tejera, A. Jatzek, K. Y. Choi, and M.
Suresh. 2012. Signal integration by Akt regulates CD8 T cell effector and memory
differentiation. J Immunol 188:4305-4314.

27.

Castro, I., A. Yu, M. J. Dee, and T. R. Malek. 2011. The basis of distinctive IL-2- and
IL-15-dependent signaling: weak CD122-dependent signaling favors CD8+ T
central-memory cell survival but not T effector-memory cell development. J Immunol
187:5170-5182.

28.

Hamai, A., H. Benlalam, F. Meslin, M. Hasmim, T. Carre, I. Akalay, B. Janji, G.
Berchem, M. Z. Noman, and S. Chouaib. 2010. Immune surveillance of human
cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call
the tune? Tissue Antigens 75:1-8.

29.

Swann, J. B., and M. J. Smyth. 2007. Immune surveillance of tumors. J Clin Invest
117:1137-1146.

30.

Fielding, A. K., S. M. Richards, R. Chopra, H. M. Lazarus, M. R. Litzow, G. Buck, I.
J. Durrant, S. M. Luger, D. I. Marks, I. M. Franklin, A. K. McMillan, M. S. Tallman, J.
M. Rowe, and A. H. Goldstone. 2007. Outcome of 609 adults after relapse of acute
lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood
109:944-950.

31.

Appelbaum, F. R. 2001. Haematopoietic cell transplantation as immunotherapy.
Nature 411:385-389.

131

32.

Sullivan, K. M., R. Storb, C. D. Buckner, A. Fefer, L. Fisher, P. L. Weiden, R. P.
Witherspoon, F. R. Appelbaum, M. Banaji, J. Hansen, P. Martin, J. E. Sanders, J.
Singer, and E. D. Thomas. 1989. Graft-Versus-Host Disease as Adoptive
Immunotherapy in Patients with Advanced Hematologic Neoplasms. New Engl J
Med 320:828-834.

33.

Collins, R. H., Jr., O. Shpilberg, W. R. Drobyski, D. L. Porter, S. Giralt, R. Champlin,
S. A. Goodman, S. N. Wolff, W. Hu, C. Verfaillie, A. List, W. Dalton, N. Ognoskie, A.
Chetrit, J. H. Antin, and J. Nemunaitis. 1997. Donor leukocyte infusions in 140
patients with relapsed malignancy after allogeneic bone marrow transplantation. J
Clin Oncol 15:433-444.

34.

Mustafa, M. M., J. Kurtzberg, P. Martin, T. Driscol, and P. Szabolcs. 2002.
Unrelated umbilical cord blood (UCB) transplantation for infants with acute
lymphoblastic leukemia (ALL) and rearrangements of the 11q23 chromosomal
region. Blood 100:855a-856a.

35.

Scaradavou, A., A. Broniscer, C. E. Stevens, J. Kurtzberg, and P. Rubinstein. 2002.
Philadelphia-chromosome (Ph+) acute lymphoblastic leukemia (ALL) in children and
adolescents: Outcome with unrelated placental cord blood (PCB) transplantation.
Blood 100:856a-856a.

36.

Jena, B., G. Dotti, and L. J. Cooper. 2010. Redirecting T-cell specificity by
introducing a tumor-specific chimeric antigen receptor. Blood 116:1035-1044.

37.

Eshhar, Z., T. Waks, G. Gross, and D. G. Schindler. 1993. Specific activation and
targeting of cytotoxic lymphocytes through chimeric single chains consisting of
antibody-binding domains and the gamma or zeta subunits of the immunoglobulin
and T-cell receptors. Proc Natl Acad Sci U S A 90:720-724.

38.

Kebriaei, P., S. S. Kelly, P. Manuri, B. Jena, R. Jackson, E. Shpall, R. Champlin,
and L. J. Cooper. 2012. Chimeric antibody receptors (CARs): driving T-cell
specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed) 4:520-531.

39.

Pule, M. A., B. Savoldo, G. D. Myers, C. Rossig, H. V. Russell, G. Dotti, M. H. Huls,
E. Liu, A. P. Gee, Z. Mei, E. Yvon, H. L. Weiss, H. Liu, C. M. Rooney, H. E. Heslop,
and M. K. Brenner. 2008. Virus-specific T cells engineered to coexpress tumorspecific

receptors:

persistence

and

antitumor

activity

in

individuals

with

neuroblastoma. Nat Med 14:1264-1270.
40.

Park, J. R., D. L. DiGiusto, M. Slovak, C. Wright, A. Naranjo, J. Wagner, H. B.
Meechoovet, C. Bautista, W. C. Chang, J. R. Ostberg, and M. C. Jensens. 2007.
132

Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte
clones in patients with neuroblastoma. Molecular Therapy 15:825-833.
41.

Kowolik, C. M., M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D.
Smith, S. J. Forman, M. C. Jensen, and L. J. Cooper. 2006. CD28 costimulation
provided through a CD19-specific chimeric antigen receptor enhances in vivo
persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res
66:10995-11004.

42.

Stephan, M. T., V. Ponomarev, R. J. Brentjens, A. H. Chang, K. V. Dobrenkov, G.
Heller, and M. Sadelain. 2007. T cell-encoded CD80 and 4-1BBL induce auto- and
transcostimulation, resulting in potent tumor rejection. Nat Med 13:1440-1449.

43.

Robbins, P. F., M. E. Dudley, J. Wunderlich, M. El-Gamil, Y. F. Li, J. Zhou, J.
Huang, D. J. Powell, Jr., and S. A. Rosenberg. 2004. Cutting edge: persistence of
transferred lymphocyte clonotypes correlates with cancer regression in patients
receiving cell transfer therapy. J Immunol 173:7125-7130.

44.

Gong, M. C., J. B. Latouche, A. Krause, W. D. Heston, N. H. Bander, and M.
Sadelain. 1999. Cancer patient T cells genetically targeted to prostate-specific
membrane antigen specifically lyse prostate cancer cells and release cytokines in
response to prostate-specific membrane antigen. Neoplasia 1:123-127.

45.

Boutin, Y., D. Leitenberg, X. Tao, and K. Bottomly. 1997. Distinct biochemical
signals characterize agonist- and altered peptide ligand-induced differentiation of
naive CD4+ T cells into Th1 and Th2 subsets. J Immunol 159:5802-5809.

46.

Kuo, C. T., and J. M. Leiden. 1999. Transcriptional regulation of T lymphocyte
development and function. Annu Rev Immunol 17:149-187.

47.

Fraser, J. D., M. E. Newton, and A. Weiss. 1992. CD28 and T cell antigen receptor
signal transduction coordinately regulate interleukin 2 gene expression in response
to superantigen stimulation. J Exp Med 175:1131-1134.

48.

Imai, C., K. Mihara, M. Andreansky, I. C. Nicholson, C. H. Pui, T. L. Geiger, and D.
Campana. 2004. Chimeric receptors with 4-1BB signaling capacity provoke potent
cytotoxicity against acute lymphoblastic leukemia. Leukemia 18:676-684.

49.

Wilkie, S., G. Picco, J. Foster, D. M. Davies, S. Julien, L. Cooper, S. Arif, S. J.
Mather, J. Taylor-Papadimitriou, J. M. Burchell, and J. Maher. 2008. Retargeting of
human T cells to tumor-associated MUC1: the evolution of a chimeric antigen
receptor. J Immunol 180:4901-4909.

133

50.

Berger, C., M. C. Jensen, P. M. Lansdorp, M. Gough, C. Elliott, and S. R. Riddell.
2008. Adoptive transfer of effector CD8+ T cells derived from central memory cells
establishes persistent T cell memory in primates. J Clin Invest 118:294-305.

51.

Hinrichs, C. S., Z. A. Borman, L. Gattinoni, Z. Yu, W. R. Burns, J. Huang, C. A.
Klebanoff, L. A. Johnson, S. P. Kerkar, S. Yang, P. Muranski, D. C. Palmer, C. D.
Scott, R. A. Morgan, P. F. Robbins, S. A. Rosenberg, and N. P. Restifo. 2011.
Human effector CD8+ T cells derived from naive rather than memory subsets
possess superior traits for adoptive immunotherapy. Blood 117:808-814.

52.

Gattinoni, L., E. Lugli, Y. Ji, Z. Pos, C. M. Paulos, M. F. Quigley, J. R. Almeida, E.
Gostick, Z. Yu, C. Carpenito, E. Wang, D. C. Douek, D. A. Price, C. H. June, F. M.
Marincola, M. Roederer, and N. P. Restifo. 2011. A human memory T cell subset
with stem cell-like properties. Nat Med 17:1290-1297.

53.

Singh, H., M. J. Figliola, M. J. Dawson, H. Huls, S. Olivares, K. Switzer, T. Mi, S.
Maiti, P. Kebriaei, D. A. Lee, R. E. Champlin, and L. J. Cooper. 2011.
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive
immunotherapy of B-lineage malignancies. Cancer Res 71:3516-3527.

54.

Kaneko, S., S. Mastaglio, A. Bondanza, M. Ponzoni, F. Sanvito, L. Aldrighetti, M.
Radrizzani, S. La Seta-Catamancio, E. Provasi, A. Mondino, T. Nagasawa, K.
Fleischhauer, V. Russo, C. Traversari, F. Ciceri, C. Bordignon, and C. Bonini. 2009.
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive selfrenewing central memory human T lymphocytes. Blood 113:1006-1015.

55.

Wang, X., P. Lupardus, S. L. Laporte, and K. C. Garcia. 2009. Structural biology of
shared cytokine receptors. Annu Rev Immunol 27:29-60.

56.

Rochman, Y., R. Spolski, and W. J. Leonard. 2009. New insights into the regulation
of T cells by gamma(c) family cytokines. Nature Reviews Immunology 9:480-490.

57.

Leonard, W. J., and J. J. O'Shea. 1998. Jaks and STATs: biological implications.
Annu Rev Immunol 16:293-322.

58.

Shuai, K., and B. Liu. 2003. Regulation of JAK-STAT signalling in the immune
system. Nature Reviews Immunology 3:900-911.

59.

Waldmann, T. A. 2006. The biology of interleukin-2 and interleukin-15: implications
for cancer therapy and vaccine design. Nat Rev Immunol 6:595-601.

60.

Morgan, D. A., F. W. Ruscetti, and R. Gallo. 1976. Selective in vitro growth of T
lymphocytes from normal human bone marrows. Science 193:1007-1008.

134

61.

Cote-Sierra, J., G. Foucras, L. Guo, L. Chiodetti, H. A. Young, J. Hu-Li, J. Zhu, and
W. E. Paul. 2004. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl
Acad Sci U S A 101:3880-3885.

62.

Dudley, M. E., J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang, S. L. Topalian, D.
J. Schwartzentruber, P. Hwu, F. M. Marincola, R. Sherry, S. F. Leitman, and S. A.
Rosenberg. 2001. Adoptive transfer of cloned melanoma-reactive T lymphocytes for
the treatment of patients with metastatic melanoma. J Immunother 24:363-373.

63.

Yee, C., J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche, E. Celis, and P. D.
Greenberg. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones
for the treatment of patients with metastatic melanoma: in vivo persistence,
migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A
99:16168-16173.

64.

Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber,
J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994.
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating
lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166.

65.

Ahmadzadeh, M., and S. A. Rosenberg. 2006. IL-2 administration increases CD4+
CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107:2409-2414.

66.

Van Parijs, L., Y. Refaeli, J. D. Lord, B. H. Nelson, A. K. Abbas, and D. Baltimore.
1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fasmediated activation-induced cell death. Immunity 11:281-288.

67.

Wallace, D. L., M. Berard, M. V. D. Soares, J. Oldham, J. E. Cook, A. N. Akbar, D.
F. Tough, and P. C. L. Beverley. 2006. Prolonged exposure of naive CD8(+) T cells
to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss
of telomere length. Immunology 119:243-253.

68.

Becker, T. C., E. J. Wherry, D. Boone, K. Murali-Krishna, R. Antia, A. Ma, and R.
Ahmed. 2002. Interleukin 15 is required for proliferative renewal of virus-specific
memory CD8 T cells. Journal of Experimental Medicine 195:1541-1548.

69.

Ramsey, C., M. P. Rubinstein, D. M. Kim, J. H. Cho, J. Sprent, and C. D. Surh.
2008. The lymphopenic environment of CD132 (common gamma-chain)-deficient
hosts elicits rapid homeostatic proliferation of naive T cells via IL-15. J Immunol
180:5320-5326.

70.

Dubois, S., J. Mariner, T. A. Waldmann, and Y. Tagaya. 2002. IL-15Ralpha recycles
and presents IL-15 In trans to neighboring cells. Immunity 17:537-547.
135

71.

Sato, N., H. J. Patel, T. A. Waldmann, and Y. Tagaya. 2007. The IL-15/IL-15Ralpha
on cell surfaces enables sustained IL-15 activity and contributes to the long survival
of CD8 memory T cells. Proc Natl Acad Sci U S A 104:588-593.

72.

Kobayashi, H., S. Dubois, N. Sato, H. Sabzevari, Y. Sakai, T. A. Waldmann, and Y.
Tagaya. 2005. Role of trans-cellular IL-15 presentation in the activation of NK cellmediated killing, which leads to enhanced tumor immunosurveillance. Blood
105:721-727.

73.

Steel, J. C., T. A. Waldmann, and J. C. Morris. 2012. Interleukin-15 biology and its
therapeutic implications in cancer. Trends Pharmacol Sci 33:35-41.

74.

Epardaud, M., K. G. Elpek, M. P. Rubinstein, A. R. Yonekura, A. BellemarePelletier, R. Bronson, J. A. Hamerman, A. W. Goldrath, and S. J. Turley. 2008.
Interleukin-15/interleukin-15R alpha complexes promote destruction of established
tumors by reviving tumor-resident CD8+ T cells. Cancer Res 68:2972-2983.

75.

Villinger, F., R. Miller, K. Mori, A. E. Mayne, P. Bostik, J. B. Sundstrom, C.
Sugimoto, and A. A. Ansari. 2004. IL-15 is superior to IL-2 in the generation of longlived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine
22:3510-3521.

76.

Berger, C., M. Berger, R. C. Hackman, M. Gough, C. Elliott, M. C. Jensen, and S. R.
Riddell. 2009. Safety and immunologic effects of IL-15 administration in nonhuman
primates. Blood 114:2417-2426.

77.

Kalos, M., B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, and C. H. June.
2011. T cells with chimeric antigen receptors have potent antitumor effects and can
establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73.

78.

Brentjens, R. J., M. L. Davila, I. Riviere, J. Park, X. Wang, L. G. Cowell, S. Bartido,
J. Stefanski, C. Taylor, M. Olszewska, O. Borquez-Ojeda, J. Qu, T. Wasielewska, Q.
He, Y. Bernal, I. V. Rijo, C. Hedvat, R. Kobos, K. Curran, P. Steinherz, J. Jurcic, T.
Rosenblat, P. Maslak, M. Frattini, and M. Sadelain. 2013. CD19-targeted T cells
rapidly induce molecular remissions in adults with chemotherapy-refractory acute
lymphoblastic leukemia. Sci Transl Med 5:177ra138.

79.

Savoldo, B., C. A. Ramos, E. Liu, M. P. Mims, M. J. Keating, G. Carrum, R. T.
Kamble, C. M. Bollard, A. P. Gee, Z. Mei, H. Liu, B. Grilley, C. M. Rooney, H. E.
Heslop, M. K. Brenner, and G. Dotti. 2011. CD28 costimulation improves expansion
and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
J Clin Invest 121:1822-1826.
136

80.

Alwan, L. M., K. Grossmann, D. Sageser, J. Van Atta, N. Agarwal, and J. A.
Gilreath. 2013. Comparison of acute toxicity and mortality after two different dosing
regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target
Oncol.

81.

Baan, C. C., A. H. Balk, I. C. van Riemsdijk, P. J. Vantrimpont, A. P. Maat, H. G.
Niesters, P. E. Zondervan, T. van Gelder, and W. Weimar. 2003. Anti-CD25
monoclonal antibody therapy affects the death signals of graft-infiltrating cells after
clinical heart transplantation. Transplantation 75:1704-1710.

82.

Lenardo, M. J. 1991. Interleukin-2 programs mouse alpha beta T lymphocytes for
apoptosis. Nature 353:858-861.

83.

Matsuoka, K., J. Koreth, H. T. Kim, G. Bascug, S. McDonough, Y. Kawano, K.
Murase, C. Cutler, V. T. Ho, E. P. Alyea, P. Armand, B. R. Blazar, J. H. Antin, R. J.
Soiffer, and J. Ritz. 2013. Low-dose interleukin-2 therapy restores regulatory T cell
homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med
5:179ra143.

84.

Zhang, H., K. S. Chua, M. Guimond, V. Kapoor, M. V. Brown, T. A. Fleisher, L. M.
Long, D. Bernstein, B. J. Hill, D. C. Douek, J. A. Berzofsky, C. S. Carter, E. J. Read,
L. J. Helman, and C. L. Mackall. 2005. Lymphopenia and interleukin-2 therapy alter
homeostasis of CD4+CD25+ regulatory T cells. Nat Med 11:1238-1243.

85.

Zhang, X., S. Sun, I. Hwang, D. F. Tough, and J. Sprent. 1998. Potent and selective
stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8:591599.

86.

Goldrath, A. W., P. V. Sivakumar, M. Glaccum, M. K. Kennedy, M. J. Bevan, C.
Benoist, D. Mathis, and E. A. Butz. 2002. Cytokine requirements for acute and Basal
homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med 195:15151522.

87.

Marks-Konczalik, J., S. Dubois, J. M. Losi, H. Sabzevari, N. Yamada, L.
Feigenbaum, T. A. Waldmann, and Y. Tagaya. 2000. IL-2-induced activationinduced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A
97:11445-11450.

88.

Klebanoff, C. A., S. E. Finkelstein, D. R. Surman, M. K. Lichtman, L. Gattinoni, M. R.
Theoret, N. Grewal, P. J. Spiess, P. A. Antony, D. C. Palmer, Y. Tagaya, S. A.
Rosenberg, T. A. Waldmann, and N. P. Restifo. 2004. IL-15 enhances the in vivo

137

antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A
101:1969-1974.
89.

Teague, R. M., B. D. Sather, J. A. Sacks, M. Z. Huang, M. L. Dossett, J. Morimoto,
X. Tan, S. E. Sutton, M. P. Cooke, C. Ohlen, and P. D. Greenberg. 2006.
Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of
established tumors. Nat Med 12:335-341.

90.

Cheever, M. A. 2008. Twelve immunotherapy drugs that could cure cancers.
Immunol Rev 222:357-368.

91.

Hsu, C., M. S. Hughes, Z. Zheng, R. B. Bray, S. A. Rosenberg, and R. A. Morgan.
2005. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene
resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of
exogenous cytokine. J Immunol 175:7226-7234.

92.

Markley, J. C., and M. Sadelain. IL-7 and IL-21 are superior to IL-2 and IL-15 in
promoting

human

T

cell-mediated

rejection

of

systemic

lymphoma

in

immunodeficient mice. Blood 115:3508-3519.
93.

Hoyos, V., B. Savoldo, C. Quintarelli, A. Mahendravada, M. Zhang, J. Vera, H. E.
Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti. 2010. Engineering CD19specific T lymphocytes with interleukin-15 and a suicide gene to enhance their antilymphoma/leukemia effects and safety. Leukemia 24:1160-1170.

94.

Stonier, S. W., L. J. Ma, E. F. Castillo, and K. S. Schluns. 2008. Dendritic cells drive
memory CD8 T-cell homeostasis via IL-15 transpresentation. Blood 112:4546-4554.

95.

Burkett, P. R., R. Koka, M. Chien, S. Chai, D. L. Boone, and A. Ma. 2004.
Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15
supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med
200:825-834.

96.

Han, K. P., X. Zhu, B. Liu, E. Jeng, L. Kong, J. L. Yovandich, V. V. Vyas, W. D.
Marcus, P. A. Chavaillaz, C. A. Romero, P. R. Rhode, and H. C. Wong. 2011. IL15:IL-15 receptor alpha superagonist complex: high-level co-expression in
recombinant mammalian cells, purification and characterization. Cytokine 56:804810.

97.

Stoklasek, T. A., K. S. Schluns, and L. Lefrancois. 2006. Combined IL-15/IL15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 177:60726080.

138

98.

Kermer, V., V. Baum, N. Hornig, R. E. Kontermann, and D. Muller. 2012. An
antibody fusion protein for cancer immunotherapy mimicking IL-15 transpresentation at the tumor site. Mol Cancer Ther 11:1279-1288.

99.

Bamford, R. N., A. P. DeFilippis, N. Azimi, G. Kurys, and T. A. Waldmann. 1998.
The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl
terminus of IL-15 participate in its multifaceted translational control. J Immunol
160:4418-4426.

100.

Jalah, R., M. Rosati, V. Kulkarni, V. Patel, C. Bergamaschi, A. Valentin, G. M.
Zhang, M. K. Sidhu, J. H. Eldridge, D. B. Weiner, G. N. Pavlakis, and B. K. Felber.
2007. Efficient systemic expression of bioactive IL-15 in mice upon delivery of
optimized DNA expression plasmids. DNA Cell Biol 26:827-840.

101.

Maiti, S. N., H. Huls, H. Singh, M. Dawson, M. Figliola, S. Olivares, P. Rao, Y. J.
Zhao, A. Multani, G. Yang, L. Zhang, D. Crossland, S. Ang, H. Torikai, B.
Rabinovich, D. A. Lee, P. Kebriaei, P. Hackett, R. E. Champlin, and L. J. Cooper.
2013. Sleeping beauty system to redirect T-cell specificity for human applications. J
Immunother 36:112-123.

102.

Singh, H., M. J. Figliola, M. J. Dawson, S. Olivares, L. Zhang, G. Yang, S. Maiti, P.
Manuri, V. Senyukov, B. Jena, P. Kebriaei, R. E. Champlin, H. Huls, and L. J.
Cooper. 2013. Manufacture of clinical-grade CD19-specific T cells stably expressing
chimeric antigen receptor using Sleeping Beauty system and artificial antigen
presenting cells. PLoS One 8:e64138.

103.

Mortier, E., A. Quemener, P. Vusio, I. Lorenzen, Y. Boublik, J. Grotzinger, A. Plet,
and Y. Jacques. 2006. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as
a selective and potent agonist of IL-15 action through IL-15R beta/gamma.
Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 281:1612-1619.

104.

Rowley, J., A. Monie, C. F. Hung, and T. C. Wu. 2008. Inhibition of tumor growth by
NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common
gamma signaling in trans. J Immunol 181:8237-8247.

105.

Huls, M. H., M. J. Figliola, M. J. Dawson, S. Olivares, P. Kebriaei, E. J. Shpall, R. E.
Champlin, H. Singh, and L. J. Cooper. 2013. Clinical application of Sleeping Beauty
and artificial antigen presenting cells to genetically modify T cells from peripheral
and umbilical cord blood. J Vis Exp:e50070.

106.

Suhoski, M. M., T. N. Golovina, N. A. Aqui, V. C. Tai, A. Varela-Rohena, M. C.
Milone, R. G. Carroll, J. L. Riley, and C. H. June. 2007. Engineering artificial
139

antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol
Ther 15:981-988.
107.

Zeng, R., R. Spolski, S. E. Finkelstein, S. Oh, P. E. Kovanen, C. S. Hinrichs, C. A.
Pise-Masison, M. F. Radonovich, J. N. Brady, N. P. Restifo, J. A. Berzofsky, and W.
J. Leonard. 2005. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion
and function. J Exp Med 201:139-148.

108.

Lin, J. X., T. S. Migone, M. Tsang, M. Friedmann, J. A. Weatherbee, L. Zhou, A.
Yamauchi, E. T. Bloom, J. Mietz, S. John, and W. J. Leonard. 1995. The Role of
Shared Receptor Motifs and Common Stat Proteins in the Generation of Cytokine
Pleiotropy and Redundancy by Il-2, Il-4, Il-7, Il-13, and Il-15. Immunity 2:331-339.

109.

Hinrichs, C. S., R. Spolski, C. M. Paulos, L. Gattinoni, K. W. Kerstann, D. C. Palmer,
C. A. Klebanoff, S. A. Rosenberg, W. J. Leonard, and N. P. Restifo. 2008. IL-2 and
IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive
immunotherapy. Blood 111:5326-5333.

110.

Gattinoni, L., C. A. Klebanoff, D. C. Palmer, C. Wrzesinski, K. Kerstann, Z. Yu, S. E.
Finkelstein, M. R. Theoret, S. A. Rosenberg, and N. P. Restifo. 2005. Acquisition of
full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of
adoptively transferred CD8+ T cells. J Clin Invest 115:1616-1626.

111.

Appay, V., P. R. Dunbar, M. Callan, P. Klenerman, G. M. Gillespie, L. Papagno, G.
S. Ogg, A. King, F. Lechner, C. A. Spina, S. Little, D. V. Havlir, D. D. Richman, N.
Gruener, G. Pape, A. Waters, P. Easterbrook, M. Salio, V. Cerundolo, A. J.
McMichael, and S. L. Rowland-Jones. 2002. Memory CD8+ T cells vary in
differentiation phenotype in different persistent virus infections. Nat Med 8:379-385.

112.

Louis, C. U., B. Savoldo, G. Dotti, M. Pule, E. Yvon, G. D. Myers, C. Rossig, H. V.
Russell, O. Diouf, E. Liu, H. Liu, M. F. Wu, A. P. Gee, Z. Mei, C. M. Rooney, H. E.
Heslop, and M. K. Brenner. 2011. Antitumor activity and long-term fate of chimeric
antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:60506056.

113.

Huang, J., K. W. Kerstann, M. Ahmadzadeh, Y. F. Li, M. El-Gamil, S. A. Rosenberg,
and P. F. Robbins. 2006. Modulation by IL-2 of CD70 and CD27 expression on
CD8+ T cells: importance for the therapeutic effectiveness of cell transfer
immunotherapy. J Immunol 176:7726-7735.

114.

Klebanoff, C. A., L. Gattinoni, P. Torabi-Parizi, K. Kerstann, A. R. Cardones, S. E.
Finkelstein, D. C. Palmer, P. A. Antony, S. T. Hwang, S. A. Rosenberg, T. A.
140

Waldmann, and N. P. Restifo. 2005. Central memory self/tumor-reactive CD8+ T
cells confer superior antitumor immunity compared with effector memory T cells.
Proc Natl Acad Sci U S A 102:9571-9576.
115.

Olsen, S. K., N. Ota, S. Kishishita, M. Kukimoto-Niino, K. Murayama, H. Uchiyama,
M. Toyama, T. Terada, M. Shirouzu, O. Kanagawa, and S. Yokoyama. 2007. Crystal
Structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into
trans and cis presentation. J Biol Chem 282:37191-37204.

116.

Rochman, Y., R. Spolski, and W. J. Leonard. 2009. New insights into the regulation
of T cells by gamma(c) family cytokines. Nat Rev Immunol 9:480-490.

117.

Ring, A. M., J. X. Lin, D. Feng, S. Mitra, M. Rickert, G. R. Bowman, V. S. Pande, P.
Li, I. Moraga, R. Spolski, E. Ozkan, W. J. Leonard, and K. C. Garcia. 2012.
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL15. Nat Immunol 13:1187-1195.

118.

Kovanen, P. E., and W. J. Leonard. 2004. Cytokines and immunodeficiency
diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9,
15, and 21, and their signaling pathways. Immunol Rev 202:67-83.

119.

Schluns, K. S., and L. Lefrancois. 2003. Cytokine control of memory T-cell
development and survival. Nat Rev Immunol 3:269-279.

120.

Hunter, M. R., M. E. Prosser, V. Mahadev, X. Wang, B. Aguilar, C. E. Brown, S. J.
Forman, and M. C. Jensen. 2013. Chimeric gammac cytokine receptors confer
cytokine independent engraftment of human T lymphocytes. Mol Immunol 56:1-11.

121.

Sandau, M. M., K. S. Schluns, L. Lefrancois, and S. C. Jameson. 2004. Cutting
edge: transpresentation of IL-15 by bone marrow-derived cells necessitates
expression of IL-15 and IL-15R alpha by the same cells. J Immunol 173:6537-6541.

122.

Rowley, J., A. Monie, C. F. Hung, and T. C. Wu. 2009. Expression of IL-15RA or an
IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function
in cis. Eur J Immunol 39:491-506.

123.

Perdreau, H., E. Mortier, G. Bouchaud, V. Sole, Y. Boublik, A. Plet, and Y. Jacques.
2010. Different dynamics of IL-15R activation following IL-15 cis- or transpresentation. Eur Cytokine Netw 21:297-307.

124.

Zakrzewski, J. L., D. Suh, J. C. Markley, O. M. Smith, C. King, G. L. Goldberg, R.
Jenq, A. M. Holland, J. Grubin, J. Cabrera-Perez, R. J. Brentjens, S. X. Lu, G.
Rizzuto, D. B. Sant'Angelo, I. Riviere, M. Sadelain, G. Heller, J. C. Zuniga-Pflucker,

141

C. Lu, and M. R. van den Brink. 2008. Tumor immunotherapy across MHC barriers
using allogeneic T-cell precursors. Nat Biotechnol 26:453-461.
125.

Yang, S., Y. Ji, L. Gattinoni, L. Zhang, Z. Yu, N. P. Restifo, S. A. Rosenberg, and R.
A. Morgan. 2013. Modulating the differentiation status of ex vivo-cultured anti-tumor
T cells using cytokine cocktails. Cancer Immunol Immunother 62:727-736.

126.

Cieri, N., B. Camisa, F. Cocchiarella, M. Forcato, G. Oliveira, E. Provasi, A.
Bondanza, C. Bordignon, J. Peccatori, F. Ciceri, M. T. Lupo-Stanghellini, F. Mavilio,
A. Mondino, S. Bicciato, A. Recchia, and C. Bonini. 2013. IL-7 and IL-15 instruct the
generation of human memory stem T cells from naive precursors. Blood 121:573584.

127.

Tejera, M. M., E. H. Kim, J. A. Sullivan, E. H. Plisch, and M. Suresh. 2013. FoxO1
controls effector-to-memory transition and maintenance of functional CD8 T cell
memory. J Immunol 191:187-199.

128.

Faham, M., J. Zheng, M. Moorhead, V. E. Carlton, P. Stow, E. Coustan-Smith, C. H.
Pui, and D. Campana. 2012. Deep-sequencing approach for minimal residual
disease detection in acute lymphoblastic leukemia. Blood 120:5173-5180.

129.

Ryan, J., F. Quinn, A. Meunier, L. Boublikova, M. Crampe, P. Tewari, A.
O'Marcaigh, R. Stallings, M. Neat, A. O'Meara, F. Breatnach, S. McCann, P.
Browne, O. Smith, and M. Lawler. 2009. Minimal residual disease detection in
childhood acute lymphoblastic leukaemia patients at multiple time-points reveals
high levels of concordance between molecular and immunophenotypic approaches.
Br J Haematol 144:107-115.

130.

Neale, G. A., E. Coustan-Smith, P. Stow, Q. Pan, X. Chen, C. H. Pui, and D.
Campana. 2004. Comparative analysis of flow cytometry and polymerase chain
reaction for the detection of minimal residual disease in childhood acute
lymphoblastic leukemia. Leukemia 18:934-938.

131.

Bradstock, K. F., G. Janossy, N. Tidman, E. S. Papageorgiou, H. G. Prentice, M.
Willoughby, and A. V. Hoffbrand. 1981. Immunological monitoring of residual
disease in treated thymic acute lymphoblastic leukaemia. Leuk Res 5:301-309.

132.

Gokbuget, N., M. Kneba, T. Raff, H. Trautmann, C. R. Bartram, R. Arnold, R.
Fietkau, M. Freund, A. Ganser, W. D. Ludwig, G. Maschmeyer, H. Rieder, S.
Schwartz, H. Serve, E. Thiel, M. Bruggemann, and D. Hoelzer. 2012. Adult patients
with acute lymphoblastic leukemia and molecular failure display a poor prognosis

142

and are candidates for stem cell transplantation and targeted therapies. Blood
120:1868-1876.
133.

Stow, P., L. Key, X. Chen, Q. Pan, G. A. Neale, E. Coustan-Smith, C. G. Mullighan,
Y. Zhou, C. H. Pui, and D. Campana. 2010. Clinical significance of low levels of
minimal residual disease at the end of remission induction therapy in childhood
acute lymphoblastic leukemia. Blood 115:4657-4663.

134.

Boyman, O., S. Letourneau, C. Krieg, and J. Sprent. 2009. Homeostatic proliferation
and survival of naive and memory T cells. Eur J Immunol 39:2088-2094.

135.

Grange, M., M. Buferne, G. Verdeil, L. Leserman, A. M. Schmitt-Verhulst, and N.
Auphan-Anezin. 2012. Activated STAT5 promotes long-lived cytotoxic CD8+ T cells
that induce regression of autochthonous melanoma. Cancer Res 72:76-87.

136.

Rabinovich, B. A., Y. Ye, T. Etto, J. Q. Chen, H. I. Levitsky, W. W. Overwijk, L. J. N.
Cooper, J. Gelovani, and P. Hwu. 2008. Visualizing fewer than 10 mouse T cells
with an enhanced firefly luciferase in immunocompetent mouse models of cancer. P
Natl Acad Sci USA 105:14342-14346.

137.

Brentjens, R. J., J. B. Latouche, E. Santos, F. Marti, M. C. Gong, C. Lyddane, P. D.
King, S. Larson, M. Weiss, I. Riviere, and M. Sadelain. 2003. Eradication of
systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated
by CD80 and interleukin-15. Nat Med 9:279-286.

138.

Hall, K., M. E. Blair Zajdel, and G. E. Blair. 2009. Defining the role of CD46, CD80
and CD86 in mediating adenovirus type 3 fiber interactions with host cells. Virology
392:222-229.

139.

Han, P., C. Story, T. McDonald, K. Mrozik, and L. Snell. 2002. Immune escape
mechanisms of childhood ALL and a potential countering role for DC-like leukemia
cells. Cytotherapy 4:165-175.

140.

Davila, M. L., C. C. Kloss, G. Gunset, and M. Sadelain. 2013. CD19 CAR-targeted T
cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse
model of B cell acute lymphoblastic leukemia. PLoS One 8:e61338.

141.

Parretta, E., G. Cassese, P. Barba, A. Santoni, J. Guardiola, and F. Di Rosa. 2005.
CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone
marrow. J Immunol 174:7654-7664.

142.

Di Rosa, F., and A. Santoni. 2002. Bone marrow CD8 T cells are in a different
activation state than those in lymphoid periphery. Eur J Immunol 32:1873-1880.

143

143.

Hombach, A. A., and H. Abken. 2013. Young T Cells Age During a Redirected AntiTumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the
Battle. Front Immunol 4:135.

144.

Hombach, A. A., M. Chmielewski, G. Rappl, and H. Abken. 2013. Adoptive
immunotherapy with redirected T cells produces CCR7- cells that are trapped in the
periphery and benefit from combined CD28-OX40 costimulation. Hum Gene Ther
24:259-269.

145.

Grupp, S. A., M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold, D. T.
Teachey, A. Chew, B. Hauck, J. F. Wright, M. C. Milone, B. L. Levine, and C. H.
June. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
N Engl J Med 368:1509-1518.

146.

Zhang, H., K. M. Snyder, M. M. Suhoski, M. V. Maus, V. Kapoor, C. H. June, and C.
L. Mackall. 2007. 4-1BB is superior to CD28 costimulation for generating CD8(+)
cytotoxic lymphocytes for adoptive immunotherapy. Journal of Immunology
179:4910-4918.

147.

Pulle, G., M. Vidric, and T. H. Watts. 2006. IL-15-dependent induction of 4-1BB
promotes antigen-independent CD8 memory T cell survival. J Immunol 176:27392748.

148.

Kermer, V., N. Hornig, M. Harder, A. Bondarieva, R. E. Kontermann, and D. Muller.
2013. Combining antibody-directed presentation of IL-15 and 4-1BBL in a
trifunctional fusion protein for cancer immunotherapy. Mol Cancer Ther.

149.

Zinkernagel, R. M., and P. C. Doherty. 1974. Restriction of in vitro T cell-mediated
cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic
system. Nature 248:701-702.

150.

Lafferty, K. J., H. S. Warren, and J. A. Woolnough. 1979. A mediator acting as a
costimulator for the development of cytotoxic responses in vitro. Adv Exp Med Biol
114:497-501.

151.

Curtsinger, J. M., C. S. Schmidt, A. Mondino, D. C. Lins, R. M. Kedl, M. K. Jenkins,
and M. F. Mescher. 1999. Inflammatory cytokines provide a third signal for
activation of naive CD4+ and CD8+ T cells. J Immunol 162:3256-3262.

152.

Joshi, N. S., and S. M. Kaech. 2008. Effector CD8 T cell development: a balancing
act between memory cell potential and terminal differentiation. J Immunol 180:13091315.

144

153.

Hinrichs, C. S., Z. A. Borman, L. Cassard, L. Gattinoni, R. Spolski, Z. Yu, L.
Sanchez-Perez, P. Muranski, S. J. Kern, C. Logun, D. C. Palmer, Y. Ji, R. N. Reger,
W. J. Leonard, R. L. Danner, S. A. Rosenberg, and N. P. Restifo. 2009. Adoptively
transferred effector cells derived from naive rather than central memory CD8+ T
cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 106:1746917474.

154.

Hand, T. W., W. Cui, Y. W. Jung, E. Sefik, N. S. Joshi, A. Chandele, Y. Liu, and S.
M. Kaech. 2010. Differential effects of STAT5 and PI3K/AKT signaling on effector
and memory CD8 T-cell survival. Proc Natl Acad Sci U S A 107:16601-16606.

155.

Tripathi, P., S. Kurtulus, S. Wojciechowski, A. Sholl, K. Hoebe, S. C. Morris, F. D.
Finkelman, H. L. Grimes, and D. A. Hildeman. 2010. STAT5 is critical to maintain
effector CD8+ T cell responses. J Immunol 185:2116-2124.

156.

Fluur, C., A. De Milito, T. J. Fry, N. Vivar, L. Eidsmo, A. Atlas, C. Federici, P.
Matarrese, M. Logozzi, E. Rajnavolgyi, C. L. Mackall, S. Fais, F. Chiodi, and B.
Rethi. 2007. Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV
infection. J Immunol 178:5340-5350.

157.

Hand, T. W., and S. M. Kaech. 2009. Intrinsic and extrinsic control of effector T cell
survival and memory T cell development. Immunol Res 45:46-61.

158.

Huang, D. W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols
4:44-57.

159.

Huang, D. W., B. T. Sherman, and R. A. Lempicki. 2009. Bioinformatics enrichment
tools: paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Research 37:1-13.

160.

Tsukumo, S., M. Unno, A. Muto, A. Takeuchi, K. Kometani, T. Kurosaki, K. Igarashi,
and T. Saito. 2013. Bach2 maintains T cells in a naive state by suppressing effector
memory-related genes. Proc Natl Acad Sci U S A 110:10735-10740.

161.

Best, J. A., D. A. Blair, J. Knell, E. Yang, V. Mayya, A. Doedens, M. L. Dustin, and
A. W. Goldrath. 2013. Transcriptional insights into the CD8(+) T cell response to
infection and memory T cell formation. Nat Immunol 14:404-412.

162.

Willinger, T., T. Freeman, H. Hasegawa, A. J. McMichael, and M. F. Callan. 2005.
Molecular signatures distinguish human central memory from effector memory CD8
T cell subsets. J Immunol 175:5895-5903.

145

163.

Michelini, R. H., A. L. Doedens, A. W. Goldrath, and S. M. Hedrick. 2013.
Differentiation of CD8 memory T cells depends on Foxo1. J Exp Med 210:11891200.

164.

Godlove, J., W. K. Chiu, and N. P. Weng. 2007. Gene expression and generation of
CD28-CD8 T cells mediated by interleukin 15. Exp Gerontol 42:412-415.

165.

Chen, Y. H., M. L. Kuo, P. J. Cheng, H. S. Hsaio, P. T. Lee, and S. J. Lin. 2012.
Regulation of CD28 expression on umbilical cord blood and adult peripheral blood
CD8+ T cells by interleukin(IL)-15/IL-21. Cytokine 58:40-46.

166.

Chiu, W. K., M. Fann, and N. P. Weng. 2006. Generation and growth of
CD28(null)CD8(+) memory T cells mediated by IL-15 and its induced cytokines.
Journal of Immunology 177:7802-7810.

167.

Rao, R. R., Q. Li, K. Odunsi, and P. A. Shrikant. 2010. The mTOR kinase
determines effector versus memory CD8+ T cell fate by regulating the expression of
transcription factors T-bet and Eomesodermin. Immunity 32:67-78.

168.

Kerdiles, Y. M., D. R. Beisner, R. Tinoco, A. S. Dejean, D. H. Castrillon, R. A.
DePinho, and S. M. Hedrick. 2009. Foxo1 links homing and survival of naive T cells
by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol 10:176-184.

169.

Lugli, E., L. Gattinoni, A. Roberto, D. Mavilio, D. A. Price, N. P. Restifo, and M.
Roederer. 2013. Identification, isolation and in vitro expansion of human and
nonhuman primate T stem cell memory cells. Nat Protoc 8:33-42.

170.

Michie, C. A., A. McLean, C. Alcock, and P. C. Beverley. 1992. Lifespan of human
lymphocyte subsets defined by CD45 isoforms. Nature 360:264-265.

171.

Akbar, A. N., and J. M. Fletcher. 2005. Memory T cell homeostasis and senescence
during aging. Curr Opin Immunol 17:480-485.

172.

Macintyre, A. N., D. Finlay, G. Preston, L. V. Sinclair, C. M. Waugh, P. Tamas, C.
Feijoo, K. Okkenhaug, and D. A. Cantrell. 2011. Protein kinase B controls
transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell
metabolism. Immunity 34:224-236.

173.

Chappell, C., C. Beard, J. Altman, R. Jaenisch, and J. Jacob. 2006. DNA
methylation by DNA methyltransferase 1 is critical for effector CD8 T cell expansion.
J Immunol 176:4562-4572.

174.

Kersh, E. N. 2006. Impaired memory CD8 T cell development in the absence of
methyl-CpG-binding domain protein 2. J Immunol 177:3821-3826.

146

175.

Kersh, E. N., D. R. Fitzpatrick, K. Murali-Krishna, J. Shires, S. H. Speck, J. M. Boss,
and R. Ahmed. 2006. Rapid demethylation of the IFN-gamma gene occurs in
memory but not naive CD8 T cells. J Immunol 176:4083-4093.

176.

Northrop, J. K., R. M. Thomas, A. D. Wells, and H. Shen. 2006. Epigenetic
remodeling of the IL-2 and IFN-gamma loci in memory CD8 T cells is influenced by
CD4 T cells. J Immunol 177:1062-1069.

177.

Shin, H. M., V. N. Kapoor, T. Guan, S. M. Kaech, R. M. Welsh, and L. J. Berg. 2013.
Epigenetic Modifications Induced by Blimp-1 Regulate CD8(+) T Cell Memory
Progression during Acute Virus Infection. Immunity 39:661-675.

178.

Hedrick, S. M. 2009. The cunning little vixen: Foxo and the cycle of life and death.
Nat Immunol 10:1057-1063.

179.

Hedrick, S. M., R. Hess Michelini, A. L. Doedens, A. W. Goldrath, and E. L. Stone.
2012. FOXO transcription factors throughout T cell biology. Nat Rev Immunol
12:649-661.

180.

Hosaka, T., W. H. Biggs, 3rd, D. Tieu, A. D. Boyer, N. M. Varki, W. K. Cavenee, and
K. C. Arden. 2004. Disruption of forkhead transcription factor (FOXO) family
members in mice reveals their functional diversification. Proc Natl Acad Sci U S A
101:2975-2980.

181.

Tothova, Z., R. Kollipara, B. J. Huntly, B. H. Lee, D. H. Castrillon, D. E. Cullen, E. P.
McDowell, S. Lazo-Kallanian, I. R. Williams, C. Sears, S. A. Armstrong, E.
Passegue, R. A. DePinho, and D. G. Gilliland. 2007. FoxOs are critical mediators of
hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128:325-339.

182.

Eijkelenboom, A., and B. M. Burgering. 2013. FOXOs: signalling integrators for
homeostasis maintenance. Nat Rev Mol Cell Biol 14:83-97.

183.

Grange, M., G. Verdeil, F. Arnoux, A. Griffon, S. Spicuglia, J. Maurizio, M. Buferne,
A. M. Schmitt-Verhulst, and N. Auphan-Anezin. 2013. Active STAT5 regulates T-bet
and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1
program with repressed IL-6/TGF-beta1 signaling. J Immunol 191:3712-3724.

184.

Kemp, R. A., C. F. Pearson, G. H. Cornish, and B. P. Seddon. 2010. Evidence of
STAT5-dependent and -independent routes to CD8 memory formation and a
preferential role for IL-7 over IL-15 in STAT5 activation. Immunol Cell Biol 88:213219.

147

185.

Nguyen, H., and N. P. Weng. 2010. IL-21 preferentially enhances IL-15-mediated
homeostatic proliferation of human CD28+ CD8 memory T cells throughout the adult
age span. J Leukoc Biol 87:43-49.

186.

Unsoeld, H., and H. Pircher. 2005. Complex memory T-cell phenotypes revealed by
coexpression of CD62L and CCR7. J Virol 79:4510-4513.

187.

Wu, D., and W. Pan. 2010. GSK3: a multifaceted kinase in Wnt signaling. Trends
Biochem Sci 35:161-168.

188.

Hoogeboom, D., M. A. Essers, P. E. Polderman, E. Voets, L. M. Smits, and B. M.
Burgering. 2008. Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell
factor activity. J Biol Chem 283:9224-9230.

189.

Geginat, J., A. Lanzavecchia, and F. Sallusto. 2003. Proliferation and differentiation
potential of human CD8+ memory T-cell subsets in response to antigen or
homeostatic cytokines. Blood 101:4260-4266.

190.

Boyman, O., C. Krieg, D. Homann, and J. Sprent. 2012. Homeostatic maintenance
of T cells and natural killer cells. Cell Mol Life Sci 69:1597-1608.

191.

Mueller, Y. M., V. Makar, P. M. Bojczuk, J. Witek, and P. D. Katsikis. 2003. IL-15
enhances the function and inhibits CD95/Fas-induced apoptosis of human CD4+
and CD8+ effector-memory T cells. Int Immunol 15:49-58.

192.

Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric
antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med
365:725-733.

193.

Joshi, N. S., W. Cui, A. Chandele, H. K. Lee, D. R. Urso, J. Hagman, L. Gapin, and
S. M. Kaech. 2007. Inflammation directs memory precursor and short-lived effector
CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity
27:281-295.

194.

Gilham, D. E., R. Debets, M. Pule, R. E. Hawkins, and H. Abken. 2012. CAR-T cells
and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med
18:377-384.

195.

Benahmed, M., B. Meresse, B. Arnulf, U. Barbe, J. J. Mention, V. Verkarre, M. Allez,
C. Cellier, O. Hermine, and N. Cerf-Bensussan. 2007. Inhibition of TGF-beta
signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac
disease. Gastroenterology 132:994-1008.

196.

Zou, W. 2005. Immunosuppressive networks in the tumour environment and their
therapeutic relevance. Nat Rev Cancer 5:263-274.
148

197.

Perna, S. K., B. De Angelis, D. Pagliara, S. T. Hasan, L. Zhang, A. Mahendravada,
H. E. Heslop, M. K. Brenner, C. M. Rooney, G. Dotti, and B. Savoldo. 2013.
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition:
implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res
19:106-117.

198.

Ben Ahmed, M., N. Belhadj Hmida, N. Moes, S. Buyse, M. Abdeladhim, H. Louzir,
and N. Cerf-Bensussan. 2009. IL-15 renders conventional lymphocytes resistant to
suppressive

functions

of

regulatory

T

cells

through

activation

of

the

phosphatidylinositol 3-kinase pathway. J Immunol 182:6763-6770.
199.

Bessard, A., V. Sole, G. Bouchaud, A. Quemener, and Y. Jacques. 2009. High
antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion
protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 8:27362745.

200.

Willemsen, R. A., C. Ronteltap, P. Chames, R. Debets, and R. L. Bolhuis. 2005. T
cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory
domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol
174:7853-7858.

201.

Vincent, M., A. Bessard, D. Cochonneau, G. Teppaz, V. Sole, M. Maillasson, S.
Birkle, L. Garrigue-Antar, A. Quemener, and Y. Jacques. 2013. Tumor targeting of
the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor
potency. Int J Cancer 133:757-765.

202.

Joensuu, H., L. Pylkkanen, and S. Toikkanen. 1994. Bcl-2 protein expression and
long-term survival in breast cancer. Am J Pathol 145:1191-1198.

203.

Grover, R., and G. D. Wilson. 1996. Bcl-2 expression in malignant melanoma and its
prognostic significance. Eur J Surg Oncol 22:347-349.

204.

Karakas, T., U. Maurer, E. Weidmann, C. C. Miething, D. Hoelzer, and L.
Bergmann. 1998. High expression of bcl-2 mRNA as a determinant of poor
prognosis in acute myeloid leukemia. Ann Oncol 9:159-165.

205.

Bincoletto, C., S. T. Saad, E. S. da Silva, and M. L. Queiroz. 1999. Haematopoietic
response and bcl-2 expression in patients with acute myeloid leukaemia. Eur J
Haematol 62:38-42.

206.

Campos, L., J. P. Rouault, O. Sabido, P. Oriol, N. Roubi, C. Vasselon, E.
Archimbaud, J. P. Magaud, and D. Guyotat. 1993. High expression of bcl-2 protein

149

in acute myeloid leukemia cells is associated with poor response to chemotherapy.
Blood 81:3091-3096.
207.

Redell, M. S., M. J. Ruiz, T. A. Alonzo, R. B. Gerbing, and D. J. Tweardy. 2011.
Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent
activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.
Blood 117:5701-5709.

208.

Epling-Burnette, P. K., J. H. Liu, R. Catlett-Falcone, J. Turkson, M. Oshiro, R.
Kothapalli, Y. Li, J. M. Wang, H. F. Yang-Yen, J. Karras, R. Jove, and T. P.
Loughran, Jr. 2001. Inhibition of STAT3 signaling leads to apoptosis of leukemic
large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107:351362.

209.

Huang, M., J. F. Dorsey, P. K. Epling-Burnette, R. Nimmanapalli, T. H. Landowski,
L. B. Mora, G. Niu, D. Sinibaldi, F. Bai, A. Kraker, H. Yu, L. Moscinski, S. Wei, J.
Djeu, W. S. Dalton, K. Bhalla, T. P. Loughran, J. Wu, and R. Jove. 2002. Inhibition
of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and
growth of CML cells. Oncogene 21:8804-8816.

210.

Frank, D. A., S. Mahajan, and J. Ritz. 1997. B lymphocytes from patients with
chronic lymphocytic leukemia contain signal transducer and activator of transcription
(STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest
100:3140-3148.

211.

Roberts, A. W., J. F. Seymour, J. R. Brown, W. G. Wierda, T. J. Kipps, S. L. Khaw,
D. A. Carney, S. Z. He, D. C. Huang, H. Xiong, Y. Cui, T. A. Busman, E. M.
McKeegan, A. P. Krivoshik, S. H. Enschede, and R. Humerickhouse. 2012.
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results
of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin
Oncol 30:488-496.

212.

Ishdorj, G., J. B. Johnston, and S. B. Gibson. 2010. Inhibition of constitutive
activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells
to apoptosis. Mol Cancer Ther 9:3302-3314.

213.

Karlsson, S. C., A. C. Lindqvist, M. Fransson, G. Paul-Wetterberg, B. Nilsson, M.
Essand, K. Nilsson, P. Frisk, H. Jernberg-Wiklund, and S. I. Loskog. 2013.
Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating
B-cell malignancy. Cancer Gene Ther 20:386-393.

150

214.

Denman, C. J., V. V. Senyukov, S. S. Somanchi, P. V. Phatarpekar, L. M. Kopp, J.
L. Johnson, H. Singh, L. Hurton, S. N. Maiti, M. H. Huls, R. E. Champlin, L. J.
Cooper, and D. A. Lee. 2012. Membrane-bound IL-21 promotes sustained ex vivo
proliferation of human natural killer cells. PLoS One 7:e30264.

215.

Curran, K. J., H. J. Pegram, and R. J. Brentjens. 2012. Chimeric antigen receptors
for T cell immunotherapy: current understanding and future directions. J Gene Med
14:405-415.

216.

Lebrec, H., M. J. Horner, K. S. Gorski, W. Tsuji, D. Xia, W. J. Pan, G. Means, G.
Pietz, N. Li, M. Retter, K. Shaffer, N. Patel, P. K. Narayanan, and E. A. Butz. 2013.
Homeostasis of Human NK Cells Is Not IL-15 Dependent. J Immunol 191:55515558.

217.

Huntington, N. D., N. Legrand, N. L. Alves, B. Jaron, K. Weijer, A. Plet, E. Corcuff,
E. Mortier, Y. Jacques, H. Spits, and J. P. Di Santo. 2009. IL-15 trans-presentation
promotes human NK cell development and differentiation in vivo. J Exp Med 206:2534.

218.

Conlon, K., J. Morris, J. Janik, D. Stewart, S. A. Rosenberg, T. Worthy, T. Fojo, T.
Fleisher, E. Lugli, L. Perera, E. Jaffe, H. C. Lane, M. Sneller, S. Creekmore, C.
Goldman, B. Bryant, J. Decker, and T. A. Waldmann. 2011. Phase I study of
intravenous recombinant human interleukin-15 in adults with metastatic malignant
melanoma and renal cell carcinoma. In Society for Immunotherapy of Cancer, North
Bethesda, MD.

219.

McInnes, I. B., B. P. Leung, R. D. Sturrock, M. Field, and F. Y. Liew. 1997.
Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha
production in rheumatoid arthritis. Nat Med 3:189-195.

220.

Mishra, A., S. Liu, G. H. Sams, D. P. Curphey, R. Santhanam, L. J. Rush, D.
Schaefer, L. G. Falkenberg, L. Sullivan, L. Jaroncyk, X. Yang, H. Fisk, L. C. Wu, C.
Hickey, J. C. Chandler, Y. Z. Wu, N. A. Heerema, K. K. Chan, D. Perrotti, J. Zhang,
P. Porcu, F. K. Racke, R. Garzon, R. J. Lee, G. Marcucci, and M. A. Caligiuri. 2012.
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia
through chromosomal instability and DNA hypermethylation. Cancer Cell 22:645655.

221.

Fehniger, T. A., K. Suzuki, A. Ponnappan, J. B. VanDeusen, M. A. Cooper, S. M.
Florea, A. G. Freud, M. L. Robinson, J. Durbin, and M. A. Caligiuri. 2001. Fatal

151

leukemia in interleukin 15 transgenic mice follows early expansions in natural killer
and memory phenotype CD8+ T cells. J Exp Med 193:219-231.
222.

Hsu, C., S. A. Jones, C. J. Cohen, Z. Zheng, K. Kerstann, J. Zhou, P. F. Robbins, P.
D. Peng, X. Shen, T. J. Gomes, C. E. Dunbar, D. J. Munroe, C. Stewart, K.
Cornetta, D. Wangsa, T. Ried, S. A. Rosenberg, and R. A. Morgan. 2007. Cytokineindependent growth and clonal expansion of a primary human CD8+ T-cell clone
following retroviral transduction with the IL-15 gene. Blood 109:5168-5177.

223.

Tey, S. K., G. Dotti, C. M. Rooney, H. E. Heslop, and M. K. Brenner. 2007. Inducible
caspase 9 suicide gene to improve the safety of allodepleted T cells after
haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13:913-924.

224.

Davies, J. K., H. Singh, H. Huls, D. Yuk, D. A. Lee, P. Kebriaei, R. E. Champlin, L.
M. Nadler, E. C. Guinan, and L. J. Cooper. Combining CD19 redirection and
alloanergization to generate tumor-specific human T cells for allogeneic cell therapy
of B-cell malignancies. Cancer Res 70:3915-3924.

225.

Loening, A. M., A. M. Wu, and S. S. Gambhir. 2007. Red-shifted Renilla reniformis
luciferase variants for imaging in living subjects. Nat Methods 4:641-643.

226.

Pletnev, S., D. Shcherbo, D. M. Chudakov, N. Pletneva, E. M. Merzlyak, A.
Wlodawer, Z. Dauter, and V. Pletnev. 2008. A crystallographic study of bright far-red
fluorescent protein mKate reveals pH-induced cis-trans isomerization of the
chromophore. J Biol Chem 283:28980-28987.

227.

Rabinovich, B. A., Y. Ye, T. Etto, J. Q. Chen, H. I. Levitsky, W. W. Overwijk, L. J.
Cooper, J. Gelovani, and P. Hwu. 2008. Visualizing fewer than 10 mouse T cells
with an enhanced firefly luciferase in immunocompetent mouse models of cancer.
Proc Natl Acad Sci U S A 105:14342-14346.

228.

Bai, X., Y. Yan, M. Coleman, G. Wu, B. Rabinovich, M. Seidensticker, and E. Alt.
2011. Tracking long-term survival of intramyocardially delivered human adipose
tissue-derived stem cells using bioluminescence imaging. Mol Imaging Biol 13:633645.

229.

Singh, H., M. J. Figliola, M. J. Dawson, S. Olivares, L. Zhang, G. Yang, S. Maiti, P.
R. Manuri, V. Senyukov, B. Jena, P. Kebriaei, R. E. Champlin, H. Huls, and L. J.
Cooper. 2013. Manufacture of clinical-grade CD19-specific T cells stably expressing
chimeric antigen receptor using Sleeping Beauty system and artificial antigen
presenting cells. PLoS One 8:e64138.

152

230.

Jena, B., S. Maiti, H. Huls, H. Singh, D. A. Lee, R. E. Champlin, and L. J. Cooper.
2013. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect
CD19-specific T cells in clinical trials. PLoS One 8:e57838.

231.

Cooper, L. J., M. S. Topp, L. M. Serrano, S. Gonzalez, W. C. Chang, A. Naranjo, C.
Wright, L. Popplewell, A. Raubitschek, S. J. Forman, and M. C. Jensen. 2003. T-cell
clones can be rendered specific for CD19: toward the selective augmentation of the
graft-versus-B-lineage leukemia effect. Blood 101:1637-1644.

232.

Singh, H., L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, Z. AlKadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, D. Colcher, A. Raubitschek, and
L. J. Cooper. 2007. Combining adoptive cellular and immunocytokine therapies to
improve treatment of B-lineage malignancy. Cancer Res 67:2872-2880.

233.

Geiss, G. K., R. E. Bumgarner, B. Birditt, T. Dahl, N. Dowidar, D. L. Dunaway, H. P.
Fell, S. Ferree, R. D. George, T. Grogan, J. J. James, M. Maysuria, J. D. Mitton, P.
Oliveri, J. L. Osborn, T. Peng, A. L. Ratcliffe, P. J. Webster, E. H. Davidson, L.
Hood, and K. Dimitrov. 2008. Direct multiplexed measurement of gene expression
with color-coded probe pairs. Nat Biotechnol 26:317-325.

234.

Maiti, S. N., H. Huls, H. Singh, M. Dawson, M. Figliola, S. Olivares, P. Rao, Y. J.
Zhao, A. Multani, G. Yang, L. Zhang, D. Crossland, S. Ang, H. Torikai, B.
Rabinovich, D. A. Lee, P. Kebriaei, P. Hackett, R. E. Champlin, and L. J. N. Cooper.
2013. Sleeping Beauty System to Redirect T-cell Specificity for Human Applications.
Journal of Immunotherapy 36:112-123.

235.

Robinson, M. D., D. J. McCarthy, and G. K. Smyth. 2010. edgeR: a Bioconductor
package for differential expression analysis of digital gene expression data.
Bioinformatics 26:139-140.

236.

Lohse, M., A. M. Bolger, A. Nagel, A. R. Fernie, J. E. Lunn, M. Stitt, and B. Usadel.
2012. RobiNA: a user-friendly, integrated software solution for RNA-Seq-based
transcriptomics. Nucleic Acids Res 40:W622-627.

237.

McCarthy, D. J., Y. Chen, and G. K. Smyth. 2012. Differential expression analysis of
multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids
Res 40:4288-4297.

238.

Robinson, M. D., and G. K. Smyth. 2007. Moderated statistical tests for assessing
differences in tag abundance. Bioinformatics 23:2881-2887.

239.

Robinson, M. D., and G. K. Smyth. 2008. Small-sample estimation of negative
binomial dispersion, with applications to SAGE data. Biostatistics 9:321-332.
153

240.

Benjamini, Y., and Y. Hochberg. 1995. Controlling the False Discovery Rate - a
Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met 57:289300.

154

VITA
Lenka Victoria Hurton was born in Victoria, British Columbia, Canada on July 13, 1978 to
Alena and Stan Hurton. She graduated from Windsor Secondary High School in 1996 and
went on to attend Fairfield University in Fairfield, CT on a full athletic scholarship. In 2000,
she completed her Bachelor’s Degree of Science in Biology along with minors in Marine
Science and Environmental Science. After graduation she moved to New York to work for
nearly a year at Cold Spring Harbor Laboratory as a research assistant in the proteomics
lab of Dr. Ryuji Kobayashi. She then relocated to Virginia to pursue a M.Sc. degree at
Virginia Polytechnic Institute and State University under the mentorship of Dr. Jim Berkson.
In 2003, she obtained her M.Sc. in Fisheries and Wildlife Sciences. In 2005 she moved to
Texas where she worked as a senior research assistant in the proteomics lab of Dr.
Kobayashi.

She enrolled in the Ph.D. program at the Graduate School of Biomedical

Sciences at the University of Texas – Houston, MD Anderson Cancer Center in August
2006. In May 2007 she joined the Immunology program and began her dissertation work in
the immunotherapy field under the mentorship of Dr. Laurence J.N. Cooper.

155

